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Although the link between oral and overall health had already been reported 
thousands of years ago by the ancient Egyptians and Greek, for many years 
this link didn’t get too much attention. The last decades, however, the number 
of studies on the association between periodontal disease and systemic disease 
is rapidly increasing. Many studies demonstrate an association between 
periodontal disease and several systemic conditions and diseases. Well known 
examples are associations between periodontal disease and diabetes mellitus, 
cardiovascular diseases, adverse pregnancy outcome, osteoporosis, respiratory 
disease and rheumatoid arthritis1-3.  
The nature of the association between periodontal disease and systemic 
diseases is considered bidirectional. Periodontal disease can be initiated or 
deteriorated by certain systemic diseases, but can also initiate or deteriorate 
certain systemic diseases4. Although there may not always be a cause and 
effect association5, many reports have shown that an increased severity of 
systemic disease is associated with increased periodontal disease severity and 
vice versa6, 7.  
Increased prevalence and severity of periodontitis in some systemic 
diseases, e.g. in diabetes mellitus, may reflect increased vulnerability to 
infection through systemic dysregulation8, 9, 10. Additionally, the link between 
periodontitis and systemic disease may reflect epiphenomena or confounding 
by factors such as age, sex, genetics, socioeconomic status and smoking. 11. 
Finally, the increased prevalence and severity of periodontitis in some 
systemic diseases may reflect periodontitis as a risk factor for these diseases. 
Periodontitis poses an inflammatory and infectious burden as evidenced by 
increased serum levels of c-reactive protein (CRP). As such, periodontitis may 
initiate or deteriorate systematic diseases by causing a proinflammatory and 
procoagulatory state. 
          A major drawback of the various clinical studies assessing the 
association between periodontal disease and systemic diseases is that a variety 
of methods has been used to define periodontitis and these studies have been 
conducted in different populations. Although most studies demonstrated an 
association between periodontitis and systemic diseases, the results also 
revealed that the existence of such associations are not unequivocal. As such, 
the method used for clinical measurement of periodontal disease might have 
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affected the observed associations12-15. Clinical measures of periodontitis, such 
as probing pocket depth (PPD), bleeding on probing (BOP), clinical 
attachment loss (CAL) are commonly used for defining periodontal diseases16. 
These tools reflect the extent of the periodontal disease process but do not 
reflect the amount of inflammatory periodontal tissue17. Recently a new 
clinical measure for periodontitis, the periodontal inflammatory surface area 
(PISA), reflecting the surface area of bleeding and inflamed pocket epithelium 
in square millimeters, has been introduced18. In addition to the different 
definitions of periodontal disease that were used in these studies, the 
difference in associations between periodontitis and systemic diseases may be 
due to the variety in the subject populations such as ethnicity, genetics, 
nutrition and cultural background. Therefore, the result of one study often can 
not be generalized to other populations19. 
Valuable contributions to the discussion on the nature of association 
between periodontal disease and systemic diseases stem from studies 
assessing the effect of periodontal treatment on systemic diseases. Treatment 
of periodontal disease may be beneficial not only for the health of periodontal 
tissue it self, but may also reduce the severity of certain systemic diseases. For 
example, periodontal treatment has been shown to improve glycaemic control 
(HbA1c) in diabetes mellitus19 and to reduce disease activity score (DAS28) in 
rheumatoid arthritis (RA) patients (0.5-1.0 point).20 Periodontal treatment  
has also been shown to reduce systemic inflammation markers such as c-
reactive protein21. Therefore, decreased severity of systemic disease after 
periodontitis treatment may be mediated by the effect of periodontal 
treatment on serum CRP level22, 23. Indeed some intervention studies have 
shown effects of periodontal treatment on serum level of CRP, not only in 
periodontitis patients24-27 but also in patients suffering from systemic diseases 
such as cardiovascular disease28-30, RA20  and diabetes mellitus31, 32.  However, 
a systematic review summarising the effect of treatment of periodontitis on 
disease activity in patients suffering from cardiovascular diseases is not yet 
available.  
 In summary, studies on the association between periodontitis and 
systemic diseases show conflicting results, possibly influenced by the 
differences in background of the study population and the definition of 
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periodontitis used. Therefore, the results of one study may not be generalized 
to other populations. In this respect it is striking that only limited data are 
available for Asia, while Asians compose 60% of the world’s population and 
the prevalence of both systemic diseases and periodontitis has been reported 
to be high in Asian countries33,34. 
The overall aim of the PhD research described in this thesis was to investigate 
associations between periodontitis and systemic diseases as diabetes mellitus 
type 2 (DM2) and rheumatoid arthritis (RA) in Indonesia as well as to 
systematically review whether patients suffering from systemic diseases, in 
particular cardiovascular diseases and metabolic disorders, eg DM2, might 
benefit from treatment of periodontitis. Therefore, a number of studies was 
performed: 
 
1. To assess the prevalence and severity of periodontitis among DM2 
patients in Indonesia, using multiple, commonly used methods to 
operationalize both periodontitis prevalence and severity (chapter 
2). 
 
2. To assess whether periodontitis severity and CRP predict HbA1c 
levels in healthy Indonesians and Indonesian DM2 patients 
(chapter 3). 
 
3. To compare periodontitis prevalence and severity in Indonesian RA 
patients with Indonesian healthy controls using a variety of 
definitions for periodontitis severity as well as a variety of serum 
parameters (chapter 4). 
 
4. To systematically assess the effect of treatment of periodontitis on 
disease activity in patients suffering from atherosclerotic and 




1. Mercado FB, Marshall RI, Bartold PM. Inter-relationships between 
rheumatoid arthritis and periodontal disease. A review. J Clin Periodontol 
2003;30(9):761-772.  
2. Abou-Raya A, Abou-Raya S, Abu-Elkheir H. Periodontal disease and 
rheumatoid arthritis: is there a link? Scand J Rheumatol 2005;34(5):408-410.  
3. Bartold PM, Marshall RI, Haynes DR. Periodontitis and rheumatoid 
arthritis: a review. J Periodontol 2005;76(11 Suppl):2066-2074.  
4. Kim J, Amar S. Periodontal disease and systemic conditions: a bidirectional 
relationship. Odontology / the Society of the Nippon Dental University 
2006;94(1):10-21.  
5. Dietrich T, Garcia RI. Associations between periodontal disease and 
systemic disease: evaluating the strength of the evidence. J Periodontol 
2005;76(11 Suppl):2175-2184.  
6. Kinane DF, Marshall GJ. Periodontal manifestations of systemic disease. 
Aust Dent J 2001;46(1):2-12.  
7. Garcia RI, Henshaw MM, Krall EA. Relationship between periodontal 
disease and systemic health. Periodontol 2000 2001;25:21-36.  
8. Teeuw WJ, Gerdes VE, Loos BG. Effect of periodontal treatment on 
glycemic control of diabetic patients: a systematic review and meta-analysis. 
Diabetes Care 2010;33(2):421-427.  
9.  Nesse W, Westra J, vander Wal JE, Abbas F, Nicholas AP, Vissink A, 
Brouwer E. The periodontium of periodontitis patients contains citrullinated 
proteins which may play role in ACPA formation. Arthritis Res Ther.2011 
(Submitted).  
10. Lundberg K, Wegner N, Yucel-Lindberg T, Venables PJ. Periodontitis in 
RA-the citrullinated enolase connection. Nat Rev Rheumatol 2010;6(12):727-
730.  
11. Borrell LN, Papapanou PN. Analytical epidemiology of periodontitis. J Clin 
Periodontol 2005;32 Suppl 6:132-158.  
12. Beck JD, Offenbacher S. Relationships among clinical measures of 
periodontal disease and their associations with systemic markers. Ann 
Periodontol 2002;7(1):79-89.  
13. Dietrich T, Garcia RI. Associations between periodontal disease and 
systemic disease: evaluating the strength of the evidence. Journal of 
periodontology 2005;76(11 Suppl):2175-84.  
6 
 
14. Demmer RT, Papapanou PN, Jacobs DR,Jr, Desvarieux M. Evaluating 
clinical periodontal measures as surrogates for bacterial exposure: the Oral 
Infections and Vascular Disease Epidemiology Study (INVEST). BMC Med 
Res Methodol 2010;10:2.  
15. Leroy R, Eaton KA, Savage A. Methodological issues in epidemiological 
studies of periodontitis--how can it be improved? BMC Oral Health 
2010;10:8.  
16. Armitage GC. The complete periodontal examination. Periodontol 2000 
2004;34:22-33.  
17. Tonetti MS, Claffey N, European Workshop in Periodontology group C. 
Advances in the progression of periodontitis and proposal of definitions of a 
periodontitis case and disease progression for use in risk factor research. 
Group C consensus report of the 5th European Workshop in Periodontology. J 
Clin Periodontol 2005;32 Suppl 6:210-213.  
18. Nesse W, Abbas F, van der Ploeg I, Spijkervet FK, Dijkstra PU, Vissink A. 
Periodontal inflamed surface area: quantifying inflammatory burden. J Clin 
Periodontol 2008;35(8):668-673.  
19. Teeuw WJ, Gerdes VE, Loos BG. Effect of periodontal treatment on 
glycemic control of diabetic patients: a systematic review and meta-analysis. 
Diabetes Care 2010;33(2):421-427.  
20. Nesse W, Brouwer E, Dijkstra PU, Huddleston Slater JJR, Spijkvert FKL, 
Abbas F, Vissink A, Treatment of periodontitis in rheumatoid arthritis 
pateints reduces rheumatoid arthritis activity. A meta analysis. J Clin 
Periodontol 2011 (submitted).  
21. Behle JH, Sedaghatfar MH, Demmer RT, et al. Heterogeneity of systemic 
inflammatory responses to periodontal therapy. J Clin Periodontol 
2009;36(4):287-294.  
22. Ioannidou E, Malekzadeh T, Dongari-Bagtzoglou A. Effect of periodontal 
treatment on serum C-reactive protein levels: a systematic review and meta-
analysis. Journal of periodontology 2006;77(10):1635-42.  
23. Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-
analyses on C-reactive protein in relation to periodontitis. Journal of clinical 
periodontology 2008;35(4):277-90.  
24. D'Aiuto F, Parkar M, Andreou G, et al. Periodontitis and systemic 
inflammation: control of the local infection is associated with a reduction in 
serum inflammatory markers. J Dent Res 2004;83(2):156-160.  
25. Blum A, Front E, Peleg A. Periodontal care may improve systemic 
inflammation. Clinical and investigative medicine 2007;30(3):E114-7.  
7 
 
26. Marcaccini AM, Meschiari CA, Sorgi CA, et al. Circulating interleukin-6 
and high-sensitivity C-reactive protein decrease after periodontal therapy in 
otherwise healthy subjects. Journal of periodontology 2009;80(4):594-602.  
27. Yamazaki K, Honda T, Oda T, et al. Effect of periodontal treatment on the 
C-reactive protein and proinflammatory cytokine levels in Japanese 
periodontitis patients. Journal of periodontal research 2005;40(1):53-8.  
28. Montebugnoli L, Servidio D, Miaton RA, et al. Periodontal health 
improves systemic inflammatory and haemostatic status in subjects with 
coronary heart disease. Journal of clinical periodontology 2005;32(2):188-
92.  
29. Hussain Bokhari SA, Khan AA, Tatakis DN, Azhar M, Hanif M, Izhar M. 
Non-surgical periodontal therapy lowers serum inflammatory markers: a pilot 
study. J Periodontol 2009;80(10):1574-1580.  
30. Vidal F, Figueredo CM, Cordovil I, Fischer RG. Periodontal therapy 
reduces plasma levels of interleukin-6, C-reactive protein, and fibrinogen in 
patients with severe periodontitis and refractory arterial hypertension. J 
Periodontol 2009;80(5):786-791.  
31. Iwamoto Y, Nishimura F, Soga Y, et al. Antimicrobial periodontal 
treatment decreases serum C-reactive protein, tumor necrosis factor-alpha, 
but not adiponectin levels in patients with chronic periodontitis. Journal of 
periodontology 2003;74(8):1231-6.  
32. Lalla E, Kaplan S, Yang J, Roth GA, Papapanou PN, Greenberg S. Effects 
of periodontal therapy on serum C-reactive protein, sE-selectin, and tumor 
necrosis factor-alpha secretion by peripheral blood-derived macrophages in 
diabetes. A pilot study. J Periodontal Res 2007;42(3):274-282.  
33. Petersen PE. The burden of oral disease: challenges to improving oral 
health in the 21st century. Bull World Health Organ 2005;83(1):3.  


























Periodontitis prevalence and severity  
















Background: The prevalence of diabetes mellitus type 2 (DM2) in Indonesia 
is high and still rising. Periodontitis is associated with DM2. No study has 
investigated this association in Indonesia, nor has any study investigated this 
association using a variety of methods to operationalize periodontitis.  The 
present study compares prevalence and severity of periodontitis in DM2 
patients to healthy controls, using different methods to operationalize 
periodontitis.  
Methods: A total of 78 subjects with DM2 and 65 healthy control subjects 
underwent a full mouth periodontal screening assessing probing pocket depth, 
gingival recession, plaque index and bleeding on probing. Using these 
measurements, periodontitis prevalence and severity was operationalized in 
various ways. Differences in periodontitis prevalence and severity between 
DM2 and healthy subjects were analyzed using univariate analyses. In 
regression analyses, prevalence and severity of periodontitis were predicted 
on the basis of DM2 presence, controlling for confounders and effect 
modification. 
Results: Prevalence of periodontitis was significantly higher in subjects with  
DM2 compared to healthy subjects, showing odds ratios of 5.0 and 6.1. 
Likewise, periodontitis severity was significantly higher in DM2 subjects.  
Conclusion: Indonesian DM2 subjects had more prevalent and more severe 
periodontitis than Indonesian healthy subjects, independent of confounding 












Diabetes mellitus (DM) is a chronic disease characterized by dysregulation of 
carbohydrate, protein and lipid metabolism. An elevation of blood glucose 
level (hyperglycemia) is the primary feature of DM and results from either a 
defect in insulin secretion by pancreatic beta cells, a decrease in insulin 
sensitivity, or a combination of both. The most common form of DM is DM 
type 2 (DM2), which accounts for 85% of all diabetes patients. 1 The estimated 
world wide prevalence of DM is 220.5 million, or 2.8 % of the world’s 
population. DM currently is the twelfth leading cause of death in the world. 
The prevalence is estimated to rise up to 4.4%, putting DM in the top ten 
leading causes of death by 2030. 2, 3 With the increasing prevalence of DM, 
this already vast and world wide epidemic will increasingly pose serious 
problems to public health. These problems mostly arise from the 
complications associated with DM like myocardial infarction, cerebrovascular 
disease, retinopathy, nephropathy and neuropathy. 4  
Periodontitis is more prevalent and severe among patients with DM2 
than among healthy controls. 5-7 Thus, DM2 may initiate or deteriorate 
periodontitis. However, the reverse could also be true, i.e. periodontitis may 
initiate or deteriorate DM2. The strongest support for this comes from studies 
showing that treatment of periodontitis improves glycaemic control in DM2 
patients. 8-13 Thus, there is an association between DM2 and periodontitis that 
appears to be bilateral causal in nature (i.e. one causes or deteriorates the 
other and vice-versa). 
The strength of associations between periodontitis and DM2 appears to 
differ geographically. Studies performed in different locations, i.e. performed 
among different ethnic groups, show different associations between 
periodontitis and DM2. 5, 14-17 These differences in the strength of associations 
may, apart from differences in study design and data analysis, be based on 
genetic, dietary, cultural and other differences between ethnic groups. 18 
Therefore, findings among one ethnic population cannot automatically be 
generalized to another ethnic population.  
South East Asia hosts approximately 10% of the world’s current 
population. With 240 million inhabitants, Indonesia is the 4th most populous 
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country in the world. The prevalence of DM in South East Asia is 5.3%. 19 In 
Indonesia, the prevalence of DM in 2008 was 5.7%, 20 putting Indonesia in the 
top ten of countries with the highest number of DM patients in the world. By 
the year 2030, the estimated number of patients with DM in Indonesia will be 
over 20 million (approximately 10% of the population). 2 With this high and 
rising prevalence of DM2 in Indonesia, periodontitis prevalence and severity 
may also rise. Only three studies report on the association between 
periodontitis and DM2 in South East Asia: Thailand, 21  Singapore, 22  
Indonesia. 23 Unfortunately, in the latter study, the way in which periodontitis 
was measured and defined remains unclear. Neither did this study make a 
distinction between DM type 1 and DM type 2 patients, leaving many 
questions unanswered.  
Also remaining unanswered is the influence of using a particular 
method to operationalize periodontitis on the strength of an association 
between periodontitis and DM2. The use of different methods to 
operationalize periodontitis prevalence and severity may influence not only 
the strength of the associations between a given disease and periodontitis, but 
may even influence whether an association is observed at all. For example, in 
research linking periodontitis to preterm low birth weight, 13 different 
methods have been used to operationalize periodontitis. Depending on the 
method used, either an association 24, 25 or no association 26 between 
periodontitis and preterm low birth weight was observed. The same may be 
true for periodontitis and DM2.  
This study assesses prevalence and severity of periodontitis among 
DM2 patients in Indonesia, using multiple, commonly used methods to 
operationalize both periodontitis prevalence and severity.  
 
Subjects and methods 
DM2 patients were recruited at three different sites:  1) Internal Medicine 
Dept. of the Dr. Sardjito Hospital, 2) Prof. Soedomo Dental Hospital, Faculty 
of Dentistry, Gadjah Mada University and 3) Diabetes Center of Jogjakarta 
International Hospital, Indonesia. DM2 patients were diagnosed according to 
World Health Organization criteria: fasting blood glucose level >126 mg/dl 
and/or a postprandial blood glucose level >200 mg/dl. 27 Healthy controls 
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were recruited in Prof. Soedomo Oral and Dental Hospital, Gadjah Mada 
University. Inclusion criteria for all subjects in this study were an age 18 years 
or over, and having >8 remaining teeth. This study was approved by the 
Ethical Committee for Research of the Medical Faculty of Gadjah Mada 
University  and was conducted from July 2008 until February 2009.  
To assess whether periodontitis prevalence and severity differed 
between DM2 patients and healthy controls, 78 DM2 patients (35 males and 
43 females) and 65 healthy controls (22 males and 43 females), who gave 
informed consent, underwent a full mouth periodontal examination. Full 
mouth periodontal probing pocket depth (PPD), gingival recession, plaque 
score and bleeding on probing (BOP) measurements were performed on all 
teeth, on six sites per tooth. All permanent fully erupted teeth were examined 
with a manual periodontal colour coded standard probe (Dentsply, London, 
UK). Measurements were made in millimetres and were rounded to the 
nearest whole millimetre. CAL was defined as the distance from the cemento 
enamel junction (CEJ) to the bottom of the pocket/sulcus, and calculated as 
the mathematical sum of the PPD and gingival recession measurements 28. 
BOP was recorded as either present or absent within 30 seconds after probing 
at 6 sites per tooth. The number of missing teeth was also recorded. Plaque 
score was defined as being present or absent at 6 points on each tooth. 29  
Periodontitis prevalence, extent and severity were operationalized 
using a variety of methods, all of which are currently used in literature 
studying the association between periodontitis and other diseases. All 
methods used to operationalize periodontitis prevalence and severity were 
calculated using conventional clinical measurements obtained during the full 
mouth periodontal examination. Periodontitis prevalence was operationalized 
by using two diagnostic threshold values; 1) having one site with PPD >4 mm 
and CAL >3 mm, 26 and 2) having one site with PPD >5 mm and CAL >2 mm. 
30 The following methods to operationalize periodontitis extent and severity 
were calculated using an online spreadsheet (www.parsprototo.info, Microsoft 
Excel 2003 spreadsheet for Windows); the number of sites with PPD >4, >5 
and >6 mm, the numbers of sites with CAL >3, >4, >5 and >6 mm, mean PPD, 




Table 1. Characteristics of healthy subjects and DM2 and potential 
determinants of periodontitis severity  














6.2 (2.8 to 9.5)  
 
<0.001‡ 
Sex: n (%)    0.180* 
         Male 22(34) 35(45)   
         Female 43(66) 43(55)   
Smoking: n (%) 10(15) 14(18)  0.683* 
Java origin: n (%) 60(92) 73(94)  0.765* 
Education: n (%)    0.762* 
Low 17(26) 18(23)   
    Middle 26(40) 29(37)   
High 22(34) 31(40)   
BMI (SD) (kg/m2) 24.6(3.9) 25.1(3.8)   0.460 
Number of tooth (SD) 
(n) 
24.5(5.5) 22.9(6.1)  0.112 
Plaque score (SD) (%) 92.5(9.2) 90.8(7.6)  0.211 
Medical conditions: n 
(%)† 






15% (0.3 to 29) 
 
<0.05*‡ 
2. Gastritis 4 (6) 10 (13)  0.182* 





0 (0) 3 (4)  0.110* 
     
 
*Results of Chi-square test, other results are the results of the independent 
samples t test,  
†Only diseases with a prevalence of at least 1% (i.e. 2 patients) were analyzed  
‡statistically significant difference (p < 0.05) between DM2 and controls 
95%CI: 95% Confidence Interval 
BMI: Body Mass Index 
DM2: Diabetes Mellitus type 2 
Education: (low: elementary & junior school, middle: high school, high: 
university) HbA1c: Glycosilated/Glycated Hemoglobin 
n: number of participants 







Additionally, two recently introduced measures of periodontitis 
severity, the Periodontal Epithelial Surface Area (PESA) and the Periodontal 
Inflamed Surface Area (PISA) 31 were both calculated using another freely 
downloadable spreadsheet (www.parsprototo.info). PESA reflects the surface 
area of all pocket epithelium in square millimetres, whereas PISA reflects the 
surface area of bleeding pocket epithelium in square millimetres. PESA and 
PISA are calculated using conventional CAL, gingival recession and BOP 
measurements. PISA quantifies the amount of inflamed periodontal tissue and 
it is suggested that PISA thereby quantifies the inflammatory burden posed by 
periodontitis.  
Furthermore, all participants completed a validated general health 
assessment questionnaire, 32-34 to identify other medical conditions that might 
be a risk factor for periodontitis. The original questionnaire was translated 
from English into Indonesian, a reverse translation to English was made to 
check for potential differences. No substantial differences were found. 
Additionally, ethnicity35, Body Mass Index (BMI)36, dental plaque, age, sex, 
smoking (pack years), and Socio Economic Status (SES, operationalized using 
level of education) were recorded for each participant, since these are 
potential determinants of periodontitis. 37  
To ensure that healthy controls were not undiagnosed patients with 
diabetes, all participants underwent venipuncture to obtain a blood sample. 
Blood glucose and glycosilated glycated haemoglobin (HbA1c) were 
determined for both DM2 patient and healthy controls. Controls with a blood 
HbA1c level of ≥6.5% were excluded from the analysis, to exclude latent DM2 
status. 
 
Statistical analysis  
Differences in periodontitis prevalence, extent and severity between DM2 and 
healthy subjects were analyzed first using univariate analyses, the 
independent sample t-test or Chi-square test as appropriate. Likewise, 
differences in potential predictors of periodontitis (namely: age, sex, BMI, 
SES, smoking, plaque score, number of teeth, ethnicity and other medical 
conditions) between DM2 patients and healthy controls were tested for 
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significance using univariate analyses. In case both periodontitis prevalence, 
extent and severity and any of the potential predictors of periodontitis differed 
significantly between DM2 patients and healthy controls, the predictors of 
periodontitis other than DM2 might act as confounders or effect modifiers. 
 









Difference (95%CI) OR (95%CI) p value† 
PPD4&CAL3 (yes)  46(71%) 72(92%) 21% 
(9% to 32%) 
5.0 (1.8 to 13.3) 0.001* 
PPD5&CAL2 (yes)  20(31%) 57(73%) 42% 
(26% to 55%) 
6.1 (2.9 to 12.6) <0.001* 
 
* Result of Chi-square test 
†statistically significant difference (p < 0.05) between DM2 and controls 
OR: Odds Ratio’s were calculated using binary logistic regression analyses 
controlling for confounders 
95%CI: 95% Confidence Interval 
DM2: Diabetes Mellitus type 2  
PPD: Probing Pocket Depth 
CAL: Clinical Attachment Loss 
PPD4&CAL3: participants with one site exhibiting both PPD 4 mm & CAL 
3 mm,  
PPD5&CAL2: participants with one site exhibiting both PPD 5 mm & CAL 











 Table 3.  Differences in periodontitis severity between Healthy Controls and 
subjects with DM2. 
 
*statistically significant difference (p < 0.05) between DM2 and controls 
95%CI: 95% Confidence Interval 
BOP: Bleeding On Probing 
CAL: Clinical Attachment Loss 
DM2: Diabetes Mellitus type 2 
PESA: Periodontal Epithelial Surface Area  
PISA: Periodontal Inflamed Surface Area  
PPD: Probing Pocket Depth 
SD: Standard Deviation 
 
Because periodontitis severity was operationalized as several interval 
variables (i.e. PISA, or number of sites with PPD >4mm),  linear regression 
analyses ( backward stepwise) were performed to predict periodontitis extent 
and severity on the basis of DM2 presence and the other potential predictors 








Difference (95%CI) p 
value* 













275.3(52.9 to 497.6) 
mm2 
0.016 
Number of sites 
with: 
    
 CAL > 3 mm 35.8(23.1) sites 63.5(29.9) sites 27.6(18.8 to 36.4) sites <0.001 
 CAL > 4 mm 12.3(15.1) sites 37.1(27.2) sites 24.8(17.7 to 31.9) sites <0.001 
 CAL > 5 mm 5.9(10.2) sites 22.9(21.4) sites 16.9(11.5 to 22.4) sites <0.001 
 CAL > 6 mm 3.1(7.3) sites 13.7(16.2) sites 10.6(6.6 to 14.7) sites <0.001 
 PPD > 4 mm 4.5(7.9) sites 16.6(21.2) sites 12.1(6.9 to 17.3) sites <0.001 
 PPD > 5 mm 1.4(3.7) sites 7.7(12.5) sites 6.3 (3.4 to 9.2) sites <0.001 
 PPD > 6 mm 
 
0.8(2.3) sites 4.5(9.3) sites 3.7(1.5 to 5.9) sites 0.001 
 BOP (%) 
 
14.2(13.3) % 24.9(16.1) % 10.7(5.8 to 15.5) % <0.001 
CAL mean (mm) 2.2(0.9) mm 3.1(1.3) mm 0.9(0.5 to 1.3) mm <0.001 





other medical conditions). To facilitate clinical interpretation of presented 
analyses, age was centered to it’s mean (53.86). Because periodontitis 
prevalence was operationalized as two dichotomous variables,  logistic 
regression analyses were performed in a similar way. Odds ratios and 95% 
confidence intervals were calculated using these logistic regression analyses. 
Interaction between different predictors of periodontitis was explored. 
Statistics were calculated using SPSS 16.0.   
 
Results 
Of the original 76 healthy controls, 11 subjects were excluded because of 
HbA1c levels >6.5%, leaving 65  healthy controls and 78 DM2 patients (table 
1). The prevalence of periodontitis in DM2 subjects was significantly higher 
than healthy controls, regardless of the definition used (table 2). The extend 
and severity of periodontitis was also significantly higher in participants with 
DM2 when compared to controls, again independent of the method used to 
operationalize periodontitis severity (table 3).  
 
Table 4. DM2 and age as statistical predictors of periodontitis extent and 
severity: 
Results of multiple linear regression analyses with periodontitis 












R2 95% CI of β 
 
PESA 






DM2  327.49 0.18 <0.05  36.65 to 618.33 
Constant  863.04  <0.001  648.25 to 1077.84 
      
PISA    0.04  
DM2  275.29 0.19 <0.05  34.69 to 515.89 
Constant 154.06  0.089  -23.63 to 331.76 
      
BOP%    0.11  
DM2  10.65 0.34 <0.001  5.71 to 15.60 
Constant  14.23  <0.001  10.58 to 17.89 
      
*PPD > 4 mm    0.12  
DM2  12.10 0.34 <0.001  6.60 to 17.60 
Constant  4.92  <0.05  0.43 to 8.56 
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*PPD > 5 mm    0.10  
DM2  6.30 0.31 <0.001  3.13 to 9.47 
Constant 1.35  0.254  -0.98 to 3.69 
      
*PPD > 6 mm    0.07  
DM2   3.70 0.26 0.002  1.36 to 6.03 
Constant 0.75  0.388  -0.97 to 2.47 
      
PPD mean    0.11  
DM2  0.37 0.33 <0.001  0.19 to 0.54 
Constant  1.83  <0.001  1.70 to 1.96 
      
*CAL > 3 mm    0.24  
DM2  24.25 0.40 <0.001  14.99 to 33.49 
Age centered 0.54 0.19 0.017  0.10 to 0.98 
Constant 37.7  <0.001  31.0 to 44.4 
      











13.31 to 28.40 
Age centered  0.64 0.26 0.001  0.28 to 1.00  
Constant 14.5  <0.001  9.0 to 19.9 
      
*CAL > 5 mm    0.25  




<0.001  8.31 to 19.94  
 




0.002  0.18 to 0.74  
 
Constant 7.5  0.001  3.26 to 11.68 
      
*CAL > 6 mm    0.19  
DM2  8.82 0.32 <0.001  4.42 to 13.22 
Age centered  0.29 0.22 0.008  0.08 to 0.50 
Constant 4.03  0.013  0.85 to 7.22 
      
*CAL mean    0.21  
DM2  0.71 0.29 <0.001  0.33 to 1.09 
Age centered  0.03 0.27 0.001  0.01 to 0.05 
Constant 2.27  <0.001  2.00 to 2.54 
*  = Number of sites with 
†  p-value of ≤0.05 was considered statistically significant 
 p = probability,  β: unstandardized coefficient 
95%CI: 95% Confidence Interval 
Independent variables:  
Age centered = Age minus  Mean age 
Constant = sites with PPD≥ that are not dependent on DM2 presence or 
increasing age  
DM2: Diabetes Mellitus type 2  
Dependent variables (periodontitis severity measures) are underlined:  
BOP: Bleeding On Probing  
Number of sites with CAL: Clinical Attachment Loss >3, >4, >5 & >6 mm 
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Number of sites with PPD: Probing Pocket Depth >4, >5 & >6 mm 
PESA: Periodontal Epithelial Surface Area 
PISA: Periodontal Inflamed Surface Area 
 
Age and hypertension were the only potential predictors of 
periodontitis prevalence and severity that differed significantly between DM2 
and healthy subjects in the univariate analysis (table 1). In the multiple linear 
regression analyses, controlling for age and hypertension as potential 
confounders, DM2 remained a significant predictor of all measures of 
periodontitis severity (table 4). Age was an additional predictor of 
periodontitis severity, together with DM2, whenever periodontitis severity was 
operationalized using CAL. Age did not modify the effect of DM2 on 
periodontitis severity. Hypertension was not a predictor of periodontitis 
prevalence or severity. 
 
Discussion 
This study revealed that Indonesian DM2 subjects had significantly increased 
prevalence, extent and severity of periodontitis compared to healthy 
Indonesian subjects. Moreover, these increases, were independent of the 
methods used to operationalize periodontitis. Furthermore, these increases  
seemed to be independent of confounding factors i.e.: age, sex, smoking, BMI, 
ethnicity, SES and other medical conditions.  
Age was an additional predictor of all methods that used CAL to 
operationalize periodontitis severity. This could have been expected since CAL 
reflects the accumulation of damage sustained by the periodontium over time. 
In other words, with increasing age, CAL increases. Nevertheless, DM2 
remained a significant predictor of every method used to operationalize 
periodontitis prevalence and severity.  
Before the study we did not perform a formal sample size calculation, 
although this study is the second on periodontitis and DM2 in Indonesia. It is 
not clear how periodontitis was measured and defined in the first study and  
no distinction was made among patients with DM1 and DM2. 23  In a post-hoc 
power analysis it seemed that we had a power of .92 to find a difference in 
prevalence of periodontitis of 21%, between controls (n=65, prevalence=71%) 
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and DM2 patients (n=78, prevalence=91%). A sample of 50 DM2 patients and 
50 controls would have been enough to detect this difference (power, 0.80).  
A limitation of this study is that we did not use a population based 
sampling scheme to select DM2 patients. However, Indonesian DM2 patients 
regularly visit hospitals to make use of the laboratory facilities. Thus, selection 
of DM2 patients at two hospitals does not mean a subset of patients with more 
severe DM2 patients was selected. Rather, these subjects may be thought to 
represent a sample of diagnosed and treated Indonesian patients with DM2 . 
However, true DM2-associated increased periodontitis risk may be 
underestimated, because a substantial portion of DM2 often goes 
undiagnosed. Likely, these patients have worse blood sugar control and 
consequently worse periodontal status. On the other hand, the DM2 patients 
that were recruited from a dental hospital may have visited this hospital for 
periodontitis, overestimating DM2 associated periodontitis prevalence in this 
subgroup. Likewise, because controls were all selected from the same dental 
hospital, the prevalence of periodontitis in controls may also have been 
overestimated. Because the prevalence in both groups might be 
overestimated, the overall effect on calculated DM2 associated periodontitis 
risk may have been small. Finally, selection of healthy controls at a dental 
hospital may not be representative of the general Indonesian population 
without DM2. Thus, although some threats to the generalizability of our 
results remain, the increased DM2 associated periodontitis risk does appear to 
have sufficient generalizability and might sooner have been underestimated 
rather than overestimated.   
The finding that DM2 subjects have an increased prevalence and 
severity of periodontitis is in accordance with other studies. 30, 38, 39 A major 
achievement of present study is that a large variety of methods to 
operationalize periodontitis prevalence and severity has been applied, and 
that the conclusions that could be drawn from the results were irrespective of 
the measures used. This indicates that this association is robust. Because the 
prevalence of DM2 in Indonesia, and South East Asia, is already high and is 
predicted to rise further, the prevalence and severity of periodontitis may also 
rise. Due the vast number of people living in Indonesia, and South East Asia, 
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and the proposed bilateral association between DM2 and periodontitis, this 
will increasingly pose serious problems to public health.  
Two main mechanisms are thought to underlie the proposed bilateral 
association between DM2 and periodontitis. One underlying mechanism is 
that DM2 may alter local immune responses within periodontal tissue. DM2 
may result in small vessel damage within the periodontium, resulting in poor 
nutrient delivery, decreased oxygen diffusion and decreased elimination of 
metabolic waste products. 40 Furthermore, hyperglycaemia alters collagen 
metabolism which predisposes to impaired wound healing. In general, 
hyperglycemia results in the formation of proteins known as advanced 
glycation end products (AGEs). AGEs may be associated with a state of 
enhanced oxidative stress, thereby accelerating tissue injury. AGEs also 
function as a chemotactic for monocytes, thereby magnifying the 
inflammatory response, delaying wound healing and tissue repair and 
inducing connective-tissue damage and bone resorption. Finally, 
hyperglycaemia and the imbalance in lipid metabolism impair neutrophil and 
monocyte functioning. 41, 42-44 All of these factors may contribute to DM2 
predisposing to periodontitis.  
The second underlying mechanism of the association between DM2 
and periodontitis is that periodontitis may play a role in initiating, or 
exacerbating DM2. 7, 43, 45 Periodontitis poses an inflammatory burden 
consisting of increased serum levels of inflammatory mediators, like C-
reactive protein and Interleukin-6. 46 This inflammatory burden in turn leads 
to deteriorating blood glucose control in DM2 patients. 43 The higher the 
amount of inflamed periodontal tissue, the higher the inflammatory burden, 
and the poorer blood glucose control in DM2 patients may be thought to be.  
PISA quantifies the amount of inflamed periodontal tissue (representing it as 
the surface area of inflamed periodontal epithelium in square millimeters), 
and it is suggested that PISA thereby quantifies the inflammatory burden 
posed by periodontitis. 31 It was shown that there is indeed a dose-relationship 
between PISA and HbA1c in DM2 patients in the Dutch Caribbean. 47 
Likewise, the  finding of a significantly higher PISA among DM2 subjects in 
the present study  may mean that periodontitis is a risk factor for poor glucose 
control. Treating periodontitis might improve blood glucose control, 8-13 and 
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prevention and treatment of periodontitis in patients with DM2 might 
contribute to better general health in patients with DM2 . 48, 49  
Conclusions 
This study shows that periodontitis prevalence is significantly higher in a 
group of Indonesian patients with DM2 patients compared to a group of 
healthy Indonesians. Furthermore, Indonesian subjects with DM2  have more 
extended and more severe periodontitis than healthy Indonesian subjects. 
Given the already high and increasing prevalence of DM2 in Indonesia, 
patients with DM2  should be screened for periodontitis and preventive oral  
health care should become part of the regular care provided to Indonesian 
patients with DM2. Given the proposed bilateral association between DM2 
and periodontitis, such care may contribute to better oral and overall health. 
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Periodontal inflamed surface area and  
c-reactive protein as predictors of HbA1c:  


























Objectives: Periodontitis may exert an infectious and inflammatory burden, 
evidenced by increased c-reactive protein (CRP). This burden may impair 
blood glucose control (HbA1c). The aim of our study was to analyze whether 
periodontitis severity as measured with the periodontal inflamed surface area 
(PISA) and CRP predict HbA1c levels in a group of healthy Indonesians and a 
group of Indonesians treated for type 2 diabetes mellitus (DM2).  
Materials and methods: A full mouth periodontal examination, including 
probing pocket depth, gingival recession, clinical attachment loss, plaque 
index and bleeding on probing, was performed in 132 healthy Indonesians and 
101 Indonesians treated for DM2. Using these data, PISA was calculated. In 
addition, HbA1c and CRP were analyzed. A validated questionnaire was used 
to assess smoking, body mass index (BMI), education and medical conditions. 
In regression analyses, it was assessed whether periodontitis severity and CRP 
predict HbA1c, controlling for confounding and effect modification (i.e. age, 
sex, BMI, pack years, education). 
Results: In healthy Indonesians, PISA and CRP predicted HbA1c as did age, 
sex, and smoking. In Indonesians treated for DM2, PISA did not predict 
HbA1c.  
Conclusions: Periodontitis may impair blood glucose regulation in healthy 
Indonesians in conjunction with elevated CRP levels. The potential effect of 
periodontitis on glucose control in DM2 patients may be masked by DM2 
treatment.  
Clinical relevance: periodontitis may impair blood glucose control through 
exerting an inflammatory and infectious burden evidenced by increased levels 









Periodontal inflamed surface area (PISA) quantifies the amount of inflamed 
periodontal tissue and is supposed to quantify the inflammatory and 
infectious burden resulting from periodontitis [1]. Periodontitis may cause an 
inflammatory burden through the production of local inflammatory mediators 
entering the systemic circulation. This inflammatory burden is evidenced by 
increased serum c-reactive protein (CRP) levels found in patients suffering 
from periodontitis [2-7].  
Periodontitis may also cause an infectious burden through bacteria and 
their products entering the systemic circulation. This burden may endanger 
overall health by for example causing atherosclerosis [8] and cardiovascular 
diseases [9]. Circulating oral bacteria and lipopolysacharides are also able to 
stimulate hepatocytes to secrete CRP [10-12]. Thus, increased levels of CRP 
associated with periodontitis may be considered as a common pathway for 
both the inflammatory and infectious burden as a resulting from periodontitis. 
The high levels of CRP accompanying periodontitis, may lead to insulin 
resistance and thereby to poor control of blood glucose in type 2 diabetes 
mellitus (DM2) and healthy subjects [13-16] resulting in increased levels of 
glycated haemoglobin (HbA1c) [17, 18]. Accordingly, high levels of CRP are 
correlated with increased HbA1c levels in DM2 patients [19, 20]. Increased 
CRP levels have also been associated with an increased risk of cardiovascular 
disease (CVD) in DM2 patients, the major cause of the increased mortality in 
DM2 patients [21, 22].  
Given the importance of blood glucose control in preventing CVD in 
DM2 patients, relatively few studies assessed whether the specific 
combination of periodontitis and CRP as a reflection of inflammatory burden, 
predict HbA1c levels [23, 24]. Furthermore, no study has investigated this 
issue in Indonesia, while this country is in the top ten of countries with the 
highest prevalence of DM in the world with a  prevalence of DM of 5,7 % in 
2005. It has been estimated that by the year 2030, the prevalence of DM in 
Indonesia will be about 10%, corresponding with 20 million DM patients [26]. 
In addition to a high DM prevalence, in Indonesia a high prevalence of 
periodontitis has been reported [27]. Finally, depending on the definition 
used, our previous study showed that Indonesian DM2 patients have a 
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prevalence of periodontitis of 72 to 93% and an increased severity of 
periodontitis [28]. Therefore, the aim of this study was to assess whether 
periodontitis severity, as measured with the periodontal inflamed surface area 
(PISA) method and CRP predict HbA1c levels in healthy Indonesians and 
Indonesian treated for DM2 patients. 
 
Materials and methods 
The participants in this study were recruited from three different sites, namely 
1) The Internal Medicine Department Dr. Sardjito Hospital, Yogyakarta 2) 
Prof. Soedomo Dental Hospital, Faculty of Dentistry, Gadjah Mada University, 
Yogyakarta and 3) Diabetes Center of Jogjakarta International Hospital, 
Yogyakarta Indonesia. All participants had to be aged > 18 years and had to 
have ≥ 8 remaining teeth. The latter inclusion criteria was proposed prior to 
commencing the study, since current inflammatory burden posed by 
periodontitis requires the presence of at least a minimum number of teeth 
affected by periodontitis. This study was approved by the Ethical Committee 
for Research of the Medical Faculty of Gadjah Mada University, Yogyakarta, 
Indonesia.  
All participants completed a validated general health assessment 
questionnaire [29, 30] to check for other medical conditions that might be a 
risk factor for periodontitis. Information on age, gender, height and weight 
(for body mass index (BMI) calculation), education and smoking were 
obtained from each participant.  
All participants underwent a periodontal examination including 
periodontal probing pocket depth (PD), gingival recession, plaque score and 
bleeding on probing (BOP) measurements by trained and calibrated 
examiners (HS, YHR, EH). All measurements were performed on all teeth, on 
six sites per tooth using a manual periodontal colour coded standard probe 
(Dentsply TM, London, UK). 
Clinical attachment loss (AL) was defined as the distance from the 
cemento enamel junction (CEJ) to the bottom of the pocket/sulcus, and 
calculated as the mathematical sum of the PD and gingival recession 
measurements [31]. Measurements were made in millimeters and were 
rounded of to the nearest millimeter. BOP was recorded as either present or 
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absent within 30 seconds of probing at 6 sites per tooth. Plaque score was 
defined as being present or absent at 6 points on each tooth [32]. The number 
of missing teeth was also recorded.   
Periodontitis extent and severity were operationalized using a variety of 
methods, all of which are currently used in literature studying the association 
between periodontitis and other diseases. All measurements were calculated 
using conventional clinical measurements obtained during the full mouth 
periodontal examination (HS and WN). The number of sites with probing PD 
>4, >5 and >6 mm, the numbers of sites with clinical AL >3, >4, >5 and >6 
mm, mean PD, mean AL [33] and the percentage of sites with BOP were 
calculated. Additionally, a recently introduced measure of periodontitis 
severity, the periodontal inflamed surface area (PISA) [1] was calculated, PISA 
quantifies the amount of inflamed periodontal tissue, and it is suggested that 
PISA thereby quantifies the inflammatory burden exerted by periodontitis [1].  
Finally, all participants underwent a venapuncture to obtain a blood sample. 
Both blood glucose (fasting blood glucose), determined by glucose oxidase 
enzymatic method, and glycosilated/glycated hemoglobin (HbA1c) values, 
determined using low pressure cation ion exchange chromatography 
(DIASTAT™, Bio-Rad, USA), were determined for all participants. 
Additionally, CRP, determined by a high-sensitivity chemiluminescent 
immunometris assay (Immulite 2000™, Diagnostic Products Corp., Los 
Angeles, CA, USA), were determined for all participants.  
 
Statistical analysis  
Differences in periodontitis severity between DM2 and healthy subjects were 
analyzed first using univariate analyses (independent sample t-test, Mann-
Whitney U-test or Chi-square test as appropriate). Likewise, differences in 
potential predictors of periodontitis (age, gender, body mass index (BMI), 
education, smoking, plaque score, number of teeth, ethnicity and other 
medical conditions) between DM2 patients and healthy subjects were tested 
for significance using univariate analyses. Since periodontitis severity was 
operationalized in 12 different ways, significance level α of 0.05 was corrected 
for multiple comparisons according to the Bonferroni-Holm method.  
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To assess periodontitis and CRP as potential predictors of HbA1c in 
subjects with and without DM2, a multiple linear regression analysis was 
performed, using a backward stepwise method. HbA1c was the dependent. As 
independent variables, i.e. predictors of HbA1c: age, sex, BMI, pack years, 
education, CRP and all measures of periodontitis severity. The latter were 
introduced in the model one by one. Statistics were calculated using SPSS 
16.0.   
 
Results 
In total  101 participants ( 40 men and 61 women ) with a mean age of 54 years 
treated for DM2, diagnosed according to WHO criteria [34] were included 
(Table 1).  Most of the participants were of Javanese origin (93.0 %). The 
mean BMI in this group was 25.5, labeling them as being overweight 
according to the World Health Organization classification (overweight: BMI 
23-27.5) [35]. The DM2 patients had an average of 24 teeth with a mean 
plaque score of 91% (Table 2). The mean HbA1c in the DM2 group was 8.9%.  
In addition, a 132 healthy controls was enrolled, 34 men and 98 women, with 
a mean age of 48 years. Again, the healthy subjects were mainly of Javanese 
origin (90%) and were on average ranked as being overweight according to the 
BMI index for Asian populations (BMI: 24.4) [35]. The healthy subjects had 
an average of 26 teeth and a mean plaque score of 93 %.  The average HbA1c 
level of this group was 5.5% (below 6.5% classified as healthy/non diabetic).  
The severity of periodontitis was significantly higher in participants 
with DM2 when compared to controls, again independent of the method used 
to operationalize periodontitis severity (table 2). In the DM2 patients, none of 
the measures of periodontitis severity predicted HbA1c. Only SES (β = -0.752, 
95% CI = -1.345 to -0.158) was a predictor of HbA1c, (r2 of 6.0%) (data not 
shown). By contrast, in healthy Indonesians, PISA (ß = 0.0004, 95% CI = 
0.00004-0.00076) was a predictor of HbA1c together with age, sex, smoking 





Table 1. Characteristics of the participants. 
 
 
*Result of Chi-square test; † result of Mann Whitney U-test, other results are 
the results of the independent samples t-test; p: probability, p values were 
Bonferroni-Holm corrected,  a p-value of < 0.05 was considered statistically 
significant; BMI: body mass index; CRP: c-reactive protein; DM2: diabetes 
mellitus type 2; HbA1c: glycated hemoglobin; IQR: inter quartile range; n: 
number of participants; NA: not applicable; SD: standard deviation; 
Education: low: elementary & junior school, middle: high school, high: 
university), yrs: years 
Variables DM2 (n=101)  Healthy controls 
(n=132)  
p value 
    
Demography    
    
Age (yrs) mean (SD)  54.4 (10.7) 47.9 (10.1) <0.001 
Smoking (pack year) median 
(IQR)† 
0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.109 
BMI (kg/m2) mean (SD) 25.5(4.2) 24.4 (3.8) 0.054 
Java origin n (%)* 94 (93) 119 (90) 0.431 
Gender n (%)*   <0.05 
              Male 40 (40) 34 (26)  
              Female 60 (60) 98 (74)  
Education n (%)*  2.18 (0.79) 2.13 (0.77) 0.662 
                  Low (6-9yrs) 32 (24)  24 (23)  
    Middle (9-12 yrs) 51 (39) 34 (34)  
   High (12-17 yrs) 49 (37) 43 (43)  
Hypertension (yes) n (%)* 26 (26) 24 (18) 0.164 
Medication n (%)    
                    Sulfonylurea  55 (54) NA NA 
                    Insulin 41 (41) NA  
                    Metformin  37 (37) NA  
                    Acarbose 33 (33) NA  
    
Laboratory serum 
markers 
   
    
HbA1c (%) Mean (SD) 8.9 (2.4) 5.5 (0.4)  <0.001 
CRP (mg/l) Median (IQR)† 2.8(1.6 to 7.0) 1.1 (0.6 to 2.3) <0.001 
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Table 2. Periodontal status of healthy controls and DM2.  
 






    
Periodontal prevalence: n 
(%)* 
   
PD ≥4mm AL ≥3mm 89 (67) 89 (88) <0.001 
PD ≥5mm AL ≥2mm 43 (33) 67 (66) <0.001 
    
Periodontal severity: 
median (IQR)† 
   
PISA (mm2) 83.9 (35.2 to 
206.4) 
170.4 (91.5 to 
392.6) 
<0.017 
AL (mm) 1.8 (1.7 to 2.3) 2.4 (2.0 to 3.4) <0.001 
PD (mm) 1.7 (1.6 to 1.9) 1.9 (1.7 to 2.4) <0.001 
Number of sites: median 
(IQR)† 
   
 AL ≥ 3 mm 30.0 (17.0 to 47.0) 54.0 (32.50 to 
74.50) 
<0.001 
 AL ≥ 4 mm 5.0 (1.0 to 15.8) 25.0 (9.0 to 48.0) <0.001 
 AL ≥ 5 mm 1.0 (0.0 to 4.8) 13.0 (2.0 to 31.50) <0.001 
 AL ≥ 6 mm 0.0 (0.0 to 1.0) 4.0 (0.0 to 19.5) <0.001 
 PD ≥ 4 mm 2.0 (0.0 to 4.0) 6.0 (2.0 to 18.0) <0.001 
 PD ≥ 5 mm 0.0 (0.0 to 1.0) 2.0 (0.0 to 8.0) <0.001 
 PD ≥ 6 mm 0.0 (0.0 to 0.0) 1.0 (0.0 to 3.0) 0.001 
 BOP (n %) 9.0 (4.0 to 20.0) 18.0 (10.0 to 31.5) <0.001 
    
Mean (SD)    
 Plaque Score (%)   93 % (8.5)   91 % (7.9)   
    
    
 
* Result of Chi-square test; † result of Mann Whitney U-test; other results are 
the results of the independent samples t-test; p: probability, p values were 
Bonferroni-Holm corrected, a p-value of < 0.05 was considered statistically 
significant; BOP: bleeding on probing; AL: clinical attachment loss; DM2: 
diabetes mellitus type 2; IQR: inter quartile range; n: number of participants; 
























































0.00004 to 0.00076 
0.00431 to 0.01674 
-0.29170 to 0.01595 
-0.00074 to 0.01805 
-0.00093 to 0.04343 
4.62706 to 5.29121 
 
* Other measures of periodontitis severity were not predictors of HbA1c; p = 
probability, a p-value of < 0.05 was considered statistically significant; β: 
unstandardized coefficient; Dependent variable: HbA1c :glycated hemoglobin; 
Independent variables: PISA, age, sex, smoking/pack years, CRP : C-reactive 
protein; Constant . 
 
Discussion 
This study showed that PISA is a predictor of HbA1c, in conjunction with CRP, 
age, sex and smoking, in healthy Indonesians. Thus, periodontitis may play a 
role in inducing impaired blood glucose control. Indeed there is evidence that 
periodontitis may induce insulin resistance [18]. It is thought that 
periodontitis exerts an inflammatory and infectious burden as evidenced by 
increased levels of CRP [3, 5, 6] which may increase HbA1c levels [19, 20, 36]. 
Accordingly, PISA predicted HbA1c together with CRP.  
It is striking that out of the various methods to operationalize 
periodontitis severity, only the PISA emerged as a predictor of HbA1c. The 
other methods for determining the severity and extent of periodontitis did not 
contribute significantly to a model that predicts HbA1c. It may be that the 
PISA is a predictor of HbA1c because it reflects the amount of inflamed 
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periodontal tissue, thereby predicting both infectious and inflammatory 
burden more accurately than other methods used to operationalize 
periodontitis [1, 18].  
In Indonesian DM2 patients,no measure for periodontitis severity 
predicted HbA1c. The observed differences between DM2 patients and healthy 
Indonesians may be explained as follows. First, almost all DM2 patients used 
a combination of medication to control blood sugar, drugs that healthy 
Indonesians obviously did not take [37]. Use such medication may mask an 
effect of periodontitis on the HbA1c level in DM2 patients. Second, DM2 
patients may have dietary restrictions, e.g. avoiding sugar rich foods. Such a 
diet may impact blood sugar and may mask an affect of periodontitis on 
HbA1c level.  
Previously, a dose-response relationship was observed between PISA 
and HbA1c in DM2 patients from the Caribbean island, Curacao [18]. 
Additionaly, an increased HbA1c was observed to be associated with increased 
severity of periodontitis. [38]. Moreover, it has been reported that periodontal 
treatment leads to improvement of glycemic control in DM2 patients [39]. 
These findings appear to be in sharp contrast with the findings in this study, 
i.e. PISA is not a predictor of HbA1c in a group of Indonesian DM2 patients. 
The difference between the current study and the study in Curacao [18] could 
be explained by differences in populations. First, substantial differences were 
observed in the frequency of antidiabetics used between DM2 from Indonesia 
and Curacao. Acarbose (33 vs. 5%), insulin (41 vs. 21%) and sulfonylurea (54 
vs. 35%) were used more often in DM2 patients from Indonesia, while 
metformin 37 vs. 67% was used more often in DM2 patients from Curacao. 
Additionally 16% of DM2 patients from Curacao used tolbutamide, while none 
of Indonesian DM2 patients used it. Differences in the frequency of 
antidiabetics used, may also explain the differences in results. As reported by 
Teeuw et al [38] and Simpson et al [39], HbA1c levels might be affected by the 
treatment DM2 patients receive. i.e. both the drugs they use and the 
periodontal treatment the patients have received. Thus a drug-related 
reduction in HbA1c levels in patients not yet adequately periodontally treated 
might be responsible for the failure of PISA to predict HbA1c levels in our 
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Indonesian DM2. Second, the average BMI of DM2 patients from Curacao was 
31, while the average BMI of Indonesian DM2 patients was substantially 
lower, namely 25. BMI may be an effect modifier, i.e. a higher BMI may 
increase the potential insulin resistance inducing effect of periodontitis in 
DM2 patients [40, 41]. Third, there is a clear difference in ethnicity between 
the two groups, i.e. one from Indonesia of Javanese origin and the other from 
Curacao of African-American origin. Possible differences in (health 
promoting) behavior, diet and genes, related to the differences in ethnicity, 
may be another explanation for the differences in results [42, 43].  
 
Conclusions  
PISA was shown to be a predictor of HbA1c in healthy Indonesians in 
conjunction with CRP, age, sex, and smoking. This implies that periodontitis 
might contribute to insulin resistance through the inflammatory and 
infectious burden leading to DM2. In Indonesian patients, treated for DM2, 
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Background: Patients with rheumatoid arthritis (RA) may have more 
prevalent and severe periodontitis than healthy controls. Periodontitis may 
increase the systemic inflammation in RA.  
Aim: To assess periodontitis prevalence and severity and its potential 
association with systemic inflammation  in Indonesian RA patients.  
Methods: A full mouth periodontal examination including probing pocket 
depth, gingival recession, plaque index and bleeding on probing was 
performed in 78 Indonesians with RA and 132 Indonesian controls. A 
validated questionnaire was used to assess smoking, body mass index, 
education and medical conditions. In addition, in all participants the use of 
drugs was noted and erythrocyte sedimentation rates and serum levels of high 
sensitivity test c-reactive protein, rheumatoid factor and anti citrullinated 
protein antibodies were measured. Differences in periodontitis prevalence 
and 12 measures of periodontitis severity between RA patients and controls 
were analyzed using univariate analyses. 
Result: There were no significant differences in periodontitis prevalence and 
12 measures of periodontitis severity between RA patients and controls, 
except the number of sites with clinical attachment level ≥3mm, which was 
significantly larger in controls (p=0.041). On the other hand, there was a 
tendency towards a lower surface area of healthy pocket epithelium in RA 
patients versus controls (p=0.052) as well as a trend towards higher high 
sensitivity c-reactive protein levels in RA patients with severe periodontitis 
compared to RA patients with no/mild or moderate periodontitis (p=0.087). 
It has to be noted that all RA subjects used anti-inflammatory drugs, while 
none of the controls used such drugs. 
Conclusion: Prevalence and severity of periodontitis in Indonesian RA 
patients is comparable to controls, but with a tendency of less healthy 
pocketepithelium than in controls and a higher inflammatory state in RA 







Rheumatoid Arthritis (RA) is an autoimmune disease characterized by 
symmetric inflammation of mainly hand and wrist joints, which leads to 
permanent deformity and destruction of these joints1. RA impairs quality of 
life and is associated with early mortality. The cause of RA is still unknown2. 
Studies in Australia, America, Europe and Africa have shown that RA patients 
have more prevalent and severe periodontitis than non-RA controls when 
controlling for important confounders like dental plaque, age, sex and 
smoking3-10. Studies in Sweden, Brazil, USA, Turkey, and Japan, however, did 
not find a higher prevalence and severity of periodontitis in RA patients11-15. In 
other words, the prevalence and severity of periodontitis in RA patients may 
be influenced by genetic, dietary, cultural and other differences associated 
with differences in nationality and ethnicity16. Although Caucasian, African 
American, Latin American, North-African and Japanese populations have 
been studied3-9, 12, no study has yet been performed in a South East Asian 
population.  
In addition to differences in results due to variations in nationality and 
ethnicity, the association between RA and periodontitis may also differ 
because a variety of definitions for periodontitis prevalence and severity has 
been used17. Although various studies have assessed the association between 
periodontitis and RA, no study has yet investigated the effect of using several 
definitions for periodontitis prevalence and severity on the association 
between periodontitis and RA. 
Recently a few pilot-intervention studies have pointed towards 
periodontitis as a risk factor for RA18-21. After treating periodontitis, a 
reduction in RA disease activity was shown, possibly related to a reduction in 
periodontitis associated inflammatory burden. Periodontitis poses an 
inflammatory burden, as evidenced by increased levels of erythrocyte 
sedimentation rate (ESR) and c-reactive protein (CRP) in RA patients with 
periodontitis3-6. Thus, periodontitis may increase systemic inflammation, 
which may in turn lead to increase RA severity17, 22. Likewise Helicobacter 
pylori infections may contribute to increase RA severity by posing 
inflammatory burden, while eradication of this bacterium in RA patients 
improves clinical condition and laboratory markers of RA disease activity23.  
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Thus, the aims of this study were to compare periodontitis prevalence 
according to the case definitions of Page and Eke (2007)24 and periodontitis 
severity in Indonesian RA patients with Indonesian controls, using a variety of 
definitions for periodontitis severity. In addition, it was analyzed whether 
inflammatory burden differed between participants with or without 
periodontitis, both for RA patients and controls. 
  
 
Subjects and methods 
Between July 2008 and February 2009, all consecutive RA patients visiting 
the Internal Medicine Department of the Dr. Sardjito Hospital Yogyakarta, the 
Clinic for rheumatology of PKU Muhammadiyah Hospital Yogyakarta, or a 
private rheumatology clinic in Surabaya, Indonesia that matched the inclusion 
criteria were informed about the nature of the study and were asked to 
participate. All RA patients had been diagnosed by rheumatologists (NK and 
JS) according to revised American College of Rheumatology (ACR) 1987 
criteria1 and were on a regular recall schedule for RA. During the same period, 
controls were recruited from the consecutive patients that visited the Prof. 
Soedomo Dental Hospital, Faculty of Dentistry Gadjah Mada University, 
Yogyakarta for their routine dental check-up. Likewise, these controls were 
informed about the nature of the study and asked to participate. The inclusion 
criteria for RA patients and controls were an age ≥18 years and having ≥ 8 
remaining teeth. The number of 8 remaining teeth was chosen since there 
should at least be a minimum periodontitis-associated inflammatory burden, 
given this inflammatory burden decreases with decreasing number of teeth 
(e.g. edentulous patients don’t have any periodontitis-associated 
inflammatory burden). Exclusion criteria were presence of other systemic 
diseases or conditions (e.g diabetes) which are known as risk factors for 
periodontitis25 and a history of treatment for periodontal disease. With regard 
to controls, additional exclusion criteria were the use of medication or 
consuming drugs which are known to be risk factors for periodontitis. This 
study was approved by the Ethical Committee for Research of the Medical 
Faculty of Gadjah Mada University, Yogyakarta, Indonesia. Informed consent 
was obtained from all patients and controls. A ratio of about 1:2 between RA 
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patients and controls was aimed, but as recruiting of control subjects was 
limited to the same period as recruiting RA patients, we ended with a 1:1.7 
ratio. We considered this ratio as sufficient for the purpose of our study.  
All participants had to complete a validated general health assessment 
questionnaire assessing the presence of other diseases and the use of 
medication. This questionnaire was composed of questions assessing 
symptoms related to systemic diseases such as heart disease, pulmonary 
disease, endocrine disorders, hematologic disease, gastro-intestinal disorders, 
genitourinary disorders and neurological disease, and the use of 
medications25. Additionally, information about age, sex, smoking (current and 
pack years), education level and body mass index (BMI) was obtained by 
means of a questionnaire.  
All participants underwent a full mouth periodontal examination on six 
sites per tooth assessing probing pocket depth (PPD), gingival recession, 
plaque score, bleeding on probing (BOP) and clinical attachment loss (CAL)26. 
All permanent fully erupted teeth were examined with a manual periodontal 
colour coded standard probe. Measurements were made in millimetres and 
were rounded to the nearest whole millimetre. BOP was recorded as either 
present or absent within 30 seconds of probing. Plaque score was defined as 
being present or absent at 6 points on each tooth3 The number of missing 
teeth was also recorded. 
Periodontitis prevalence was established according to Page and Eke 
(2007)24 case definitions. Periodontitis severity was operationalized using a 
variety of methods (number of sites with PPD >4, >5 and >6 mm, number of 
sites with CAL >3, >4, >5 and >6 mm, mean PPD, mean CAL and percentage 
of sites with BOP anywhere in the dentition) all currently used to study the 
association between periodontitis and other diseases27-29. To facilitate 
calculation a freely accessible spreadsheet was used online. Furthermore, two 
recently introduced measures of periodontitis severity, the periodontal 
epithelial surface area (PESA) and the periodontal inflamed surface area 
(PISA) 30 were calculated, again using the same spreadsheet†. PESA reflects 
                                               
 Dentsply, London, United Kindom 
† www.parsprototo.info; Microsoft Excel 2003 spreadsheet for Windows 
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the surface area of all pocket epithelium in square millimetres, whereas PISA 
reflects the surface area of bleeding pocket epithelium in square millimetres. 
PESA and PISA were calculated using conventional CAL, gingival recession 
and BOP measurements. PISA quantifies the surface area of inflamed 
periodontal tissue in square mm. PISA is a measure of inflammatory burden 
posed by periodontitis28, 30 
Finally, a blood sample via vena puncture was taken from all 
participants (RA patients and controls) to determine CRP, ESR, RF, and 
ACPA. High sensitivity c-reactive protein (hsCRP) was determined by 
chemiluminescent enzyme immunoassay‡ (Immulite 2000™, Diagnostic 
Products Corp., Los Angeles, CA, USA), ESR was determined by Westergren, 
rheumatoid factor (RF) was determined by latex agglutination methods and 




Data are presented as mean and standard deviation (SD) in case of normal 
distribution, medians and interquartile range (IQR) in case of non-normal 
distribution and percentages for categorical data. Differences between RA 
patients and controls were analyzed using independent sample t-test or Mann 
Whitney U, in case of a non-normal distribution, and Chi-square test. 
Differences between periodontal status groups within RA patients and 
controls were analyzed using non-parametric analyses, i.e. Kruskall-Wallis 




Prevalence and severity of periodontitis in RA patients and controls 
In total, 78 RA patients (median disease duration 4 years (IQR 2.0; 6.5, range; 
1- 15 years) and 132 controls were included. All consecutive RA patients and 
controls that fulfilled the inclusion criteria during the recruiting period agreed 
                                               
‡ Immulite 2000™, Diagnostic Products Corp., Los Angeles, CA, USA 
§ ELISA; Euroimmun™, Medizinische Labordiagnostika AG, Germany  
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to participate in this study. The characteristics of the participants, including 
the use of medication, are summarized in table 1. Mean BMI of RA patients 
was significantly lower than controls (p<0.001) and there was a tendency 
towards a significantly higher plaque score in RA patients (p=0.062). None of 
controls used medication, other than birth control pills or antihypertensives. 
No significant differences were observed regarding periodontitis prevalence. 
Periodontal disease severity was significantly lower in RA group compared to 
control group when defined as number of sites with CAL ≥3 mm. There was a 
tendency towards a significantly (p=0.052) lower PESA, the surface area of 
healthy pocket epithelium, for RA patients compared to controls. (table 2). 
 
Serum laboratory markers in RA patients and controls according to 
periodontal status 
RA patients with severe periodontitis had a lower plaque score (p=0.014) and 
were older (p=0.075) than RA patients with no, mild or moderate 
periodontitis. There was a trend towards higher hsCRP levels in RA patients 
with severe periodontitis (p=0.087).  
Low education level and smoking were more common among RA patients 
with severe periodontitis (p-values resp. 0.044 and 0.092). Smoking was 
more common among controls with severe periodontitis (p-value 0.081) 
(table 4). 
 
Table 1. Characteristic of RA patients and controls including factors 
associated with periodontitis severity.  




p value Difference  
(95% CI) 
Sex (woman) n (%) 62 (80%) 98 (74%) 0.389*  
Education (low) n (%) 46 (59%) 83 (63%) 0.574*  
Java origin (yes) n (%) 66 (85%) 119 (90%) 0.231*  
Smoking (yes) n (%) 5 (6%) 14 (11%) 0.306*  
Age (yr) mean (SD) 45.5 (12.2) 47.9 (10.1) 0.145† 2.4 (-0.84 to 5.6) 
BMI (kg/m2) mean (SD) 22.3 (3.8) 24.4 (3.8) <0.001† 2.2 (1.1 to 3.3) 
Number of teeth median (IQR) 27 (22; 29) 27 (24; 29) 0.379‡  
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Plaque score (%) mean (SD)  
Medication: 
- Corticosteroid (prednisolone) 
- Methotrexate 
- Cloroquine 






- Birth control pills 



























*Results of Chi-square test; †results are the results of the independent samples t-test; 95% CI: 95% confidence 
interval; ‡result of Mann-Whitney U test; BMI: body mass index; Education: low: elementary, junior & high 
school; p: probability; RA: rheumatoid arthritis; SD: standard deviation; yr: year
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Table 2. Differences in periodontitis prevalence and severity between RA patients 
and controls. 




p value Difference  
(95% CI) 
Periodontitis prevalence n (%) n (%)   
 - No/mild periodontitis§ 25 (32%) 35 (27%) 0.420*  
 - Moderate periodontitis 37 (47%) 75 (57%)   
 - Severe periodontitis 16 (21%) 22 (17%)   
Periodontitis severity: mean (SD)     
PESA (mm2)  816.7 (305.8) 892.2 (247.1) 0.052† 75.5 (-151.6 to 0.6) 
PISA (mm2)  96 (42; 176) 84 (35; 206) 0.832‡  
Number of sites:     
 CAL ≥ 3 mm  22 (9; 41) 30 (17; 47) 0.041‡  
 CAL ≥ 4 mm  5 (1; 15) 5 (1; 16) 0.872‡  
 CAL ≥ 5 mm  1 (0; 5) 1 (0; 5) 0.838‡  
 CAL ≥ 6 mm 0 (0; 1) 0 (0; 1) 0.688‡  
 PPD ≥ 4 mm 1 (0; 4) 2 (0; 4) 0.296‡  
 PPD ≥ 5 mm 0 (0; 1) 0 (0; 1) 0.632‡  
 PPD ≥ 6 mm 0 (0; 0) 0 (0; 0) 0.709‡  
 BOP  10 (6; 20) 9 (4; 20) 0.255‡  
PPD (mm)  1.7 (0.4)) 1.8 (0.3) 0.148† 0.07 (-1.2 to 0.03) 
CAL (mm)  2.0 (0.8) 2.0 (0.7) 0.841† 0.02 (-0.2 to 0.2) 
*Result of Chi-square test; †results of the independent samples t-test; ‡result of Mann-Whitney U test; 
§According to the criteria of Page and Eke (2007); 95% CI: 95% confidence interval; BOP: bleeding on probing; 
CAL: clinical attachment loss; p: probability; PESA: periodontal epithelium surface area; PISA: periodontal 
inflammation surface area; PPD: probing pocket depth; RA: rheumatoid arthritis; SD: standard deviation  
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Table 3. Biomarkers and characteristics of RA patients according to periodontal status.  
 










 Med IQR Med IQR Med IQR  




50.5 43.0; 55.5 0.075 
BMI 21.0 19.4; 
25.0 
22.2 19.8; 25.2 22.6 20.2; 
24.6 
0.828 




92.5 91.0; 97.5 0.014 
RA Since (years) 5.5 2.0; 10.0 4.0 2.0; 6.0 3.0 2.0; 5.0 0.222 
ACPA igG (RU/ml) 1.2 0.0; 46.1 0.0 0.0; 31.6 1.5 0.0; 78.4 0.588 







hsCRP (mg/l) 4.4 2.6; 6.6 3.3 0.8; 24.9 15.4 6.3; 21.8 0.087 
 % N % N % n  
Gender (women) 84% 21 84% 31 63% 10 0.134 
Education (low) 40% 10 68% 25 69% 11 0.044 
Smoking (yes) 0% 0 8% 3 13% 2 0.092 
RF (yes) 36% 9 16% 6 38% 6 0.838 
Med: median; IQR: Interquartile range; %: collum percentage. Differences in medians are tested using Kruskal-
Wallis test. Difference in percentages are tested using chi- square analyses (Linear by linear association), except 
differences in percentages of smokers, which is tested exactly because of expected cell count was not sufficient to 
meet the assumptions of the chi- square test. ACPA: anti citrullinated protein antibody; BMI: body mass index; 
hsCRP: high sensitivity c-reactive protein; ESR: erythrocyte sedimentation rate; hr: hour; n: number; p: 
probability; RU: relative unit; RF: rheumatoid factor; n: number 
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Table 4. Biomarkers and characteristics of controls according to periodontal status. 
 
 No or mild 
Periodontitis 
Moderate Periodontitis Severe Periodontitis p-value 
 n=35 n=75 n=22  
 Med IQR Med IQR Med IQR  























0.0 0.0; 0.6 0.0 0.0; 1.0 0.0 0.0; 0.0 0.967 







hsCRP (mg/l) 0.9 0.5; 1.7 1.2 0.6; 2.5 1.4 0.6; 3.4 0.152 
 % N % n % n  
Sex (women) 77% 27 71% 53 82% 18 0.880 
SES (low) 74% 26 59% 44 59% 13 0.183 
Smoking (yes) 3% 1 12% 9 18% 4 0.081 
RF (yes) 6% 2 0% 0 0% 0 0.096 
Med: median; IQR: Interquartile range, %: collum percentage. Differences in medians are tested using Kruskal-
Wallis test. Difference in percentages are tested using chi- square analyses (Linear by linear association), except 
differences in percentages of smokers, which is tested exactly because of expected cell count was not sufficient to 
meet the assumptions of the chi- square test. ACPA: anti citrullinated protein antibody; BMI: body mass index; 
hsCRP: high sensitivity c-reactive protein; ESR: erythrocyte sedimentation rate; hr: hour; n: number; p: 
probability; RU: relative unit; RF: rheumatoid factor; n: number 
 
Discussion 
The prevalence of moderate to severe periodontitis in RA patients in the current 
study is fairly high (68%), but similar to those reported in other studies3, 9. However, 
the prevalence of moderate to severe periodontitis in controls was also high (73%) 
and not significantly different. Likewise, some other studies reported no significant 
differences in periodontitis prevalence between RA patients and controls11-15. The vast 
majority of studies did find a higher prevalence of periodontitis in RA patients as 
compared to controls3, 7-9, however. Furthermore, an association between 
periodontitis and RA also has been shown in animal studies31-33. Both human and 
animal studies point towards an association between periodontitis and RA that might 
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be due to sharing similar inflammatory markers, viz. increased cytokines, matrix 
metalloproteinase and c-reactive proteins.  
The fact that the number of sites with CAL >3mm was significantly higher in 
Indonesian controls than in RA patients is apparently in sharp contrast with the 
above mentioned studies since it points towards healthy controls having more severe 
periodontitis than RA patients. However, the cut-off point of CAL ≥3mm is low and 
could even be considered as borderline pathology. Thus, the number of sites with 
CAL ≥3mm could simply be higher because RA patients were older than controls, 
given CAL increases with age. Furthermore, the surface area of healthy pocket 
epithelium (PESA) trended to be lower in RA patients than controls (p=0.052), 
pointing towards more severe periodontitis in RA patients. Another possible 
explanation for our findings may be the remarkably high periodontitis prevalence in 
Indonesian controls. This is not surprising, as the prevalence of periodontitis in 
Indonesian general population may, depending on the definition used, has been 
reported to be as high as 80%34. Furthermore, our findings might also in part be 
explained by the use of medication in RA patients. Since drugs used for RA reduce 
periodontitis severity12. More than half of the RA patients in our study were on 
corticosteroids (table 1). Corticosteroids have anti inflammatory activities by 
inhibiting proinflammatory protein as cyclooxygenase 2, interleukins (IL) 1, 2 and 6, 
tumor necrosis factor alpha and adhesion molecules35. Some RA patients used 
diclofenac (non-steroidal anti-inflammatory drug; NSAID). Diclophenac has anti-
inflammatory activity inhibiting cyclooxygenase, an enzyme that catalyzes the 
conversion of arachidonic acid to prostaglandins and tromboxanes. NSAIDs also have 
been shown to reduce alveolar bone loss in periodontitis36, 37. A high number of RA 
patients (table 1) also used disease modifying anti-rheumatoid drugs (DMARD) such 
as methotrexate, sulfasalazine, chloroquine, leflunomide. These drugs are taken to 
reduce the inflammatory component in RA36. Methotrexate in combinations with 
prednisolone decrease blood levels of Il-1β and IL-6 and inhibits the intensity of free 
radical-mediated processes in RA38, which also may decrease periodontal 
inflammation. 
Noteworthy is the fact that there was a tendency towards higher hsCRP levels 
in RA patients with moderate to severe periodontitis compared to those with no/mild 
periodontitis. Other studies also found higher levels of hsCRP in RA patients with 
periodontitis3, 6. No significant difference in hsCRP was observed between controls 
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with periodontitis and controls without periodontitis (table 4). Two main 
explanations can be given for these findings. Firstly, periodontitis may aggravate RA. 
Since periodontitis is accompanied by higher CRP levels39-43. The elevation of 
inflammatory cytokines (such as IL-1, IL-6) that are locally induced by periodontitis 
44 is thought to induce systemic inflammation by increasing serum CRP levels and 
thus to contribute to an increased systemic inflammation in RA45. Secondly, RA may 
aggravate periodontitis. Since more severe RA is also accompanied by higher CRP 
levels45, 46, higher CRP levels may be a reflection of active RA, which may contribute 
to an increased inflammatory state in periodontitis. Interestingly, CRP level reduces 
in RA patients after periodontal therapy21, lending support to the hypothesis that 
periodontitis may contribute to an increased systemic inflammation in RA.  
Another explanation of higher CRP levels in RA patients with moderate to 
severe periodontitis compared to RA patients with no/mild periodontitis may be 
confounding by impaired maintenance of oral hygiene, smoking and low education 
level. Regarding oral hygiene, RA affects the wrist joint and the small joints of the 
hand. The joint afflictions may impair motor function of the hand and as a result may 
impair maintenance of proper oral hygiene resulting in periodontitis47. However, RA 
patients with moderate to severe periodontitis had lower mean plaque score than RA 
patients with no/mild periodontitis. Therefore, impaired maintenance of oral hygiene 
in RA patients has probably not confounded the association between periodontitis 
and higher hsCRP levels. 
Smoking and low education level on the other hand may be negatively 
associated with general health and may thus confound the observed association 
between moderate to severe periodontitis and increased hsCRP levels in RA patients.  
Periodontitis prevalence and severity are not higher in Indonesian RA patients than 
in controls. However, the presence of moderate to severe periodontitis in RA patients 
appears to be associated with an increased hsCRP level. Recognition of the fact that 
periodontitis could promote a whole that is greater than the sum of its parts, i.e. a 
combination of hyperinflammation, hypercoagulation, hyperglycaemia, 
hypertriglyceridaemia and hypertension, could lead to new insights into the causes of 
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Treatment of periodontal disease improves  
the atherosclerotic profile: 
















Background - We designed a systematic review and meta-analysis to study the 
robustness of observations that treatment for periodontitis improves the 
cardiovascular risk profile. 
Methods and Results - A literature search (until January 2012) was performed. 
Selection of publications was based on two criteria: 1) original investigations, and 2) 
controlled periodontal intervention trials where the non-intervention group received 
no treatment. An independent screening of 3463 unique titles and abstracts 
(retrieved from three libraries) resulted in 14 publications, representing 19 
intervention trials that met the eligibility criteria. These studies enrolled 1034 
periodontitis patients. Seven trials enrolled periodontitis patients that were otherwise 
healthy, whereas 12 trials recruited periodontal patients also suffering from 
cardiovascular diseases (CVD) and/or metabolic disorders. In our meta-analysis, 
periodontitis was the predictor and inflammatory, metabolic and/or vascular markers 
were defined as outcomes. The meta-analysis, that included all available trials, 
demonstrated significant weighted mean differences (WMD) for hsCRP (-0.43 mg/L, 
CI: -0.70;-0.16; p=0.002), total cholesterol (-0.14 mM, CI: -0.24;-0.03; p=0.009) 
and HbA1c (-0.45%, CI:-0.70; -0.19; p=0.0006) favoring periodontal intervention. 
Importantly, periodontitis patients suffering from CVD and/or metabolic disorders 
benefited most from periodontal therapy; significant WMD were observed for levels 
of hsCRP (-0.62 mg/L, CI:-0.97;-0.27; p=0.0005), IL-6 (-1.15 ng/L, CI:-1.63;-0.67; 
p<0.00001), total cholesterol (-0.15 mM, CI:-0.29;-0.01; p=0.03) and HbA1c  (-
0.45%, CI:-0.70;-0.19, p=0.0006).  
Conclusions - Our systematic review and meta-analysis demonstrates that 
periodontal treatment reduces biomarkers of atherosclerotic disease in periodontitis 
subjects, especially in those already suffering from CVD and/or metabolic disorders. 
This emphasizes the need for periodontal diagnosis and therapy in atherosclerotic 
and diabetic individuals to improve their cardiovascular risk profile to prevent the 




A large number of trials have reported on the relationship between periodontal (PD) 
and cardiovascular disease (CVD).1 PD is a common chronic multifactorial infectious 
disease of the supporting structures of the teeth (periodontal ligament and alveolar 
bone) and a major cause of tooth loss. This condition occurs in about 10-15% of the 
population. The increase in relative risk estimates for developing CVD in subjects 
with PD ranges from 1.24 to 1.34.2 These estimates increase to 1.44 in subjects  
younger than 65 years of age.3 In addition, the risk for stroke in PD patients is 
estimated to be 1.85 compared to subjects without PD.3-4 Several causal mechanisms 
have been proposed whereby bacterial pathogens, antigens, endotoxins, and/or 
inflammatory cytokines from periodontal lesions in the oral cavity contribute to the 
process of atherogenesis as well as to thromboembolic events and thereby increase 
the risk for CVD.1-2, 5-6 Treatment of periodontitis includes mechanical removal of 
supra- and subgingival bacterial plaque deposits with scalers, curettes and ultrasonic 
devices (scaling and root planing [SRP]) and intensive oral hygiene instructions. 
Optimal oral hygiene is the only way to prevent formation of a new dental plaque 
biofilm on the roots of the teeth and re-infection of the supporting tissue of the teeth. 
Albeit effective in selected cases, the routine use of systemic or local antibiotics as an 
adjunctive therapy to SRP is still controversial.7-9 Regularly, periodontal surgery is 
needed to reduce or eliminate residual periodontitis lesions. 
 In the last two decades, clinical studies have investigated the effect of 
periodontal therapy on primary and/or secondary outcomes of CVD. These trials 
were often uncontrolled, provided conflicting data and many report only short-term 
results. However, because of the chronic nature of CVD, may be only long-term 
results (e.g. 6 month follow-up) of periodontal intervention should be considered. 
Therefore, we hypothesized that, if periodontitis is somehow causally related to the 
common atherosclerotic form of CVD, then periodontal treatment should effect 
primary or surrogate parameters for CVD, including inflammatory and thrombotic 
markers, markers for lipid and glucose metabolism, and vascular markers. We 
therefore performed a systematic review of clinical  intervention trials (RCT/CCT 
designs) to assess the question whether periodontal treatment affects surrogate 






This systematic review was conducted in accordance with the guidelines of 
Transparent Reporting of Systematic Reviews and Meta-Analyses [PRISMA 
statement10]. The focused question was as follows: What is the effect of periodontal 
therapy on cardiovascular disease and/or  surrogate markers in patients suffering 
from periodontitis? 
Search Strategy 
Three literature databases were used to search for appropriate papers that satisfied 
the study purpose. These included the National Library of Medicine, Washington, 
D.C. (Medline-PubMed), the Cochrane Central Register of Controlled Trials 
(CENTRAL) and EMBASE (Excerpta Medical Database by Elsevier). The databases 
were searched for trials conducted in the period up to and including January 31, 
2012. The structured search strategy was designed to include any publication that 
evaluated the effect of periodontal therapy on cardiovascular disease markers (for 
detail on the used search terms, see BOX 1). The following eligibility criteria for 
publications were used: 
(a) Original Clinical Trials 
(b) Randomized Controlled Trials (RCT’s) or Controlled Clinical Trials (CCT’s), 
containing the following  aspects:  
- Human subjects with periodontitis  
- Intervention group receiving periodontal treatment and a non-
intervention group receiving no periodontal treatment 
- Outcome parameters must be clinical CVD parameters (i.e. clinical 
event, such as angina pectoris, myocardial infarction, stroke, death) 
and/or surrogate CVD markers, including systemic inflammation and 








Box 1. Search terms used for PubMed-MEDLINE, Cochrane-CENTRAL 
and EMBASE. The search strategy was customized according to the 




{(periodontal diseases [MesH] OR periodontal disease OR periodontitis OR 




 (cardiovascular diseases [MesH] OR cardi OR cardiac disease OR stroke OR cerebro 
OR cerebrovascular accident OR stroke OR Atherosclerosis OR arthero* OR 
myocardial* OR Myocardial ischemia OR myocardial disease OR chronic heart 
disease OR cardiovascular disease OR cardio* OR acute myocardial infarction OR 
coronary vascular disease OR peripheral arterial disease OR CRP OR c-reactive 
protein OR inflammatory cytokine OR cytokine* OR interleukin OR IL-* OR 
Endothelial OR endothelial function OR triglyceride OR cholesterol OR flow 




 (therapy OR therapeutics OR intervention trials [Mesh]) OR (treatment OR therapy 









Screening and Selection 
Two reviewers (W.J.T. and H.S.) independently screened titles and abstracts for 
eligible papers. If information relevant to the eligibility criteria was not available in 
the abstract, or if the title was relevant but the abstract was not available, the paper 
was selected for full reading of the text. Next, full-text papers that fulfilled the 
eligibility criteria were identified and included into this study. The two reviewers 
hand-searched the reference lists of all the selected trials for additional published 
papers that could possibly meet the eligibility criteria of this study. Papers that 
fulfilled all of the selection criteria were processed for data extraction. 
Heterogeneity of trials.  
The heterogeneity across the trials was detailed according to the following factors: 
 Population characteristics  
 Study design  
 Definition of diseases 
 Type of periodontal intervention 
Quality Assessment 
Two reviewers (W.J.T. and D.E.S.) scored the methodological quality of the included 
trials, as proposed by Van der Weijden et al.11  
Data Extraction 
Data from the papers that met the selection criteria were processed for analysis. 
Outcomes for CVD and/or surrogate markers were extracted with regard to the effects 
of periodontal therapy in comparison to no periodontal therapy. For the trials that 
presented intermediate assessments, the baseline and final evaluations were used for 
this review. All data were extracted by W.J.T. and D.E.S. If some mean values and 
standard deviations of outcome data could not be extracted from a paper (e.g. data 
were presented in a graph, median values were used, etc.) the corresponding author of 
the publication were asked to provide the requested data. 
Data Analysis 
A descriptive manner of data presentation was used for all trials included in the 
analyses. Where appropriate, a meta-analysis was performed for trials in which the 
‘intervention’ group received periodontal treatment and the ‘non-intervention’ group 
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received no periodontal therapy. When not reported in the publication, the difference 
() in mean values of a given parameter (x) between baseline and end, was calculated 
for both the ‘intervention’ and ‘non-intervention’ groups by with the formula:12 
x  = x end – x baseline 
Further, if not reported for some trials, the variance (S) of x was estimated as 
follows: 
Sx  = (SDx end )2 + (SDx baseline)2 – 2r .  SDx end . SDx baseline 
where SD is the reported standard deviation and r is the correlation between the 
baseline and end values; we assumed r to be 0.5 as was used by us before.13 The SDx 
was calculated as √Sx.  Subsequently from the x and corresponding SDx  and 
seize of study population, weighted mean difference (WMD) values between 
intervention and non-intervention at both baseline and end were calculated using a 
random (≥5 trials included) or fixed effect model (2-4 trials included)  (Review 
Manager (RevMan) [Computer program] Version 5.1. Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2011). 
Grading the ‘Body of Evidence’ 
The Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) system as proposed by the GRADE working group14 was used for grading 
evidence merging from this review. Two reviewers (W.J.T. and D.E.S.) rated the 
quality of the evidence and strength of recommendations on the following aspects: 
risk of bias of the individual trials, consistency and precision among the study 
outcomes, directness of the study results and the detection of publication bias. Any 














Search and Selection Results 
The combined MEDLINE (via PubMed), Cochrane CENTRAL and EMBASE searches 
resulted in 3464 potentially eligible manuscripts (Figure 1). Subsequently, 14 
publications were identified as eligible for inclusion in this review according to the 
defined criteria for the study design, participants, intervention and outcome. Of these 
14 studies, 1 article described 3 different treatment groups together with 3 different 
non-intervention groups using the same study design,15 1 article described 2 different 
trials together with 2 different non-intervention groups using a different study 
design16 and 2 articles used 2 different treatment groups with 1 non-intervention 
group and 1 study design.17-18 Therefore, all together, 19 trials were identified as 



































 Figure 1. Flowchart of literature search and study selection







































































General trial characteristics 
Detailed information regarding the trial characteristics, including study population, 
periodontal treatment  and the medical and oral status of the subjects, is summarized in 
Supplemental Table 1. All trials described a study population suffering from periodontitis. 
Some of the trials used an otherwise healthy population,16, 18-22 whereas other trials 
described a diseased population. The systemic diseases can be divided in the following 
categories: i) CVD (ideopathic edema,23 coronary artery disease,24), ii) a metabolic disorder 
(diabetes mellitus,15, 17, 25-26 metabolic syndrome,27 impaired glucose tolerance,15 
hypertension,16 hypercholesterolemia28) or iii) a combination of CVD and a metabolic 
disorder.15  
 All subjects in the intervention group received SRP, whereas no subject of the non-
intervention group received any form of periodontal therapy. In 14 trials adjunctive local or 
systemic administration of antibiotics or antiseptics, extraction of hopeless teeth and/or 
periodontal surgery in addition to SRP were applied.15-16, 18, 21-25, 27-28 The follow-up time 
among the 19 included trials ranged from 4 weeks to 12 months. 
 Further, the authors’ estimated risk of bias is formulated and also included in 
Supplemental Table 1. Details of quality assessment values, including the internal, external, 
and statistical validity, are presented in Supplemental Table 2. 
Study outcomes 
None of the trials used a real endpoint for CVD as the outcome parameter (i.e. clinical 
event, such as angina pectoris, myocardial infarction, stroke, death). The outcome 
parameters of all trials were known as surrogate endpoint markers for CVD and can be 
divided in three groups: systemic inflammation and thrombosis, lipid and glucose 
metabolism and vascular function. 
Periodontal intervention and systemic inflammation and thrombosis. 
Eighteen of the 19 trials reported changes in hsCRP levels as risk marker for CVD. Eleven 
trials showed a significant decrease of hsCRP levels in the treatment group after periodontal 
treatment compared with baseline levels.15-17, 20, 23-24, 27 In addition, two of these trials 
showed also a significant decrease in the non-intervention group compared to baseline 
levels after the study period.23, 27 The majority of the trials that showed a decrease in hsCRP 
levels after periodontal treatment used a systemically diseased population.15 , 16-17, 23-25, 27 
Baseline levels of hsCRP for the experimental groups ranged from 1.0 ± 0.8 mg/L to 12.5 ± 
73 
 
15.9 mg/L, and the baseline values for the non-intervention groups ranged from 0.8 ± 1.0 
mg/L to 6.6 ± 1.2 mg/L (Supplemental Table 3A). The significant reduction of hsCRP levels 
after periodontal treatment compared to baseline ranged from -0.5 ± 0.7 mg/L to -8.8 ± 
13.7 mg/L. No treatment group showed an significant increase in hsCRP levels compared to 
baseline levels after the study period.  
 Similar results as reported above were obtained by 10 trials using IL-6 as an outcome 
parameter. Six trials showed a significant decrease in IL-6 levels after periodontal treatment 
compared to baseline levels.15-16, 18, 24 This significant reduction ranged from -0.4 ± 0.8 ng/L 
to -1.4 ± 1.5 ng/L and was more often seen in systemically diseased subjects.15-16, 24 No 
treatment group showed a significant increase in IL-6 levels compared to baseline levels 
after the study period (Supplemental Table 3B).  
 Five trials used TNF-α as an outcome to study the effect of periodontal treatment on 
the inflammatory state. Two trials showed a significant decrease in TNF-α levels after 
periodontal treatment compared to baseline levels (-1.4 ± 1.2 pg/L, -1.5 ± 2.2 pg/L15) 
(Supplemental Table 3C). Both trials used a systemically diseased population. 
 Several other inflammatory markers have been used as study outcome to determine 
the effect of periodontal treatment on the systemic inflammatory state. In summary, IL-
1β,19 sialic acid,19 soluble E-selectin (sE-selectin),22 number of leukocytes21-22 and number of 
lymphocytes.21 Only the levels of sE-selectin were slightly reduced after periodontal 
treatment compared to the non-treatment group.22 Regarding the other markers, no change 
was observed after periodontal treatment. 
 Some trials also used markers reflecting the pro-thrombotic state, like fibrinogen,19, 
27 Von Willibrand factor,22 plasminogen activator inhibitor-1 (PAI)-122 and tissue 
plasminogen activator (tPA).22 No changes in these surrogate parameters after periodontal 
treatment were observed in 2 available trials.19, 22 In contrast, 1 trial showed a slight 
reduction in fibrinogen levels after periodontal treatment compared to baseline levels, but 
this was not significantly different from the non-treatment group.27 
Periodontal intervention and lipid and glucose metabolism 
Eleven trials used at least 4 different lipid parameters (triglycerides, total cholesterol [TC], 
high density and low density lipoproteins [HDL-C and LDL-C, respectively]) to study the 
effect of periodontal treatment on lipid metabolism. One trial showed a significant decrease 
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of triglycerides levels after periodontal treatment compared to baseline levels (-0.8 ± 1.5 
mmol/L),17 while one trial showed a significant increase compared to baseline levels for this 
biochemical parameter in the non-intervention group after the study period (0.2 ± 0.7 
mmol/L), whereas the treatment group showed no difference (0.0 ± 1.3 mmol/L)28 
(Supplemental Table 3D). Further, two trials showed a significant reduction in TC levels 
after periodontal treatment compared to baseline, whereas the non-intervention group 
showed no significant change after the study period. The reduction in both trials was similar 
(-0.3 ± 0.7 mmol/L18and -0.3 ± 0.3 mmol/L)28 (Supplemental Table 3E). One article 
described in 2 intervention groups and 1 non-intervention group, a significant reduction in 
HDL-C levels compared to baseline levels, regardless the type of periodontal treatment 
(Range ΔHDL-C: -0.2 ± 0.5 mmol/L to -0.1 ± 0.4 mmol/L)17 and one trial demonstrated a 
significant reduction for HDL-C in the non-intervention group after the study period 
compared to baseline (-0.03 ± 0.1 mmol/L)28 (Supplemental Table 3F). The latter two 
publications showed significant reductions of LDL levels after periodontal treatment 
compared with baseline levels;17, 28 notably, one trial showed also a reduction of LDL-C in 
the non-treatment group after the study period (Supplemental Table 3G).17 No trial showed 
an increase after periodontal treatment compared to baseline for any of the levels of lipid 
biomarkers. Some trials reported on other lipid markers, including Very Low Density 
Lipoprotein (VLDL-C),28 Apoliproteins, Lipoproteins21 and Malondialdehyde-LDL-C,24 
however no significant changes were observed after periodontal treatment compared to 
baseline levels and the non-treatment group. 
 Several trials used markers reflecting glucose metabolism. The main marker used in 
diabetes care and related to CVD is the percentage of glycosylated hemoglobin  (HbA1c). 
Five trials, using a diabetes study population, reported absolute changes in HbA1c after 
periodontal treatment. Four trials showed a significant reduction in HbA1c after periodontal 
treatment compared to baseline levels and the non-intervention group receiving no 
periodontal treatment (Range ΔHbA1c:  -0.72 ± 0.93 % to -0.42 ± 1.39 %)15, 17, 26 
(Supplemental Table 3H). The majority of the trials showed no differences in glucose levels 
after periodontal treatment compared to baseline levels and no treatment,16, 22, 24-25 while 
only one trial showed a significant decrease in glucose levels after periodontal treatment 
and intensive maintenance period for 6 months compared to baseline levels (-0.73 
mmol/L).17 Other markers, like albumin23 and insulin16, 24 did not change after periodontal 
treatment. One article, with 3 trials included, described the effect of periodontal treatment 
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on adiponectin levels.15 The authors showed that after periodontal treatment the levels of 
adiponectin were increased in a population diagnosed with impaired glucose tolerance or 
diabetes mellitus.15 In a study population with diabetes mellitus together with CVD no 
changes after periodontal treatment were observed.15 
Periodontal intervention and vascular function 
The primary outcome of several trials was vascular function, assessed through the effects of 
periodontal treatment on endothelial function. One trial showed that periodontal treatment 
positively affected the endothelial function as demonstrated by an increase in flow-
mediated dilation (FMD) compared to the non-treated group after 6 months (2.0%; CI: 1.2-
2.9).22 Comparable results were described in 3 other trials.16, 24 Forearm blood flow (FBF) 
responses to acetylcholine (ACh), an endothelium-dependent vasodilator, after periodontal 
treatment were also evaluated. All trials showed that ACh-FBF was significantly increased 
in the periodontal treatment groups compared to baseline, whereas the non-treatment 
groups showed no differences.16, 24 Furthermore, one trial described a reduction of CD34+ 
cells after periodontal treatment; these are endothelial progenitor cells and closely related 
to the risk of CVD.21 
 Other markers of vascular function, like nitroglycerine-mediated dilation, brachial-
artery diameter, reactive hyperemia ratio,22 FBF, sodium-nitroprusside-dependent FBF, 
ACH-FBF in the presence of a NO-synthase-inhibitor16, 24 and pulse amplitude tonometry,21 
systolic and diastolic blood pressure16, 22, 24, 27 (Supplemental Table 3I) did not change after 
periodontal treatment compared to baseline levels of the treatment group and/or end levels 
of the non-treatment group. 
Meta-analyses 
The effect of periodontal treatment on primary or secondary markers of inflammation 
(hsCRP, IL-6, TNF-α), lipid and glucose metabolism (triglycerides, TC, HDL-C, LDL-C and 
HbA1c) and vascular function (systolic and diastolic blood pressure) could be analyzed in a 
series of meta-analyses. The weighted mean differences (WMD) and 95% confidence 
intervals (CI) baseline to end between intervention groups and non-intervention groups for 
each parameter were calculated (Supplemental Figures 1-12)  and summarized in Table 1. A 
significant WMD including all trials was found for hsCRP (-0.43 mg/L), TC (-0.14 mmol/L) 
and HbA1c (-0.45%). Notably, sub-analyses showed that periodontitis patients suffering 
from cardiovascular and/or metabolic disease benefited the most from periodontal therapy; 
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significant WMD were observed for hsCRP (-0.62 mg/L, CI:-0.97;-0.27; p=0.0005), IL-6 (-
1.15 ng/L, CI:-1.63;-0.67; p<0.00001), TC (-0.15 mM, CI:-0.29;-0.01; p=0.03) and HbA1c  (-
0.45%, CI:-0.70;-0.19; p=0.0006). Significant WMD were not observed in systemically 
healthy periodontitis patients. Figure 2 depicts the WMD for hsCRP of all studies and sub-
analyses. 
 In trials which recruited periodontitis patients with cardiovascular and/or metabolic 
disease, we observed differences in WMD for studies with different follow-up periods 
(Supplemental Table 4).  For example, 4 trials15, 23 with <6 months duration, showed for 
hsCRP a WMD of -0.81 mg/L (CI:-1.06 ; -0.56; p<0.00001), while another 7 trials16-17, 24-27 
with ≥6 months follow-up showed for hsCRP a WMD of -0.24 mg/L (CI:-0.47 ; -0.01; 
p=0.04). For Il-6, a significant WMD was found for 3 trials15 with <6 months follow-up (-
1.16 ng/L, CI:-1.66 ; -0.66; p<0.00001).  
 With the available trials, no significant WMD were observed regarding triglycerides, 
HDL-C, LDL-C, systolic and diastolic blood pressure. 
Grading the ‘Body of Evidence’ 
Since the data regarding the inflammatory markers and glucose metabolism is consistent 
(Supplemental Table 5) with on average a low to moderate risk of bias, the precision is good 
and the study results are general applicable. The quality of ‘Body of Evidence’ that 
periodontal treatment affects levels of systemic inflammatory markers and glucose 
metabolism is high (Supplemental Table 6). Because of the inconsistent data regarding lipid 
metabolism and blood pressure with on average a moderate to high risk of bias, the 
precision is moderate and the study results cannot be generalized. The quality of ‘Body of 






































I C  p-value I² -value % 
CRP (mg/L) 
Overall  R 545 451 -0.43 [-0.70 ; -0.16] 0.002 0.002 55 
 Non diseased 16, 18-22 R 182 154 -0.09 [-0.60 ; 0.42] 0.73 0.06 51 
 Diseased 15-17, 23-27 R 363 297 -0.62 [-0.97 ; -0.27] 0.0005 0.005 60 
IL-6 (ng/L) 
Overall  R 258 222 -0.38 [-0.88 ; 0.13] 0.14 0.01 57 
 Non diseased 16, 18-19, 22 R 139 111 0.10 [-0.26 ; 0.47] 0.58 0.45 0 
 Diseased 15-16, 24 R 119 111 -1.15 [-1.63 ; -0.67] <0.00001 0.97 0 
TNF-α (pg/mL_ Overall 15, 17, 19 R 187 134 -0.77 [-1.57 ; 0.04] 0.06 0.002 74 
Triglycerides (mM) 
Overall  R 366 296 -0.01 [-0.13 ; 0.11] 0.84 1.00 0 






-0.05 [-0.27 ; 0.17] 0.64 0.95 0 
TC (mM) 
Overall  R 366 296 -0.14 [-0.24 ; -0.03] 0.009 0.72 0 






-0.15 [-0.29 ; -0.01] 0.03 0.48 0 
HDL (mM) 
Overall  R 366 296 0.01 [-0.03 ; 0.05] 0.58 0.97 0 








0.03 [-0.02 ; 0.08] 0.27 1.00 0 
LDL (mM) 
Overall  R 366 296 -0.13 [-0.27 ; 0.00] 0.06 0.14 32 






-0.09 [-0.32 ; 0.13] 0.42 0.11 44 
Systolic BP (mm 
Hg) 
Overall  R 197 188 -0.11 [-1.87 ; 1.65] 0.90 0.99 0 
 Non diseased 16, 22 F 74 72 -0.45 [-3.83 ; 2.92] 0.79 0.76 0 
 Diseased 16, 24, 27 F 123 116 0.02 [-2.04 ; 2.09] 0.98 0.96 0 
Diastolic BP (mm 
Hg) 
 
Overall  R 197 188 0.59 [-0.47 ; 1.65] 0.27 0.74 0 
 Non diseased 16, 22 F 74 72 -0.62 [-2.91 ; 1.66] 0.59 0.68 0 




15, 17, 25-26 R 200 
141 
-0.45 [-0.70 , -0.19] 0.0006 0.06 56 
 
1 A random effect model was used if at least 5 trials per analysis could be included. Otherwise a fixed effect model was performed.   
 
Abbreviations: BP = Blood Pressure; C = Non-intervention Group; CI = Confidence Interval; CRP = C-Reactive Protein; F= Fixed; HbA1c = 
Glycated Hemoglobin; HDL = High Density Lipoprotein; I = Intervention group; IL-6 = Interleukin-6; LDL = Low Density Lipoprotein; R = 







- 1 article described 3 different 
RCTs15 
- 1 article described 2 different 
RCTs16 
- 2 articles described 2 different 
treatment groups with 1 non-
treatment group17-18  
                    +5 
Figure 2. Weighted mean differences (WMD) and confidence 
intervals (CI) of CRP levels between the intervention groups 











































Mean age (SD) 
Gender 
Mean BMI (SD) 


































Mean mm PPD (SD) 
Mean mm CAL (SD) 
Mean % BOP (SD) 
Mean # Teeth (SD) 
Mean # or % sites 





























≥6 teeth with PPD 



















Age: 47 (3) years 
Gender: ♀: 8 ♂:10 
BMI: 25 (2) kg/m2 




PPD:  NR 
CAL:  NR 
BOP: NR 
# Teeth: 27 (1) 
% Sites ≥4mm: 39 (NR) 
 
I: SRP 





Age: 45 (3) years 
Gender: ♀: 8 ♂:10 
BMI: 25 (1) kg/m2 




PPD:  NR 
CAL:  NR 
BOP: NR 
# Teeth: 27 (1) 
% Sites ≥4mm: 41 (NR) 
 
C: No periodontal 
treatment 






















CVD risk markers: 
- Type 2 diabetes; 
















I (IPT):   
Age : 60 (9) years    
Gender: ♀:19 ♂:23 
BMI: 24 (3) kg/m2 




I (IPT):   
PPD:  2.7 (0.7) 
CAL:  3.6 (1.3) 
BOP: 38 (20) 
# Teeth: NR 
% Sites ≥4mm: 17 (NR) 
 
I (IPT): SRP + 
subgingival 
debridement at 3 
months follow-up  
# 45 (42) 
 
I (SPT):  
Age: 58 (11) years   
Gender: ♀:17 ♂:26 
BMI: 24 (4) kg/m2 
# Smokers: 10 (23) 
 
 
I (SPT):  
PPD:  2.6 (0.7) 
CAL:  3.0 (1.2) 
BOP: 32 (17) 
# Teeth: NR 
% Sites ≥4mm: 15 (NR) 
 
I (SPT): SRP + 
supragingival 
prohylaxis at 3 months 
follow-up 
# 45 (43) 
 
C:  
Age: 63 (9)years 
Gender: ♀:24 ♂:17 
BMI: 24 (3) kg/m2 




PPD:  2.5 (0.6) 
CAL:  3.4 (1.2) 
BOP: 34 (19) 
# Teeth: NR 
% Sites ≥4mm: 12 (NR) 
 
C: No periodontal 
treatment 
















≥ 4 teeth with ≥1 pocket 





CVD risk factors:  
- Metabolic syndrome 
(obesity, dyslipidemia, 


















Age: 54 (9) years 
Gender: ♀:58 ♂:24 
BMI: 30 (4) kg/m2 











PPD:  NR 
CAL:  3.8 (1.5) 
BOP: 52 (17) 
# Teeth: 21 (4) 












elevated fasting glucose) 
 
 
I: SRP + extraction of 
hopeless teeth + 
systemic antibiotics 
(Metronidazol 250mg 
and Amoxicillin 500mg 
3 times a day for 1 
week) 























Age: 56 (9) years 
Gender: ♀:17 ♂:13 
BMI: 30 (4) kg/m2 





PPD:  NR 
CAL:  3.5 (1.4) 
BOP: 51 (17) 
# Teeth: 20 (5) 




scaling and 2 placebo 
tablets for antibiotics (3 
times a day for 1 week) 


















≥8 sites with PPD ≥6mm 
and ≥4 sites with CAL 
≥5mm distributed in at 




CVD risk factors: 









levels in patients 
with type 2 
diabetes, but did 





Age: 60 (8) years 
Gender: ♀:13 ♂:17 
BMI: 28 (4) kg/m2 




PPD:  NR 
CAL:  NR 
BOP: 72 (27) 
# Teeth: 24 (4) 
% Sites ≥4mm: 67 (NR) 
 
I: SRP  









Age: 59 (10) years 
Gender: ♀:16 ♂:14 
BMI: 28 (4) kg/m2 




PPD:  NR 
CAL:  NR 
BOP: 69 (26) 
# Teeth: 24 (4) 





















≥1 pocket with PPD 



















leads to a 
clinical benefit 






Age: 40 (10) years 
Gender: ♀:15 ♂:0 
BMI: 27 (4) kg/m2 





PPD:  NR 
CAL:  NR 
BOP: NR 
# Teeth: NR 
# Sites ≥4mm: NR 
  
I: SRP + extraction of 
hopeless teeth + 
systemic  antibiotics 
(doxycycline) + 
mouthwash twice a day 
(chlorhexydine)  




Age: 34 (8) years 
Gender: ♀:15 ♂:0 
BMI: 28 (6) kg/m2 
# Smokers: NR 
 
C: 
PPD:  NR 
CAL:  NR 
BOP: NR 
# Teeth: NR 
 
C: no periodontal 
treatment 





















CVD : No  


















Age: 59 (12) years 
Gender: ♀:15 ♂:10 
BMI: 25 (4) kg/m2 




PPD:  NR 
CAL:  NR 
BOP: 45 (19) 
# Teeth: NR 
% Sites ≥4mm: 13 (14) 
 
I: SRP + chlorhexydine 
gel in all sites with PPD 
≥4mm + extraction of 
hopeless teeth 




Age: 60 (10) years 
Gender: ♀:12 ♂:13 
BMI: 23 (4) kg/m2 




PPD:  NR 
CAL:  NR 
BOP: 46 (21) 
# Teeth: NR 
% Sites ≥4mm: 10 (10) 
 
C: no periodontal 
treatment 















- ≥20 teeth 
- PPD ≥5mm  
- ≥30% of teeth with 
CAL >4mm, or ≥60% of 
teeth with PPD >4mm 






I: SRP + periodontal 
surgery when indicated 
+ extraction of 
hopeless teeth + 
antibiotics (tinidazole 
1.0g , bid and ampicillin 














Trial 1:  
I:  
Age: 56 (12) years 
Gender: ♀:11 ♂:14 
BMI: 23 (3) kg/m2 
# Smokers: 0 (0) 
 
C:  
Age: 56 (13) years 
Gender: ♀:11 ♂:14 
BMI: 23 (3) kg/m2 





PPD:  NR 
CAL:  NR 
BOP: NR 
# Teeth: NR 




CVD risk markers: 










and after periodontal 
intervention) 
 




I: # 25 (25) 












Age: 56 (11) years 
Gender: ♀:12 ♂:17 
BMI: 23 (3) kg/m2 
# Smokers: 0 (0) 
 
C:  
Age: 58 (11) years 
Gender: ♀:12 ♂:17 
BMI: 24 (3) kg/m2 






PPD:  4.3 (0.7) 
CAL:  4.5 (1.3) 
BOP: 94 (11) 
# Teeth: NR 




CVD risk markers: 
- Type 2 diabetes; 
Diagnosis ≥1 year; Good 
glucose control (Fasting 
glucose <7.0 mmol/L and 









I: Similar as group 1 
# 29 (29) 
C: Similar as group 1  








Trial 3:  
I:  
Age: 58 (11) years 
Gender: ♀:10 ♂:14 
BMI: 24 (3) kg/m2 
# Smokers: 0 (0) 
 
C:  
Age: 56 (10) years 
Gender: ♀:10 ♂:14 
BMI: 24 (3) kg/m2 





- Heart disease (#20) 
- Carotid artery 
atherosclerosis (#12) 
- Lower extremity 
atherosclerosis (#14) 
- CHD (#2) 
 
CVD risk markers: 
- Type 2 diabetes; 
Diagnosis ≥1 year; Good 
glucose control (Fasting 
glucose <7.0 mmol/L and 





I: Similar as group 1  
# 24 (24) 
C: Similar as group 1  

















- ≥ 11 teeth 




CVD risk markers: 




















Age: 60 (10) years 
Gender: ♀:11 ♂:21 
BMI: 24 (4) kg/m2 








PPD:  3.0 (0.9) 
CAL:  NR 
BOP: 37 (23) 
# Teeth: 24 (5) 
# Sites ≥4mm: NR 
 
I: SRP + local 
application of 
antibiotics (Minocyline 
10mg in every 
periodontal pocket) + 
extraction op hopeless 
teeth  






Age: 59 (5) years 
Gender: ♀:11 ♂:6 
BMI: 26 (5) 




PPD:  2.8 (0.9) 
CAL:  NR 
BOP: 25 (15) 
# Teeth: 24 (3) 
# Sites ≥4: NR 
 
C: No periodontal 
treatment 
# 17 (17) 
 






















swelling and bleeding, 




≥2 teeth with PPD ≥4mm 




- Coronary artery disease 
(stenosis in ≥70% in at 
least one proximal 
epicardial coronary artery 
and with objective 
evidence of myocardial 
infarction or at least one 
coronary stenosis ≥80% 
and classic angina without 













Age: 63 (12) years 
Gender: ♀:5 ♂:19 
BMI: 24 (3) kg/m2 





PPD:  5.1 (0.8) 
CAL:  6.0 (1.1) 
BOP: 51 (18) 
# Teeth: NR 
# Sites ≥4mm: NR 
 
I: SRP + antibiotics  for 
4 to 7 days + 
mouthwash every day 
for 6 months 




Age: 62 (13) years 
Gender: ♀: 6 ♂: 18 
BMI: 24 (3) kg/m2 




PPD:  4.8 (0.7) 
CAL:  5.7 (1.0) 
BOP: 54 (17) 
# Teeth: NR 
# Sites ≥4mm: NR 
 
C: no periodontal 
treatment 





















swelling and bleeding, 
purulent discharge, and 
tooth mobility 
 




CVD : No  













Age: 25(3) years 
Gender: ♀:0 ♂:16 
BMI: 23 (2) kg/m2 





PPD:  NR 
CAL:  NR 
BOP: NR 
# Teeth: NR 
# Sites ≥4mm: NR 
 
I: SRP + antibiotics  for 
4 to 7 days + 
mouthwash every day 
for 6 months 




Age: 25(4) years 
Gender: ♀:0 ♂:16 
BMI: 24 (2) kg/m2 




PPD:  NR 
CAL:  NR 
BOP: NR 
# Teeth: NR 
# Sites ≥4mm: NR  
 
C: no periodontal 
treatment 





















swelling and bleeding, 
purulent discharge, and 
tooth mobility 
 





Medication (> 6 
months): 
Calcium antagonist (n=42) 
Rennin-angiotension 
inhibitors (n=16)  
β-blockers (n=9)   














Age: 53(14) years 
Gender: ♀:6 ♂:11 
BMI: 23 (3) kg/m2 





PPD:  NR 
CAL:  NR 
BOP: NR 
# Teeth: NR 
# Sites ≥4: NR 
 
I: SRP + antibiotics for 
4 to 7 days + 
mouthwash every day 
for 6 months 




Age: 55(11) years 
Gender: ♀:2 ♂:7 
BMI: 23 (3) kg/m2 




PPD:  NR 
CAL:  NR 
BOP: NR 
# Teeth: NR 
# Sites ≥4mm: NR 
 
C: no periodontal 






















CVD risk factors:  
-hypercholesterolemia 
(Triglyceride <200 mg/dL, 
HDL <35 mg/dL,  
LDL<130 mg/dL, 
VLDL <40 mg/dL 














Age: 49 (6) years 
Gender ♀:15 ♂:10 
BMI: NR 





PPD:  3.4 (0.9) 
CAL:  2.7 (0.9) 
BOP: 62 (20) 
# Teeth: NR 
# Sites ≥4mm: NR 
 
I:Hypercholesterolimia 
duration : 5.5 + 2.6 years  
 
I: SRP + 5 patients 
received open flap 
debridement  




Age: 52 (8) years 
Gender: ♀:16 ♂:9 
BMI: NR 




PPD:  2.8 (0.8) 
CAL:  2.4 (0.6) 
BOP: 62 (18) 
# Teeth: NR 
# Sites ≥4mm: NR 
 
C:Hypercholesterolimia 
duration : 4.8 + 2.7 year 
 
 
C: no periodontal 
treatment 


















≥50% of teeth with PPD 
≥6mm and ≥30% ABL 
 
CVD : No 














Age: 48 (8) years 
Gender: ♀:31 ♂:30 
BMI: 27 (5) kg/m2 






PPD:  NR 
CAL:  NR 
BOP: 66 (18) 
# Teeth: 27 (3) 
# Sites ≥4mm: 82 (27) 
 
I: SRP + local 
application of 
antibiotics (Arestin®) + 
extraction op hopeless 
teeth  




Age: 48 (6) years 
Gender: ♀:29 ♂:30 
BMI: 27 (5) kg/m2 





PPD:  NR 
CAL:  NR 
BOP: 68 (17) 
# Teeth: 27 (3) 




scaling and polishing 




















≥50% of teeth with PPD 
≥6mm and ≥30% ABL 
 
CVD : No 















I (IPT):   
Age : 49 (7) years    
Gender: ♀:8 ♂:12 
BMI: 26 (4) kg/m2 




PPD:  4.5 (0.8) 
CAL:  5.5 (1.5) 
BOP: NR 
# Teeth: NR 
# Sites ≥4mm: 80 (25) 
 
I (IPT): SRP + local 
delivery of minocycline 
(Arestin®) 
# 20 (20) 
 
 
I (SPT):  
Age: 48 (7) years   
Gender: ♀:10 ♂:11 
BMI: 26 (4) kg/m2 




PPD:  4.3 (0.8) 
CAL:  5.3 (1.5) 
BOP: NR 
# Teeth: NR 
# Sites ≥4mm: 79 (28) 
 
I (SPT): SRP 





Age: 48 (6)years 
Gender: ♀:9 ♂:15 
BMI: 25 (3) kg/m2 




PPD:  4.6 (0.8) 
CAL:  5.5 (1.6) 
BOP: NR 
# Teeth: NR 
# Sites ≥4mm: 80 (26) 
 
C:  no periodontal 
treatment  

















≥20  teeth without 
periapical lesions   
≥5 teeth with PPD 
≥6mm and radiographic 
evidence of ABL 
 
 
CVD : No 
 















I :  
Age: 48 (8) years 
Gender: ♀:11 ♂:13 
BMI: NR 




PPD:  NR 
CAL:  NR 
BOP: 42 (17) 
# Teeth: 27 (3) 
# Sites ≥4mm: NR 
 
I: SRP 






Age: 46 (6) years  
Gender: ♀:5 ♂:10 
BMI: NR 
# Smokers: 0 (0) 
 
C: 
PPD:  NR 
CAL:  NR 
BOP: 45 (23) 
# Teeth: 28 (3) 
# Sites ≥4mm: NR 
 
C: no periodontal  
treatment  





Abbreviations: ABL = Alveolar Bone Loss; BMI = Body Mass Index; BOP = Bleeding On Probing; C = Non-intervention group; CAL = Clinical 
Attachment Level; CCT = Controlled Clinical Trial; CHD = Coronary Heart Disease; CRP = C-Reactive Protein; CVD = Cardiovascular 
Disease; d-8-iso = d-8-iso prostaglandin F2a; HbA1c = Glycated Hemoglobin; HDL = High Density Lipoprotein; hsCRP = high-sensitive C-
Reactive Protein; I = Intervention group; IPT = Intensive Periodontal Treatment; MMP = Matrix Metalloproteinase; LDL = Low Density 
Lipoprotein; NR = Not Reported; PPD = Probing Pocket Depth; RCT = Randomized Clinical Trial; SD = Standard Deviation; SPT = Standard 






















Random allocation* + + + + - + + + + + ? + + + + 
Allocation concealment + + ? ? NA + ? ? ? ? ? ? + + - 
Blinded to patient* NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
Blinded to examiner* ? + + ? ? + ? ? ? ? ? ? + + ? 
Blinding during statistical analysis  ? ? ? ? ? ? ? ? ? ? ? ? + + + 
Balanced experimental groups * + + + + + + + + + + + + + + + 
Reported loss to follow up* + + + + + + + + + + + + + + + 






































 Representative population group  + ± ± ± ± + ± ± ± + ± ± + + + 











Sample size calculation and power - + + + ? + ? ? ? ? ? ? + + ? 
Point estimates + + + + + + + + + + + + - + + 
Measures of variability presented for the 
primary outcome + + + + + + + + + + + + - + + 
Include a per protocol analysis + + - - + - + + + + + + - - + 
Include an intention- to-treat analysis - - + + - + - - - - - - + + - 
 Authors estimated risk of bias Mod Low Low Low High Low Mod Mod Mod Mod High Mod Low Low Mod 
 
Abbreviations: ? = not specified/unclear; + = yes; - = no; * = reporting criteria for estimating the potential risk of bias; NA = Not Applicable; 
Mod = Moderate  
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Supplemental Table 3A: Overview of selected trials investigating CRP levels for treatment and 








































20 PT NPT 
2.3 ± 0.7 
2.3 ± 0.7 
1.8 ± 0.6 
2.4 ± 0.7 
-0.5 ± 0.7  







3.2 ± 4.5 
3.1 ± 4.6 
2.8 ± 4.1 
1.6 ± 1.3 
1.5 ± 1.3 
3.2 ± 5.5 
-1.6 ± 4.0  
-1.6 ± 4.2  




26 PT NPT 
2.5 ± 2.3 
2.4 ± 2.1 
2.2 ± 2.4 
2.4 ± 2.4 
-0.3 ± 2.7 
-0.1 ± 2.4 
NO 
NO 
27 PT NPT 
4.4 ± 3.1 
4.4 ± 3.2 
3.6 ± 3.8 
3.4 ± 3.1 
-0.8 ± 3.5  
-1.0 ± 3.1  
YES 
YES 
23 PT NPT 
12.5 ± 15.9 
6.1 ± 10.6 
3.7 ± 7.9 
8.5 ± 11.8 
-8.8 ± 13.7  
-2.4 ± 4.3  
YES 
YES 
21 PT NPT 
2.1 ± 2.4 
3.0 ± 3.7 
2.4 ± 2.8 
2.1 ± 3.4 
0.3 ± 2.3 
-0.9 ± 2.3 
NO 
NO 
15 (Trial 1) PT NPT 
3.3 ± 0.6 
3.3 ± 0.6 
2.3 ± 0.4 
3.1 ± 0.5 
-0.9 ± 0.5  
-0.2 ± 0.6  
YES 
NO 
15 (Trial 2) PT NPT 
4.9 ± 1.0 
5.1 ± 1.1 
4.2 ± 0.9 
5.2 ± 1.2 
-0.7 ± 1.0  
0.2 ± 1.1  
YES 
NO 
15 (Trial 3) PT NPT 
6.7 ± 1.2 
6.6 ± 1.2 
5.7 ± 1.1 
6.4 ± 1.3 
-1.0 ± 1.2  
-0.2 ± 1.3  
YES 
NO 
25 PT NPT 
1.9 ± 2.5 
2.3 ± 2.6 
1.5 ± 1.6 
2.1 ± 3.2 
-0.3 ± 0.4 
-0.1 ± 0.2 
NO 
NO 
24 PT NPT 
2.7 ± 1.9 
2.6 ± 2.2 
1.8 ± 0.9 
2.5 ± 2.1 
-0.9 ± 1.7  
-0.1 ± 2.2  
YES 
NO 
16 (Trial 1) PT NPT 
2.1 ± 1.9 
2.0 ± 2.0 
1.3 ± 1.2 
2.1 ± 2.3 
-0.8 ± 1.7  
0.1 ± 2.2  
YES 
NO 
16 (Trial 2) PT NPT 
2.4 ± 2.2 
2.2 ± 2.3 
1.4 ± 1.2 
2.1 ± 2.0 
-1.0 ± 1.9  
-0.1 ± 2.2  
YES 
NO 
22 PT NPT 
2.5 ± 2.7 
3.8 ± 5.3 
2.7 ± 4.9 
3.0 ± 3.4 
0.2 ± 3.9 









2.9 ± 2.2 
2.0 ± 1.1 
2.4 ± 1.6 
2.9 ± 2.3 
1.6 ± 0.9 
2.5 ± 1.7 
0.0 ± 2.3  
-0.4 ± 1.0  




19 PT NPT 
1.0 ± 0.8 
0.8 ± 1.0 
1.0 ± 1.0 
0.8 ± 0.9 
0.1 ± 0.9  




Abbreviations: SD = Standard Deviation; PT = Periodontal Therapy; NPT = No Periodontal 
Therapy; IPT = Intensive Periodontal Treatment; PTA = Periodontal Therapy with 




Supplemental Table 3B: Overview of selected trials investigating IL-6 levels for treatment and 



































15 (Trial 1) PT NPT 
5.0 ± 1.3  
5.0 ± 1.4 
4.0 ± 1.1 
5.2 ± 1.4 
-1.1 ± 1.3  
0.2 ± 1.4  
YES 
NO 
15 (Trial 2) PT NPT 
7.2 ± 1.6 
7.3 ± 1.6 
5.9 ± 1.3 
7.1 ± 1.4 
-1.4 ± 1.5  
-0.2 ± 1.5  
YES 
NO 
15 (Trial 3) PT NPT 
11.3 ± 2.9 
11.4 ± 2.9 
10.8 ± 2.6 
11.7 ± 2.7 
-0.4 ± 2.7  
0.2 ± 2.8  
NO 
NO 
24 PT NPT 
2.6 ± 3.4 
2.7 ± 3.9 
1.6 ± 2.6 
2.6 ± 4.4 
-1.0 ± 3.1  
-0.1 ± 4.2  
YES 
NO 
16 (Trial 1) PT NPT 
2.3 ± 3.9 
2.6 ± 3.8 
1.5 ± 2.2 
2.7 ± 4.0 
-0.8 ± 3.4  
0.1 ± 3.9  
YES 
NO 
16 (Trial 2) PT NPT 
2.8 ± 4.4 
2.5 ± 4.2 
1.7 ± 2.5 
2.6 ± 4.3 
-1.1 ± 3.8  
0.1 ± 4.3  
YES 
NO 
22 PT NPT 
2.4 ± 5.4 
2.0 ± 3.9 
2.4 ± 5.7 
1.7 ± 3.4 
0.1 ± 2.1 







2.0 ± 1.1 
1.5 ± 0.9 
1.9 ± 1.0 
1.9 ± 1.1 
1.0 ± 0.6 
1.7 ± 0.3 
-0.1 ± 1.1  
-0.4 ± 0.8  




19 PT NPT 
1.7 ± 0.8 
2.9 ± 3.6 
1.5 ± 1.4 
1.6 ± 1.5 
-0.2 ± 1.2  




Abbreviations: SD = Standard Deviation; PT = Periodontal Therapy; NPT = No Periodontal 




Supplemental Table 3C: Overview of selected trials investigating TNF-α levels for treatment and 












































11.2 ± 4.0 
12.4 ± 15.6 
10.5 ± 3.4 
10.8 ± 3.0 
11.0 ± 3.8 
11.0 ± 2.4 
-0.4 ± 3.6  
-1.4 ± 14.1  




15 (Trial 1) PT NPT 
6.7 ± 1.2 
6.8 ± 1.2 
5.3 ± 1.2 
6.6 ± 1.4 
-1.4 ± 1.2  
-0.1 ± 1.3  
YES 
NO 
15(Trial 2) PT NPT 
8.8 ± 2.4 
8.8 ± 2.3 
7.3 ± 2.0 
8.6 ± 2.3 
-1.5 ± 2.2  
-0.2 ± 2.3  
YES 
NO 
15 (Trial 3) PT NPT 
12.3 ± 2.2 
12.5 ± 2.2 
11.6 ± 2.4 
12.6 ± 2.3 
-0.7 ± 2.3  
0.1 ± 2.3  
NO 
NO 
19 PT NPT 
2.2 ± 0.5 
2.0 ± 0.5 
2.2 ± 0.5 
1.8 ± 0.5 
-0.0 ± 0.5  




Abbreviations: SD = Standard Deviation; PT = Periodontal Therapy; NPT = No Periodontal 




Supplemental Table 3D: Overview of selected trials investigating triglyceride levels for 

































20  PT NPT 
1.2 ± 0.4 
1.2 ± 0.3 
1.2 ± 0.4 
1.2 ± 0.3 
0.0 ± 0.4  







5.9 ± 1.2 
6.0 ± 1.6 
6.4 ± 1.9 
5.6 ± 1.4 
5.3 ± 1.4 
5.8 ± 1.6 
-0.3 ± 1.3  
-0.8 ± 1.5  




27 PT NPT 
2.0 ± 1.1 
1.8 ± 1.3 
2.0 ± 1.6 
1.9 ± 1.2 
0.0 ± 1.5  
0.1 ± 1.3  
NO 
NO 
24 PT NPT 
1.3 ± 0.8 
1.3 ± 0.7 
1.3 ± 0.7 
1.3 ± 0.6 
-0.1 ± 0.7  
-0.0 ± 0.7  
NO 
NO 
16 (Trial 1) PT NPT 
1.3 ± 0.7 
1.2 ± 0.6 
1.2 ± 0.7 
1.2 ± 0.6 
-0.0 ± 0.7  
-0.0 ± 0.6  
NO 
NO 
16 (Trial 2) PT NPT 
1.2 ± 0.8 
1.3 ± 0.7 
1.2 ± 0.6 
1.3 ± 0.6 
0.0 ± 0.7  
-0.0 ± 0.7  
NO 
NO 
28 PT NPT 
1.8 ± 0.9 
1.8 ± 0.5 
1.8 ± 1.4 
2.0 ± 0.7 
0.0 ± 1.3  
0.2 ± 0.7  
NO 
YES 
22 PT NPT 
1.4 ± 1.0 
1.3 ± 1.1 
1.3 ± 0.8 
1.3 ± 0.8 
-0.1 ± 0.6 







1.7 ± 1.1 
1.4 ± 1.1 
1.7 ± 1.2 
1.6 ± 1.0 
1.3 ± 0.8 
1.4 ± 0.9 
-0.1 ± 1.1  
-0.1 ± 1.0  





Abbreviations: SD = Standard Deviation; PT = Periodontal Therapy; NPT = No Periodontal 
Therapy; IPT = Intensive Periodontal Treatment; PTA = Periodontal Therapy with 




Supplemental Table 3E: Overview of selected trials investigating total cholesterol levels for 




































20  PT NPT 
5.4 ± 0.4 
5.5 ± 0.5 
5.2 ± 0.6 
5.3 ± 0.4 
-0.2 ± 0.5  







2.1 ± 1.2 
2.6 ± 1.3 
2.4 ± 1.8 
1.9 ± 1.1 
2.2 ± 1.9 
2.3 ± 2.0 
-0.2 ± 1.1  
-0.5 ± 1.7  




27 PT NPT 
5.4 ± 1.2 
5.6 ± 1.3 
5.5 ± 1.1 
5.5 ± 1.0 
0.1 ± 1.2  
-0.1 ± 1.2  
NO 
NO 
24 PT NPT 
5.0 ± 1.3 
4.8 ± 1.2 
4.9 ± 1.3 
4.8 ± 1.7 
-0.1 ± 1.3  
-0.0 ± 1.5  
NO 
NO 
16 (Trial 1) PT NPT 
5.0 ± 0.7 
4.6 ± 0.7 
4.6 ± 0.7 
4.6 ± 0.7 
-0.4 ± 0.7  
-0.0 ± 0.7  
NO 
NO 
16 (Trial 2) PT NPT 
4.6 ± 0.7 
4.7 ± 0.9  
4.6 ± 0.8 
4.7 ± 0.9 
-0.0 ± 0.8  
0.0 ± 0.9  
NO 
NO 
28 PT NPT 
2.5 ± 0.2 
2.4 ± 0.2 
2.1 ± 0.3 
2.3 ± 0.3 
-0.3 ± 0.3  
-0.1 ± 0.3  
YES 
NO 
22 PT NPT 
5.2 ± 1.0 
5.3 ± 1.2 
5.1 ± 0.9 
5.3 ± 1.0 
-0.1 ± 0.6 







5.3 ± 0.7 
5.5 ± 0.7 
5.4 ± 0.7 
5.4 ± 0.9 
5.2 ± 0.7 
5.3 ± 0.8 
0.1 ± 0.8  
-0.3 ± 0.7  





Abbreviations: SD = Standard Deviation; PT = Periodontal Therapy; NPT = No Periodontal 
Therapy; IPT = Intensive Periodontal Treatment; PTA = Periodontal Therapy with 




Supplemental Table 3F: Overview of selected trials investigating HDL levels for treatment and 






























20 PT NPT 
1.5 ± 0.3 
1.4 ± 0.2 
1.4 ± 0.2 
1.4 ± 0.2 
-0.1 ± 0.3  







1.3 ± 0.4 
1.3 ± 0.5 
1.4 ± 0.5 
1.2 ± 0.3 
1.1 ± 0.4 
1.3 ± 0.5 
-0.1 ± 0.4  
-0.2 ± 0.4  




27 PT NPT 
1.3 ± 0.3 
1.3 ± 0.4 
1.3 ± 0.3 
1.3 ± 0.4 
-0.0 ± 0.3  
-0.0 ± 0.4  
NO 
NO 
24 PT NPT 
1.2 ± 0.6 
1.2 ± 0.7 
1.2 ± 0.6 
1.2 ± 0.6 
-0.0 ± 0.6  
-0.0 ± 0.7  
NO 
NO 
16 (Trial 1) PT NPT 
1.2 ± 0.5 
1.2 ± 0.5 
0.2 ± 0.6 
1.2 ± 0.5 
0.0 ± 0.5  
-0.0 ± 0.5  
NO 
NO 
16 (Trial 2) PT NPT 
1.2 ± 0.6 
1.2 ± 0.6 
1.2 ± 0.4 
1.2 ± 0.4 
-0.0 ± 0.6  
0.0 ± 0.6  
NO 
NO 
28 PT NPT 
0.5 ± 0.1 
0.5 ± 0.1 
0.5 ± 0.1 
0.5 ± 0.1 
0.0 ± 0.1  
-0.0 ± 0.1  
NO  
YES 
22 PT NPT 
1.5 ± 0.4 
1.5 ± 0.4 
1.5 ± 0.4 
1.5 ± 0.4 
0.1 ± 0.2 







1.3 ± 0.5 
1.5 ± 0.5 
1.3 ± 0.5 
1.4 ± 0.5 
1.4 ± 0.4 
1.3 ± 0.4 
0.1 ± 0.5  
-0.1 ± 0.5  





Abbreviations: SD = Standard Deviation; HDL = High Density Lipoprotein; PT = Periodontal 
Therapy; NPT = No Periodontal Therapy; IPT = Intensive Periodontal Treatment; PTA = 





Supplemental Table 3G: Overview of selected trials investigating LDL levels for treatment and 





























20 PT NPT 
3.4 ± 0.5 
3.4 ± 0.5 
3.1 ± 0.6 
3.5 ± 0.4 
-0.3 ± 0.6  







3.6 ± 1.0 
3.5 ± 1.3 
3.8 ± 1.5 
3.3 ± 0.9 
3.0 ± 1.2 
3.3 ± 1.3 
-0.4 ± 0.9  
-0.5 ± 1.3  




27 PT NPT 
3.2 ± 1.1 
3.4 ± 1.0 
3.2 ± 0.9 
3.4 ± 0.9 
0.0 ± 1.1  
0.0 ± 1.0  
NO 
NO 
24 PT NPT 
2.9 ± 1.1 
2.9 ± 1.0 
2.8 ± 0.9 
2.9 ± 1.0 
-0.1 ± 1.0  
-0.0 ± 1.0  
NO 
NO 
16 (Trial 1) PT NPT 
2.6 ± 0.7 
2.6 ± 0.7 
2.6 ± 0.7 
2.5 ± 0.7 
-0.0 ± 0.7  
-0.0 ± 0.7  
NO 
NO 
16 (Trial 2) PT NPT 
2.4 ± 0.7 
2.7 ± 0.7 
2.4 ± 0.6 
2.6 ± 0.5 
0.0 ± 0.7  
-0.1 ± 0.7  
NO 
NO 
28 PT NPT 
1.6 ± 0.2 
1.5 ± 0.2 
1.2 ± 0.4 
1.4 ± 0.2 
-0.4 ± 0.3  
-0.0 ± 0.2  
YES  
NO  
22 PT NPT 
3.1 ± 0.9 
3.1 ± 1.0 
3.0 ± 0.8 
3.1 ± 0.9 
-0.1 ± 0.5 







3.2 ± 0.6 
3.4 ± 0.6 
3.2 ± 0.6 
3.4 ± 0.9 
3.2 ± 0.6 
3.2 ± 0.7 
0.2 ± 0.7  
-0.2 ± 0.8  





Abbreviations: SD = Standard Deviation; LDL = Low Density Lipoprotein; PT = Periodontal 
Therapy; NPT = No Periodontal Therapy; IPT = Intensive Periodontal Treatment; PTA = 




Supplemental Table 3H: Overview of selected trials investigating HbA1c levels for treatment and 






























7.3 ± 1.2 
7.3 ± 1.6 
7.3 ± 1.5 
7.1 ± 1.3 
6.9 ± 1.1 
7.4 ± 1.6 
-0.2 ± 1.3  
-0.4 ± 1.4  




26 PT NPT 
7.9 ± 0.7 
7.6 ± 0.7 
NR 
NR 
-0.7 ± 0.9 
-0.1 ± 0.5 
YES 
NO 
15 (Trial 2,3) PT NPT 
7.1 ± 0.3 
7.1 ± 0.3 
6.6 ± 0.4 
7.2 ± 0.3 
-0.6 ± 0.4  
0.1 ± 0.3  
YES 
NO 
25 PT NPT 
7.2 ± 0.9 
6.9 ± 0.9 
NR 
NR 
-0.1 ± 0.6 




Abbreviations: SD = Standard Deviation; HbA1c = Glycated Hemoglobin; PT = Periodontal 
Therapy; NPT = No Periodontal Therapy; IPT = Intensive Periodontal Treatment; NR = Not 















Supplemental Table 3I: Overview of selected trials investigating systolic and diastolic blood 






































27 PT NPT 
149.0 ± 6.9 
147.0 ± 6.8 
148.0 ± 7.0 
146.0 ± 7.1 
-1.0 ± 6.9  
-1.0 ± 7.0  
NO 
NO 
24 PT NPT 
141.3 ± 20.2 
141.3 ± 19.8 
140.3 ± 19.3 
140.8 ± 19.1 
-1.0 ± 19.8  
-0.5 ± 19.5  
NO 
NO 
16 (Trial 1) PT NPT 
115.1 ± 10.9 
114.9 ± 11.1 
114.6 ± 10.4 
113.8 ± 10.7 
-0.5 ± 10.7  
-1.1 ± 10.9  
NO 
NO 
16 (Trial 2) PT NPT 
140.1 ± 20.3 
141.2 ± 20.1 
141.3 ± 21.4 
140.0 ± 19.3 
1.2 ± 20.9  
-1.2 ± 19.7  
NO 
NO 
22 PT NPT 
125.7 ± 16.6 
125.2 ± 18.3 
122.6 ± 14.3 
122.9 ± 15.5 
-3.0 ± 11.3 






















27 PT NPT 
97.0 ± 4.1 
98.0 ± 3.8 
96.8 ± 3.8 
96.8 ± 4.2 
-0.2 ± 4.0  
-1.2 ± 4.0  
NO 
NO 
24 PT NPT 
82.5 ± 13.3 
82.3 ± 12.7 
80.7 ± 12.9 
81.9 ± 12.1 
-1.8 ± 13.1  
-0.4 ± 12.4  
NO 
NO 
16 (Trial 1) PT NPT 
66.1 ± 7.4 
66.2 ± 7.6 
67.4 ± 7.9 
97.1 ± 8.1 
1.3 ± 7.7  
0.9 ± 7.9  
NO 
NO 
16 (Trial 2) PT NPT 
89.2 ± 14.1 
90.2 ± 13.8 
88.7 ± 13.7 
89.9 ± 13.3 
-0.5 ± 13.9  
-0.3 ± 13.6  
NO 
NO 
22 PT NPT 
80.5 ± 11.4 
79.3 ± 11.2 
77.8 ± 9.0 
77.5 ± 10.1 
-2.7 ± 7.5 




Abbreviations: SD = Standard Deviation; PT = Periodontal Therapy; NPT = No Periodontal 
Therapy;  = values were calculated 
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20 PT ? □ □ ? ? ? ? □ □ □ NPT 
21 PT 0 □ □ □ □ □ □ □ □ □ NPT 
16 (Trial 1) PT 0 0 □ 0 0 0 0 □ 0 0 NPT 
22 SRP 0 0 □ 0 0 0 0 □ 0 0 NPT 














0 □ □ □ NPT 

































26 PT 0 □ □ □ □ □ □ + □ □ NPT 
27 PT 0 □ □ 0 0 0 0 □ 0 0 NPT 
23 PT ? □ □ □ □ □ □ □ □ □ NPT 
15 (Trial 1) PT + + + □ □ □ □ □ □ □ NPT 
15 (Trial 2) PT + + + □ □ □ □ 
+ 
□ □ NPT 
15 (Trial 3) PT + 0 0 □ □ □ □ □ □ NPT 
25 PT + □ □ □ □ □ □ 0 □ □ NPT 
24 PT 0 0 □ ? ? ? ? □ 0 0 NPT 
16 (Trial 2) PT 0 0 □ 0 0 0 0 □ 0 0 NPT 
28 PT □ □ □ 0 + 0 + □ □ □ NPT 
 
Abbreviations: CRP = C-Reactive Protein; IL-6= Interleukin-6; TNF-α = Tumor Necrosis Factor-α; TG = Tryglycerides; TC = Total Cholesterol; HDL = High Density Lipoprotein; LDL = Low Density Lipoprotein; 
HbA1c = Glycated Hemoglobin; PT = Periodontal Treatment; IPT = Intensive Periodontal Treatment; PTA = Periodontal Treatment with Antibiotics; NPT = No Periodontal Treatment;  + = significant difference in 




































Test for heterogeneity 
  
I C 
p-value I² -value (%) 
CRP 
< 6 months 15, 23 F 93 93 -0.81 [-1.06 ; -0.56] <0.00001 0.50 0 
≥ 6 months 16-17, 24-27 R 270 204 -0.24 [-0.47 ; -0.01] 0.04 0.40 3 
IL-6 
< 6 months 15  F 78 78 -1.16 [-1.66 ; -0.66] <0.00001 0.78 0 
≥ 6 months 16, 24 F 41 33 -0.98 [-2.74 ; 0.77] 0.27 0.88 0 
 
1 A random effect model was used if at least 5 trials per analysis could be included. Otherwise a fixed effect model was performed.   
 
Abbreviations: C = Non-intervention group; CI = Confidence Interval; CRP = C-Reactive Protein; F= Fixed; I = Intervention group; IL-6 = 




Supplemental Table 6: Evidence profile for impact of periodontal treatment compared no 














Risk of bias 
 
















Possible Possible Possible 
 
Quality  
body of evidence 
 
















Heterogeneity: Tau² = 0.21; Chi² = 12.25, df = 6 (P = 0.06); I² = 51%














Heterogeneity: Tau² = 0.13; Chi² = 25.08, df = 10 (P = 0.005); I² = 60%
Test for overall effect: Z = 3.47 (P = 0.0005)
Total (95% CI)
Heterogeneity: Tau² = 0.12; Chi² = 37.96, df = 17 (P = 0.002); I² = 55%
Test for overall effect: Z = 3.12 (P = 0.002)
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Supplemental Figure 1. (A) Forest plot, based on the systemic health of the study population,  
presenting WMD of baseline-end CRP levels between the treatment groups (experimental) and non-
treatment groups (control) including a systemically healthy and systemically diseased study 
population with periodontitis, heterogeneity and overall effect for treatment studies; a random effect 












Heterogeneity: Tau² = 0.00; Chi² = 2.38, df = 3 (P = 0.50); I² = 0%










Heterogeneity: Tau² = 0.01; Chi² = 6.22, df = 6 (P = 0.40); I² = 3%
Test for overall effect: Z = 2.02 (P = 0.04)
Total (95% CI)
Heterogeneity: Tau² = 0.13; Chi² = 25.08, df = 10 (P = 0.005); I² = 60%
Test for overall effect: Z = 3.47 (P = 0.0005)
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Heterogeneity: Chi² = 2.38, df = 3 (P = 0.50); I² = 0%










Heterogeneity: Chi² = 6.22, df = 6 (P = 0.40); I² = 3%
Test for overall effect: Z = 2.59 (P = 0.010)
Total (95% CI)
Heterogeneity: Chi² = 25.08, df = 10 (P = 0.005); I² = 60%
Test for overall effect: Z = 5.64 (P < 0.00001)
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Supplemental Figure 2. (A) Forest plots, based on study duration, presenting WMD of baseline-
end CRP levels between the treatment groups (experimental) and non-treatment groups (control) 
including a systemically diseased study population with periodontitis, heterogeneity and overall effect 













Heterogeneity: Tau² = 0.00; Chi² = 3.69, df = 4 (P = 0.45); I² = 0%








Heterogeneity: Tau² = 0.00; Chi² = 0.55, df = 4 (P = 0.97); I² = 0%
Test for overall effect: Z = 4.68 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 0.31; Chi² = 20.75, df = 9 (P = 0.01); I² = 57%
Test for overall effect: Z = 1.46 (P = 0.14)





































































































Experimental Control Mean Difference Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2















Supplemental Figure 3. (A) Forest plot, based on the systemic health of the study population,  
presenting WMD of baseline-end IL-6 levels between the treatment groups (experimental) and non-
treatment groups (control) including a systemically healthy and systemically diseased study 
population with periodontitis, heterogeneity and overall effect for treatment studies; a random effect 











Heterogeneity: Chi² = 0.49, df = 2 (P = 0.78); I² = 0%





Heterogeneity: Chi² = 0.02, df = 1 (P = 0.88); I² = 0%
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI)
Heterogeneity: Chi² = 0.55, df = 4 (P = 0.97); I² = 0%
Test for overall effect: Z = 4.68 (P < 0.00001)
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Supplemental Figure 4. (A) Forest plot, based on study duration, presenting WMD of baseline-
end IL-6 levels between the treatment groups (experimental) and non-treatment groups (control) 
including a systemically diseased study population with periodontitis, heterogeneity and overall effect 
















Heterogeneity: Tau² = 0.60; Chi² = 19.37, df = 5 (P = 0.002); I² = 74%
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Supplemental Figure 5. (A) Forest plot presenting WMD of baseline-end TNF-α levels between 
the treatment groups (experimental) and non-treatment groups (control) including a systemically 
healthy and systemically diseased study population with periodontitis, heterogeneity and overall effect 













Heterogeneity: Tau² = 0.00; Chi² = 0.57, df = 4 (P = 0.97); I² = 0%









Heterogeneity: Tau² = 0.00; Chi² = 1.12, df = 5 (P = 0.95); I² = 0%
Test for overall effect: Z = 0.47 (P = 0.64)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.87, df = 10 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.20 (P = 0.84)
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Supplemental Figure 6. (A) Forest plot, based on the systemic health of the study population,  
presenting WMD of baseline-end triglycerides levels between the treatment groups (experimental) 
and non-treatment groups (control) including a systemically healthy and systemically diseased study 
population with periodontitis, heterogeneity and overall effect for treatment studies; a random effect 












Heterogeneity: Tau² = 0.00; Chi² = 2.46, df = 4 (P = 0.65); I² = 0%









Heterogeneity: Tau² = 0.00; Chi² = 4.49, df = 5 (P = 0.48); I² = 0%
Test for overall effect: Z = 2.17 (P = 0.03)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 7.05, df = 10 (P = 0.72); I² = 0%
Test for overall effect: Z = 2.61 (P = 0.009)
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Supplemental Figure 7. (A) Forest plot, based on the systemic health of the study population,  
presenting WMD of baseline-end total cholesterol levels between the treatment groups (experimental) 
and non-treatment groups (control) including a systemically healthy and systemically diseased study 
population with periodontitis, heterogeneity and overall effect for treatment studies; a random effect 












Heterogeneity: Tau² = 0.00; Chi² = 2.13, df = 4 (P = 0.71); I² = 0%









Heterogeneity: Tau² = 0.00; Chi² = 0.22, df = 5 (P = 1.00); I² = 0%
Test for overall effect: Z = 1.09 (P = 0.27)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 3.49, df = 10 (P = 0.97); I² = 0%
Test for overall effect: Z = 0.56 (P = 0.58)
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Supplemental Figure 8. (A) Forest plot, based on the systemic health of the study population,  
presenting WMD of baseline-end HDL levels between the treatment groups (experimental) and non-
treatment groups (control) including a systemically healthy and systemically diseased study 
population with periodontitis, heterogeneity and overall effect for treatment studies; a random effect 












Heterogeneity: Tau² = 0.00; Chi² = 4.53, df = 4 (P = 0.34); I² = 12%









Heterogeneity: Tau² = 0.03; Chi² = 8.97, df = 5 (P = 0.11); I² = 44%
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 14.79, df = 10 (P = 0.14); I² = 32%
Test for overall effect: Z = 1.89 (P = 0.06)
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Supplemental Figure 9. (A) Forest plot, based on the systemic health of the study population,  
presenting WMD of baseline-end LDL levels between the treatment groups (experimental) and non-
treatment groups (control) including a systemically healthy and systemically diseased study 
population with periodontitis, heterogeneity and overall effect for treatment studies; a random effect 
model. (B) Funnel plot of studies using LDL as an outcome parameter. 
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Heterogeneity: Tau² = 0.00; Chi² = 0.10, df = 1 (P = 0.76); I² = 0%






Heterogeneity: Tau² = 0.00; Chi² = 0.09, df = 2 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.24, df = 4 (P = 0.99); I² = 0%
Test for overall effect: Z = 0.12 (P = 0.90)
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Heterogeneity: Chi² = 0.10, df = 1 (P = 0.76); I² = 0%






Heterogeneity: Chi² = 0.09, df = 2 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI)
Heterogeneity: Chi² = 0.24, df = 4 (P = 0.99); I² = 0%
Test for overall effect: Z = 0.12 (P = 0.90)
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Supplemental Figure 10. (A) Forest plots, based on the systemic health of the study population,  
presenting WMD of baseline-end systolic blood pressure between the treatment groups 
(experimental) and non-treatment groups (control) including a systemically healthy and systemically 
diseased study population with periodontitis, heterogeneity and overall effect for treatment studies; a 











Heterogeneity: Tau² = 0.00; Chi² = 0.17, df = 1 (P = 0.68); I² = 0%






Heterogeneity: Tau² = 0.00; Chi² = 0.45, df = 2 (P = 0.80); I² = 0%
Test for overall effect: Z = 1.51 (P = 0.13)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.00, df = 4 (P = 0.74); I² = 0%
Test for overall effect: Z = 1.09 (P = 0.27)
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Heterogeneity: Chi² = 0.17, df = 1 (P = 0.68); I² = 0%






Heterogeneity: Chi² = 0.45, df = 2 (P = 0.80); I² = 0%
Test for overall effect: Z = 1.51 (P = 0.13)
Total (95% CI)
Heterogeneity: Chi² = 2.00, df = 4 (P = 0.74); I² = 0%
Test for overall effect: Z = 1.09 (P = 0.27)
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Supplemental Figure 11. (A) Forest plots, based on the systemic health of the study population,  
presenting WMD of baseline-end diastolic blood pressure between the treatment groups 
(experimental) and non-treatment groups (control) including a systemically healthy and systemically 
diseased study population with periodontitis, heterogeneity and overall effect for treatment studies; a 













Heterogeneity: Tau² = 0.04; Chi² = 9.11, df = 4 (P = 0.06); I² = 56%
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Supplemental Figure 12. (A) Forest plot, based on the systemic health of the study population,  
presenting WMD of baseline-end HbA1c levels between the treatment groups (experimental) and non-
treatment groups (control) including a systemically healthy and systemically diseased study 
population with periodontitis, heterogeneity and overall effect for treatment studies; a random effect 





The current review aimed to answer the question as to whether periodontal 
treatment reduces systemic levels of important risk markers for atherosclerosis. The 
vast majority of trials (18 out of 19) have investigated hsCRP levels before and after 
periodontal intervention. The main finding of the current study was that hsCRP was 
significantly reduced in all intervention trials combined into one meta-analysis. 
Interestingly, when we restricted the trials into including patients who were suffering 
from CVD and/or a metabolic disease (e.g. diabetes mellitus, metabolic syndrome, 
hyperlipidemia) hsCRP was significantly reduced, while this was not found in the 
intervention trials enrolling otherwise healthy periodontitis patients. In the 
systemically diseased population (11 trials), a total of 358 patients in the treatment 
group showed significantly more reduction of hsCRP compared to the 290 patients in 
the non-intervention group (ΔhsCRP -0.62 mg/L, CI: -0.97;-0.27; p=0.0005). This 
reduction in hsCRP is in our opinion clinically relevant; hsCRP levels exhibit a 
continuous association with the risk of coronary heart disease, ischemic stroke and 
vascular mortality,29 suggesting that every decrease in hsCRP level may be beneficial 
for reducing the risk for CVD. It should be considered that baseline hsCRP values 
ranged from 0.8 ± 1.0 mg/L to 12.5 ± 15.9 mg/L.  
 Somewhat to our surprise and in contrast with previous meta-analyses30-31 we 
did not observe significant reductions of hsCRP after treatment in periodontitis 
patients, who were systemically healthy (ΔCRP: -0.09 mg/L, CI: -0.60 ; 0.42; 
p=0.73). Perhaps, this could be explained by the Hawthorn effect in the non-
intervention group. Another explanation is that hsCRP is not a good marker for 
successful periodontal therapy. More recently, clinical trials on periodontal 
intervention include vascular function parameters. All 5 trials showed a significant 
improvement in vascular function after periodontal therapy as measured by flow 
mediated dilation, acetylcholine-dependent vasodilatation or a decrease in CD34+ 
cells. These results on markers of improved vascular function were observed in both 
systemically healthy and systemically diseased study populations. However, these 
results should be interpreted cautiously, because different methods for assessment of 
endothelial function were used and no proper meta-analysis could be performed.  
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 A second major finding of this study was that periodontal treatment resulted 
in improvement of metabolic control in diabetic patients as shown by a significant 
reduction in HbA1c levels. In the current meta-analysis, we observed a significant 
change in HbA1c of 0.45% for the treatment group compared to the non-treatment 
group. This was found in 5 trials of which only 1 overlapped with our previous study 
on the effect of periodontal therapy on metabolic control;13 in the latter publication 
we found a very comparable and significant improvement also (ΔHbA1c: -0.40%). In 
the current analysis, metabolic diseased patients were included, since it is known 
that patients with elevated levels of HbA1c run a higher risk for CVD.  
 A third important finding of the current study was, that after periodontal 
treatment, total cholesterol (TC) was also significantly reduced in periodontitis 
patients with CVD and/or metabolic disease compared to the non-treatment group. 
Similar to hsCRP and IL-6, this was not observed in otherwise healthy subjects with 
periodontitis. Elevated TC levels are strongly associated with increased risk for 
CVD.32 
 In all included trials of this systematic review, only surrogate markers were 
used to evaluate the effect of periodontal treatment on CVD. No hard clinical 
outcomes (e.g. secondary myocardial infarction, stroke, death, etc.) have been 
investigated. However, this latter is impossible to investigate, since it is unethical to 
leave patients with periodontitis untreated for a follow-up of at least 5-10 years to 
record a substantial number of clinical events. The current systematic review shows 
clearly that patients with known CVD or metabolic disease benefit from periodontal 
therapy, which could be present up to 12 months. 
 It has been widely accepted that low grade systemic inflammation contributes 
to an elevated risk for CVD. In this respect, elevated hsCRP levels are strongly 
associated with increased risk.33 The elevated levels of hsCRP and other 
inflammatory markers in periodontitis (e.g. IL-6 and TNF-α)34 might be related to 
the chronicity of periodontitis and the concomitant periodontal inflamed surface 
area (PISA35). The PISA in patients with severe periodontitis may be as large as 39 
cm2.35 This breach in epithelial lining opens up the possibility for oral pathogens to 
enter the circulation and induce systemic inflammation, metabolic discontrol and 
vascular dysfunction. Periodontal therapy reduces PISA and the current meta-
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analyses are highly suggestive that this reduction results in lower levels of systemic 
inflammation and improvement of metabolic control. 
 Some issues regarding the current study need discussion. First, although we 
combined trials in meta-analyses, we noted quite some heterogeneity between trials 
(Range I2: 0%-74%, Table 1). Ideally, I2 should be ≤40% and χ2-test should result in p 
≥0.1. Furthermore, systematic reviews and meta-analyses run the risk that included 
studies may have some form of bias. Third, the follow-up of the included trials 
ranged between 4 weeks and 12 months and it should be questioned which follow-up 
time is appropriate to be able to draw clinical relevant conclusions about the effect of 
periodontal therapy on the biochemical risk markers of CVD. The issue of reporting 
surrogate outcomes is already discussed above. 
 A strong positive aspect of the current study is that we made a very broad 
search of the literature and that we performed a sub-analysis based on the systemic 
health of the subjects in the selected trials. This is the first study that indicates that 
especially those suffering from CVD and/or metabolic diseases, benefit from 
periodontal therapy with regard to biomarkers of atherosclerotic diseases.  
 Thus, we conclude from the current systematic review, based on strict 
inclusion criteria and quality control of literature, that periodontal treatment might 
reduce the risk for CVD by reducing plasma levels of inflammatory (CRP, IL-6) and 
metabolic (TC, HbA1c) markers. This improvement was especially observed in 
periodontitis patients also suffering from systemic diseases, like CVD and/or 
diabetes mellitus, and this improvement was still present 6 month after periodontal 
intervention. This emphasizes the effectiveness and need for periodontal diagnosis 
and periodontal therapy in atherosclerotic and diabetic individuals to improve their 
systemic health. We recommend that cardiologists and diabetologists ask their 
patients to be screened for the presence of periodontal disease and if so, to undergo 
periodontal therapy as we have shown here that this will reduce systemic 
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An increasing number of studies have demonstrated an association between 
periodontal disease and several systemic conditions and diseases such as diabetes 
mellitus type 2 (DM2) 1-10, rheumatoid arthritis (RA) 11-22, cardiovascular diseases 
(CVD)  23-35, adverse pregnancy outcome 36-43, osteoporosis44-47  and respiratory 
diseases 48-56. However the associations reported differ in magnitude between 
studies, which may be due to differences in either populations studied,  severity of 
systemic diseases or the way in which periodontitis is operationalized. In case of 
Diabetes Mellitus type 2 (DM2) for example, periodontitis has been categorized as 
mild, moderate or severe on the basis of a variety of cut off points for pocket depth 
(PD), bleeding on probing (BOP), clinical attachment loss (CAL), bone loss (BL) and 
tooth mobility 4, 5, 7, 57. Only one of those studies did not show a significant difference 
in prevalence and severity of periodontitis between DM2 and healthy controls 57. One 
study operationalized periodontitis according to the community periodontal index of 
treatment need (CPITN) did not find significant differences in prevalence and 
severity of periodontitis between patients with DM2 and healthy controls 58.  
Thus, different methods to define periodontitis may influence not only the 
strength of the associations between a given disease and periodontitis, but also 
whether an association is observed at all. In addition to DM2, in research linking 
periodontitis to preterm low birth weight, 13 different methods have been used to 
operationalize periodontitis. Depending on the method used, either an association 59, 
60 or no association 43 between periodontitis and preterm low birth weight was 
observed. Like DM2 and preterm low birth weight, associations between 
periodontitis and  RA may be influenced by periodontitis operationalization. 
Therefore,  whether the method of operationalizing periodontitis affects the results of  
studies on the association between periodontitis and systemic disease was 
investigated in the present thesis. 
To study possible associations, the commonly used and above mentioned 
methods to operationalize periodontitis prevalence and severity  were used. In 
addition, a recently introduced measure to quantify periodontitis, the Periodontal 
Inflamed Surface Area (PISA) 61 was applied. Other indicators of inflammatory 
burden in patients with DM2 or RA were measured, such as erythrocyte 
sedimentation (ESR), serum levels of c-reactive proteins (CRP), rheumatoid factor 





PISA was introduced by Nesse et al (2008)61 in order to quantify the amount of 
inflamed periodontal tissue. Commonly applied other methods use continuous 
variables e.g. mean probing pocket depth (PPD) and mean clinical attachment levels 
(CAL) or certain cut off points to classify patients as being either unaffected or 
affected by mild, moderate or severe/advanced periodontitis 62. Nesse et al. (2008) 
stated in their landmark paper that these outcome measures do not necessarily 
quantify the amount of inflamed periodontal tissue. Therefore, they added a second 
dimension by calculating the inflamed (bleeding) pocket surface area in 
periodontitis, to quantify the inflammatory burden produced by periodontitis. PISA 
is calculated using CAL, PPD, recession and bleeding on probing (BOP). Although 
PISA seems to be a promising tool to better assess the inflammatory burden of 
periodontal disease than, e.g. PPD, CAL and BOP do, PISA has also some 
shortcomings. These shortcomings include measurement errors in assessing the 
various variables (similar to PPD, CAL, BOP etc.) and the use of population based 
mean values for root surface areas and root lengths. Furthermore, the extend and 
composition of the inflammatory infiltrate and underlying  inflamed surface area are 
not assessed by PISA. Finally  PISA, like all other variables used to operationalize 
periodontal disease thus far, does not provide information on the periodontal 
pathogenic flora and serum inflammatory mediators. Despite these shortcomings, 
PISA has demonstrated a dose response relationship between control of blood 
glucose levels over time as expressed by HbA1c in Afro-American DM2 patients from 
Curacao9. The observed association was independent of confounding factors as sex, 
oral hygiene, SES, BMI, smoking and the number of years since DM2 was diagnosed. 
In the present thesis, the prevalence and severity of periodontitis in 
Indonesians with DM2 was investigated. PISA, but also traditional parameters as 
PPD, CAL and BOP were able to demonstrate a higher prevalence and severity of 
periodontitis in DM2 patients compared to controls in this ethnic different 
population, indicating the robust association between periodontitis and DM2. It also 
indicates that these methods, including PISA, can be applied in different ethnic 
populations. Furthermore, PISA together with CRP emerged as predictor of HbA1c in 
controls indicating that periodontitis may pose an inflammatory burden that 
contributes to developing DM2 (chapter 2). In Indonesian DM2 patients, however, 
the assumed association between PISA and HbA1c levels could not be confirmed . 
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The latter may be due to the antidiabetic drug regimes used in Indonesian DM2 
patients (many of them used insulin derivates) as well as substantial lower body 
mass index  (BMI) scores in Indonesia as compared to individuals in the Curacao 
study of Nesse et al (2009) who were mainly on oral antidiabetics or just a diet.  
Thus, periodontitis (expressed as PISA) may pose an inflammatory burden 
that impairs blood glucose regulation (expressed as HbA1c), however this effect may 
be masked by use of antidiabetic drugs and modified by BMI.  Furtehermore, based 
on our data it is suggested that subjects with a high PISA score as predictor for 
HbA1c but not yet known with DM2 should be tested for DM2. 
 
Inflammatory markers 
Additional information on the presence of inflammatory markers, e.g., CRPs, 
interleukins  IL 1 and IL6, and tumor necrosis factor alpha (TNFα) and the 
periodontal pathogenic flora should be considered as indicators of  the impact of 
periodontitis as an inflammatory burden and risk factor for systemic diseases and 
disorders. Our studies in Indonesia, presented in this thesis, indeed indicated that 
periodontitis may cause an infectious and inflammatory burden as evidenced by 
increased CRP levels, which may impair blood glucose control 63.  In chapter 4 we 
were able to demonstrate that the presence of periodontitis in RA patients was 
associated with an increased inflammatory state as indicated by higher CRP and ESR 
levels.  The increased levels of inflammatory markers in patients with RA may be 
explained by several factors. First, periodontitis may aggravate RA. Since 
periodontitis is accompanied by higher CRP levels 64-68 , long standing untreated 
periodontitis may contribute to a proinflammatory state in RA. Secondly, RA may 
aggravate periodontitis. Since more severe RA is also accompanied by higher CRP 
levels, 69, 70  higher CRP levels may be a reflection of active RA, which may contribute 
to a proinflammatory state in periodontitis. The same explanations may apply to 
higher ESR in patients with RA and  periodontitis 12, 15 . Interestingly, studies 
reporting on the effect of periodontal treatment in RA patients not only show a 
reduction in  ESR levels,14, 18, 22, 71  but also a reduction in CRP levels  after periodontal 
therapy 22 . These findings support periodontitis as contributer to a higher disease 
activity in RA. It should be noted that these are preliminary results of just a few 
intervention studies with small samples size. The existence and nature of an 
association between RA and periodontal disease needs further research in which 
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proper attention is paid to specific confounders like maintenance of proper oral 
hygiene. 
RA affects the wrist and the small joints of the hand impairing handfunction 
of RA patients. As a result  maintenance of proper oral hygiene may be impaired, 
thus posing a riskfactor for periodontitis 17  21 . Although RA patients had significantly 
higher plaque scores than non-RA controls, thus supporting the previous hypothesis, 
RA patients with periodontitis had lower mean plaque scores than RA patients 
without periodontitis. Therefore, impaired maintenance of oral hygiene in RA 
patients probably does not appear toconfound the association between periodontitis 
and increased disease activity in RA.. Smoking and duration of RA may also serve as 
confounding factors. Although smoking is a risk factor for both RA 72  and 
periodontitis73  and duration of RA is also associated with severity of periodontal 
disease, both smoking and duration of RA did not appear to confound the association 
between periodontitis and higher ESR and CRP levels in RA patients (chapter 4).  
 
Treatment studies 
Recently, it was demonstrated in a systematic review that treatment of periodontitis 
in RA patients reduces RA disease activity with fair evidence on reduction of the 
Disease Activity Score for Rheumatoid Arthritis DAS28 scores 74. DAS28 is a 
composite, numerical score combining key components as tender and swollen joints, 
ESR, CRP and the patients global assessment of general health, measured on a visual 
analogue scale (VAS) 75.Regarding DM2, a meta-analysis showed that periodontal 
treatment led to improvement of glycaemic control probably due to reduction of CRP 
levels and inflammatory cytokines 10. Thus, meta-analyses have shown that a 
reduction in inflammatory burden, as evidenced by a reduction in CRP levels, after 
periodontal treatment appears beneficial to patients with RA and DM2. CRP levels 
also play a key role in the risk for atherosclerotic diseases. Consequently, in the 
systemic review described in chapter 5  the effect of periodontal treatment on the 
reduction of the levels of biomarkers of atherosclerotic disease was investigated.  
Significant reductions could be demonstrated of inflammatory markers (CRP, Il-6 
levels) and metabolic markers (total cholesterol and HbA1c) after periodontal 
treatment, especially in periodontitis patients already suffering from cardiovascular 
and/or metabolic diseases. This finding demonstrates that periodontal treatment 




Conclusion and future perspectives 
Our studies on the association between periodontitis and DM2 and RA have shown 
that Indonesians patients with DM2  had more prevalent and severe periodontitis 
than controls. Furthermore, it appeared that PISA and CRP were predictors of 
glycaemic control of Indonesian subjects not on antidiabetics . On the contrary, in 
Indonesian patients with RA  the prevalence and severity of periodontitis appeared 
was not higher than in healthy controls. However, within the group of RA patients, 
periodontitis presence was associated with an increased inflammatory state. CRP 
appears to play a major role in these associations as CRP levels can be reduced by 
periodontal treatment, thereby improving DM2 and RA conditions and reducing the 
risk for CVD. In future research the role of CRP’s in different forms of periodontal 
diseases and the reduction induced by different therapeutic protocols should be 
investigated. Furthermore, diagnosis and treatment of periodontal disease should be 
an integral part of medical treatment of DM2 and RA and  also deserves attention in  
the prevention of CVD.  Periodontitis appears to cause a proinflammatory and 
procoagulatory state. Further research into the magnitude and nature of the 
contribution of periodontitis to the initiation and deterioration of systemic diseases 
is necessary. This may well lead to insights that further improve health of patients 




1. Sandberg GE, Sundberg HE, Fjellstrom CA, Wikblad KF. Type 2 diabetes and oral 
health: a comparison between diabetic and non-diabetic subjects. Diabetes Res Clin 
Pract 2000;50(1):27-34.  
2. Tsai C, Hayes C, Taylor GW. Glycemic control of type 2 diabetes and severe 
periodontal disease in the US adult population. Community Dent Oral Epidemiol 
2002;30(3):182-192.  
3. Lu HK, Yang PC. Cross-sectional analysis of different variables of patients with 
non-insulin dependent diabetes and their periodontal status. Int J Periodontics 
Restorative Dent 2004;24(1):71-79.  
4. Campus G, Salem A, Uzzau S, Baldoni E, Tonolo G. Diabetes and periodontal 
disease: a case-control study. J Periodontol 2005;76(3):418-425.  
5. Saremi A, Nelson RG, Tulloch-Reid M, et al. Periodontal disease and mortality in 
type 2 diabetes. Diabetes Care 2005;28(1):27-32.  
6. Jansson H, Lindholm E, Lindh C, Groop L, Bratthall G. Type 2 diabetes and risk 
for periodontal disease: a role for dental health awareness. J Clin Periodontol 
2006;33(6):408-414.  
7. Shultis WA, Weil EJ, Looker HC, et al. Effect of periodontitis on overt nephropathy 
and end-stage renal disease in type 2 diabetes. Diabetes Care 2007;30(2):306-311.  
8. Novak MJ, Potter RM, Blodgett J, Ebersole JL. Periodontal disease in Hispanic 
Americans with type 2 diabetes. J Periodontol 2008;79(4):629-636.  
9. Nesse W, Linde A, Abbas F, et al. Dose-response relationship between periodontal 
inflamed surface area and HbA1c in type 2 diabetics. J Clin Periodontol 
2009;36(4):295-300.  
10. Teeuw WJ, Gerdes VE, Loos BG. Effect of periodontal treatment on glycemic 
control of diabetic patients: a systematic review and meta-analysis. Diabetes Care 
2010;33(2):421-427.  
11. Mercado F, Marshall RI, Klestov AC, Bartold PM. Is there a relationship between 
rheumatoid arthritis and periodontal disease? J Clin Periodontol 2000;27(4):267-
272.  
12. Mercado FB, Marshall RI, Klestov AC, Bartold PM. Relationship between 
rheumatoid arthritis and periodontitis. J Periodontol 2001;72(6):779-787.  
13. Miranda LA, Fischer RG, Sztajnbok FR, Figueredo CM, Gustafsson A. Periodontal 




14. Ribeiro J, Leao A, Novaes AB. Periodontal infection as a possible severity factor 
for rheumatoid arthritis. J Clin Periodontol 2005;32(4):412-416.  
15. Havemose-Poulsen A, Westergaard J, Stoltze K, et al. Periodontal and 
hematological characteristics associated with aggressive periodontitis, juvenile 
idiopathic arthritis, and rheumatoid arthritis. J Periodontol 2006;77(2):280-288.  
16. Miranda LA, Braga F, Fischer RG, Sztajnbok FR, Figueredo CM, Gustafsson A. 
Changes in periodontal and rheumatological conditions after 2 years in patients with 
juvenile idiopathic arthritis. J Periodontol 2006;77(10):1695-1700.  
17. Reichert S, Machulla HK, Fuchs C, John V, Schaller HG, Stein J. Is there a 
relationship between juvenile idiopathic arthritis and periodontitis? J Clin 
Periodontol 2006;33(5):317-323.  
18. Al-Katma MK, Bissada NF, Bordeaux JM, Sue J, Askari AD. Control of 
periodontal infection reduces the severity of active rheumatoid arthritis. J Clin 
Rheumatol 2007;13(3):134-137.  
19. de Pablo P, Dietrich T, McAlindon TE. Association of periodontal disease and 
tooth loss with rheumatoid arthritis in the US population. J Rheumatol 
2008;35(1):70-76.  
20. Ishi Ede P, Bertolo MB, Rossa C,Jr, Kirkwood KL, Onofre MA. Periodontal 
condition in patients with rheumatoid arthritis. Braz Oral Res 2008;22(1):72-77.  
21. Pischon N, Pischon T, Kroger J, et al. Association among rheumatoid arthritis, 
oral hygiene, and periodontitis. J Periodontol 2008;79(6):979-986.  
22. Pinho Mde N, Oliveira RD, Novaes AB,Jr, Voltarelli JC. Relationship between 
periodontitis and rheumatoid arthritis and the effect of non-surgical periodontal 
treatment. Braz Dent J 2009;20(5):355-364.  
23. Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Periodontal disease and 
coronary heart disease risk. JAMA 2000;284(11):1406-1410.  
24. Janket SJ, Baird AE, Chuang SK, Jones JA. Meta-analysis of periodontal disease 
and risk of coronary heart disease and stroke. Oral Surg Oral Med Oral Pathol Oral 
Radiol Endod 2003;95(5):559-569.  
25. Persson RG, Ohlsson O, Pettersson T, Renvert S. Chronic periodontitis, a 
significant relationship with acute myocardial infarction. Eur Heart J 
2003;24(23):2108-2115.  
26. Khader YS, Albashaireh ZS, Alomari MA. Periodontal diseases and the risk of 
coronary heart and cerebrovascular diseases: a meta-analysis. J Periodontol 
2004;75(8):1046-1053.  
27. D'Aiuto F, Tonetti MS. Contribution of periodontal therapy on individual 
cardiovascular risk assessment. Archives of internal medicine 2005;165(16):1920-1.  
137 
 
28. Montebugnoli L, Servidio D, Miaton RA, et al. Periodontal health improves 
systemic inflammatory and haemostatic status in subjects with coronary heart 
disease. Journal of clinical periodontology 2005;32(2):188-92.  
29. Spahr A, Klein E, Khuseyinova N, et al. Periodontal infections and coronary heart 
disease: role of periodontal bacteria and importance of total pathogen burden in the 
Coronary Event and Periodontal Disease (CORODONT) study. Arch Intern Med 
2006;166(5):554-559.  
30. Beck JD, Couper DJ, Falkner KL, et al. The Periodontitis and Vascular Events 
(PAVE) pilot study: adverse events. Journal of periodontology 2008;79(1):90-6.  
31. Higashi Y, Goto C, Jitsuiki D, et al. Periodontal infection is associated with 
endothelial dysfunction in healthy subjects and hypertensive patients. Hypertension 
2008;51(2):446-53.  
32. Humphrey LL, Fu R, Buckley DI, Freeman M, Helfand M. Periodontal disease 
and coronary heart disease incidence: a systematic review and meta-analysis. J Gen 
Intern Med 2008;23(12):2079-2086.  
33. Higashi Y, Goto C, Hidaka T, et al. Oral infection-inflammatory pathway, 
periodontitis, is a risk factor for endothelial dysfunction in patients with coronary 
artery disease. Atherosclerosis 2009;206(2):604-10.  
34. Lockhart PB, Brennan MT, Thornhill M, et al. Poor oral hygiene as a risk factor 
for infective endocarditis-related bacteremia. Journal of the American Dental 
Association (1939) 2009;140(10):1238-44.  
35. Offenbacher S, Beck JD, Moss K, et al. Results from the Periodontitis and 
Vascular Events (PAVE) Study: a pilot multicentered, randomized, controlled trial to 
study effects of periodontal therapy in a secondary prevention model of 
cardiovascular disease. Journal of periodontology 2009;80(2):190-201.  
36. Jeffcoat MK, Geurs NC, Reddy MS, Cliver SP, Goldenberg RL, Hauth JC. 
Periodontal infection and preterm birth: results of a prospective study. J Am Dent 
Assoc 2001;132(7):875-880.  
37. Lopez NJ, Smith PC, Gutierrez J. Periodontal therapy may reduce the risk of 
preterm low birth weight in women with periodontal disease: a randomized 
controlled trial. J Periodontol 2002;73(8):911-924.  
38. Lopez NJ, Smith PC, Gutierrez J. Higher risk of preterm birth and low birth 
weight in women with periodontal disease. J Dent Res 2002;81(1):58-63.  
39. Radnai M, Gorzo I, Nagy E, Urban E, Novak T, Pal A. A possible association 




40. Bobetsis YA, Barros SP, Offenbacher S. Exploring the relationship between 
periodontal disease and pregnancy complications. J Am Dent Assoc 2006;137 
Suppl:7S-13S.  
41. Offenbacher S, Boggess KA, Murtha AP, et al. Progressive periodontal disease and 
risk of very preterm delivery. Obstet Gynecol 2006;107(1):29-36.  
42. Novak MJ, Novak KF, Hodges JS, et al. Periodontal bacterial profiles in pregnant 
women: response to treatment and associations with birth outcomes in the obstetrics 
and periodontal therapy (OPT) study. J Periodontol 2008;79(10):1870-1879.  
43. Vettore MV, Leal M, Leao AT, da Silva AM, Lamarca GA, Sheiham A. The 
relationship between periodontitis and preterm low birthweight. J Dent Res 
2008;87(1):73-78.  
44. Mohammad AR, Hooper DA, Vermilyea SG, Mariotti A, Preshaw PM. An 
investigation of the relationship between systemic bone density and clinical 
periodontal status in post-menopausal Asian-American women. Int Dent J 
2003;53(3):121-125.  
45. Brennan RM, Genco RJ, Hovey KM, Trevisan M, Wactawski-Wende J. Clinical 
attachment loss, systemic bone density, and subgingival calculus in postmenopausal 
women. J Periodontol 2007;78(11):2104-2111.  
46. Megson E, Kapellas K, Bartold PM. Relationship between periodontal disease 
and osteoporosis. Int J Evid Based Healthc 2010;8(3):129-139.  
47. Martinez-Maestre MA, Gonzalez-Cejudo C, Machuca G, Torrejon R, Castelo-
Branco C. Periodontitis and osteoporosis: a systematic review. Climacteric 
2010;13(6):523-529.  
48. Garcia RI, Nunn ME, Vokonas PS. Epidemiologic associations between 
periodontal disease and chronic obstructive pulmonary disease. Ann Periodontol 
2001;6(1):71-77.  
49. Scannapieco FA, Ho AW. Potential associations between chronic respiratory 
disease and periodontal disease: analysis of National Health and Nutrition 
Examination Survey III. J Periodontol 2001;72(1):50-56.  
50. Terpenning MS, Taylor GW, Lopatin DE, Kerr CK, Dominguez BL, Loesche WJ. 
Aspiration pneumonia: dental and oral risk factors in an older veteran population. J 
Am Geriatr Soc 2001;49(5):557-563.  
51. Yoneyama T, Yoshida M, Ohrui T, et al. Oral care reduces pneumonia in older 
patients in nursing homes. J Am Geriatr Soc 2002;50(3):430-433.  
52. Scannapieco FA, Bush RB, Paju S. Associations between periodontal disease and 
risk for nosocomial bacterial pneumonia and chronic obstructive pulmonary disease. 
A systematic review. Ann Periodontol 2003;8(1):54-69.  
139 
 
53. Leuckfeld I, Obregon-Whittle MV, Lund MB, Geiran O, Bjortuft O, Olsen I. 
Severe chronic obstructive pulmonary disease: association with marginal bone loss in 
periodontitis. Respir Med 2008;102(4):488-494.  
54. Gomes-Filho IS, Santos CM, Cruz SS, et al. Periodontitis and nosocomial lower 
respiratory tract infection: preliminary findings. J Clin Periodontol 2009;36(5):380-
387.  
55. Sharma N, Shamsuddin H. Association between respiratory disease in 
hospitalized patients and periodontal disease: a cross-sectional study. J Periodontol 
2011;82(8):1155-1160.  
56. Zhou X, Wang Z, Song Y, Zhang J, Wang C. Periodontal health and quality of life 
in patients with chronic obstructive pulmonary disease. Respir Med 2011;105(1):67-
73.  
57. Borges-Yanez SA, Irigoyen-Camacho ME, Maupome G. Risk factors and 
prevalence of periodontitis in community-dwelling elders in Mexico. J Clin 
Periodontol 2006;33(3):184-194.  
58. Chuang SF, Sung JM, Kuo SC, Huang JJ, Lee SY. Oral and dental manifestations 
in diabetic and nondiabetic uremic patients receiving hemodialysis. Oral Surg Oral 
Med Oral Pathol Oral Radiol Endod 2005;99(6):689-695.  
59. Scannapieco FA, Bush RB, Paju S. Periodontal disease as a risk factor for adverse 
pregnancy outcomes. A systematic review. Ann Periodontol 2003;8(1):70-78.  
60. Khader YS, Ta'ani Q. Periodontal diseases and the risk of preterm birth and low 
birth weight: a meta-analysis. J Periodontol 2005;76(2):161-165.  
61. Nesse W, Abbas F, van der Ploeg I, Spijkervet FK, Dijkstra PU, Vissink A. 
Periodontal inflamed surface area: quantifying inflammatory burden. J Clin 
Periodontol 2008;35(8):668-673.  
62. Page RC, Eke PI. Case definitions for use in population-based surveillance of 
periodontitis. J Periodontol 2007;78(7 Suppl):1387-1399.  
63. Susanto H, Nesse W, DijkstraPU, Hoedemaker E, van Reenen YH, Agustina D, 
Vssink A, Abbas F. Periodontal inflamed surface area and c-ceartive as predictors of 
HbA1c: A astudy in Indonesia. Clin Oral Invest 2011 
64. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal 
infections contribute to elevated systemic C-reactive protein level. J Periodontol 
2001;72(9):1221-1227.  
65. Craig RG, Yip JK, So MK, Boylan RJ, Socransky SS, Haffajee AD. Relationship of 




66. Salzberg TN, Overstreet BT, Rogers JD, Califano JV, Best AM, Schenkein HA. C-
reactive protein levels in patients with aggressive periodontitis. J Periodontol 
2006;77(6):933-939.  
67. Linden GJ, McClean K, Young I, Evans A, Kee F. Persistently raised C-reactive 
protein levels are associated with advanced periodontal disease. J Clin Periodontol 
2008;35(9):741-747.  
68. Pitiphat W, Savetsilp W, Wara-Aswapati N. C-reactive protein associated with 
periodontitis in a Thai population. J Clin Periodontol 2008;35(2):120-125.  
69. Otterness IG. The value of C-reactive protein measurement in rheumatoid 
arthritis. Semin Arthritis Rheum 1994;24(2):91-104.  
70. Golub LM, Payne JB, Reinhardt RA, Nieman G. Can systemic diseases co-induce 
(not just exacerbate) periodontitis? A hypothetical "two-hit" model. J Dent Res 
2006;85(2):102-105.  
71. Ortiz P, Bissada NF, Palomo L, et al. Periodontal therapy reduces the severity of 
active rheumatoid arthritis in patients treated with or without tumor necrosis factor 
inhibitors. J Periodontol 2009;80(4):535-540.  
72. Pedersen M, Jacobsen S, Klarlund M, et al. Environmental risk factors differ 
between rheumatoid arthritis with and without auto-antibodies against cyclic 
citrullinated peptides. Arthritis Res Ther 2006;8(4):R133.  
73. Borrell LN, Papapanou PN. Analytical epidemiology of periodontitis. J Clin 
Periodontol 2005;32 Suppl 6:132-158.  
74.Nesse W, Brouwer E, Dijkstra PU, Huddleston Slater JJR, Spijkvert FKL, Abbas F, 
Vissink A. Treatment of periodontitis in rheumatoid arthritis pateints reduces 
rheumatoid arthritis activity. A meta analysis. PhD Thesis. 2011. 
75. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van 
Riel PL. Modified disease activity scores that include twenty-eight-joint counts. 
Development and validation in a prospective longitudinal study of patients with 


















Many studies suggest that periodontitis is associated with systemic diseases such as, 
diabetes mellitus (DM), rheumatoid arthritis (RA), cardiovascular diseases, bacterial 
pneumonia, adverse pregnancy outcome, osteoporosis and cerebrovascular disease. 
The association between periodontitis and certain systemic diseases is  bidirectional. 
Not only may systemic disease aggravate periodontitis, but similarly periodontitis 
may aggravate systemic disease. 
  
In chapter 1 the theoretical background of the bidirectional association 
between periodontitis and systemic diseases is explained. Systemic diseases may 
affect periodontitis through a systemic inflammatory response by releasing systemic 
inflammation markers such as C-reactive protein (CRP). This systemic inflammation 
marker may amplify the local inflammatory response in periodontitis. On the other 
hand, periodontitis may aggravate systemic disease  by direct translocation of 
bacteria or bacterial products as well as through a systemic inflammatory response 
by production of CRP. The assumed association between periodontitis and systemic 
diseases can also be demonstrated by the evidence that periodontal treatment is 
accompanied by a reduction of,  e.g., serum CRP level, which in turn is involved in a 
reduction of the activity of systemic disease. However, both in periodontitis and 
systemic disease other confounding and/or modifying risk factors have to be 
considered  such as age, sex, and smoking.   
In chapter 1 it is also explained why the various studies were conducted in 
Indonesia. The main reason was the still conflicting results amongst studies reported 
in the literature assessing the association between periodontitis and systemic 
diseases as well as that to date only few studies have been conducted in Asia. As a 
consequence, it is uncertain whether the results of the studies reported in the 
international literature to date may be generalized to Asian populations such as 
Indonesians. Finally, the application of different methods in defining periodontitis 
may have contributed to the different asscociations found between periodontitis and 
systemic diseases. Therefore, the aim of the PhD research described in this thesis was 
to investigate associations between periodontitis and systemic diseases as diabetes 
mellitus type 2 (DM2) and rheumatoid arthritis (RA) in Indonesia.  In addition, it 
was systematically reviewed whether patients suffering from atherosclerotic diseases 




In chapter 2 the prevalence of periodontitis in patients with DM2 in an 
Indonesian population is reported. In addition, this study investigated the 
association between periodontitis and DM2 using a variety of methods to 
operationalize periodontitis. The use of different methods to operationalize 
periodontitis prevalence and severity has shown to influence the strength of the 
association of, e.g., in the linking of periodontitis and preterm birth. The same 
influence may be true for the association of periodontitis and DM2. In total 78 DM2 
and 65 healthy subjects underwent full mouth periodontal screening including 
assessment of probing pocket depth, gingival recession, plaque index and bleeding 
on probing. Using these data the periodontal inflammatory surface area (PISA) was 
calculated. The results of the study presented in chapter 2 showed differences in 
periodontitis prevalence and severity between patients with DM2 and healthy 
subjects, with odds ratios of 5.0 and 6.1, respectively. Univariate analyses showed a 
significantly higher prevalence and severity of periodontitis in patients with DM2 . 
With regard to the risk factors for periodontitis, only age and hypertension were 
found significantly higher in DM2 as compared to controls. In regression analyses 
only DM2 and age were predictors for periodontitis. It was concluded that 
Indonesian patients with DM2 had more prevalent and more severe periodontitis 
than Indonesian controls , independent of confounding factors or the methods used 
to operationalize periodontitis.  
 
In chapter 3 a study is described in which it was shown that periodontitis 
may raise an infectious and inflammatory burden to DM2 as evidenced by increased 
CRP. This burden may impair blood glucose control as monitored by HbA1c. In 132 
Indonesian controls and 101 Indonesians treated for DM2, a full mouth periodontal 
examination was performed. HbA1c and CRP were measured. Regression analyses 
were applied to assess whether periodontitis severity and CRP predict HbA1c when 
controlling for confounding and effect modification. The results of these analyses 
showed that periodontitis severity and CRP were predictors of HbA1c levels in a 
group of healthy Indonesians. Such an association could not be demonstrated in a 
group of Indonesians treated for DM2. While in Indonesian controls , PISA predicted 
HbA1c together with CRP, age, sex and smoking, this was not the case in Indonesians 
treated for DM2. It was assumed that the potential effect of periodontitis on glucose 
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control in patients with DM2 might be masked by treatment of DM2 in these 
patients, and probably will be present in untreated and non-diagnosed DM2 subjects.  
 
 In chapter 4 a study is described assessing the prevalence and severity of 
periodontitis and its potential association with systemic  inflammation in 
Indonesians with RA. In total 132 Indonesian controls and 78 Indonesians with RA 
were investigated. Full mouth periodontal examination was performed. Serum levels 
of CRP, ESR, rheumatoid factor and anti cyclic citrullinated antibodies (ACPAs) were 
measured. No significant differences in periodontitis prevalence and severity were 
observed between RA patients and controls. It could, however, be shown that ESR 
and CRP were higher in RA patients with periodontitis compared to RA patients 
without periodontitis. It was concluded that, although periodontitis prevalence and 
severity were not higher in Indonesian RA patients than in Indonesians controls, 
periodontitis apparently is associated with an increased systemic inflammation in RA 
patients.  
  
In chapter 5 a systemic review and meta-analyses is described reporting on 
the robustness of observations that periodontal treatment reduces the levels of 
biomarkers of atherosclerotic diseases. A literature search was performed based on 
original investigations, in which effects of periodontal intervention were compared 
relative to no  periodontal treatment. Periodontal treatment was the predictor and 
inflammatory, metabolic and/or vascular markers were outcomes. Meta-analyses 
including all available studies, demonstrated significant differences in weighted 
means for CRP, IL-6, total cholesterol and HbA1c favoring periodontal intervention 
especially in patients suffering from cardiovascular and/or metabolic diseases like 
DM2. This reduction of biomarkers emphasizes the effectiveness and need of 
periodontal therapy in these individuals to improve their health. 
 
In chapter 6 the main research findings are discussed and future 
perspectives are given. In general, also in Indonesia periodontal disease may have a 
considerable impact on general health, amongst others in DM2 and RA subjects.  It 
was also concluded that CRPs may play a key role in the systemic effects of 
periodontal diseases and that CRP serum levels can be reduced by periodontal 
treatment. Moreover, improved periodontal health is accompanied by better 
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glycaemic control, reduction of RA disease activity and a reduced risk for 
atherosclerotic diseases. Periodontal disease, diagnosis and treatment should, 
therefore, be an integral part of health care thereby not only improving oral health, 

































Parodontitis lijkt te zijn geassocieerd met ziektes zoals diabetes mellitus, reumatoïde 
artritis, hart en vaatziekten, bacteriële pneumonie, zwangerschapscomplicatie, 
osteoporose en cerebrovasculaire accidenten. De samenhang tussen parodontitis en 
bepaalde aandoeningen kan beide kanten opgaan ofwel is bidirectioneel. Niet alleen 
kunnen ziekten parodontitis verergeren, maar kan parodontitis ook aandoeningen 
verergeren. 
 
In hoofdstuk 1 wordt het tweerichtingsverkeer tussen parodontitis en 
systeemziekten uitgelegd. Systeemziekten kunnen parodontitis beïnvloeden door een 
systemische ontstekingsreactie waarbij systemische ontstekingsfactoren vrijkomen 
zoals c-reatieve eiwitten (CRP). Deze systemische ontstekingsfactor kan de lokale 
ontstekingsreactie bij parodontitis verergeren. Aan de andere kant kan parodontitis 
systemische aandoeningen verergeren door directe verplaatsing (translocatie) van 
bacteriën of bacteriële producten of door een systemische ontstekingsreactie 
(productie van CRP). Het veronderstelde verband tussen parodontitis en systemische 
aandoeningen blijkt ook uit de observatie dat behandeling van parodontitis vergezeld 
wordt door een afname van bijvoorbeeld serum CRP. Het gevolg hiervan is dat de 
ziekteactiviteit van de systemische aandoening ook afneemt. Men moet hierbij 
bedenken dat bij parodontitis en systeemziektes voor een deel dezelfde oorzakelijke 
factoren hebben en dat confounders (verstorende variabelen) en/of risicofactoren 
een rol kunnen spelen zoals leeftijd, geslacht en roken bij de tot nu toe gevonden 
resultaten. In hoofdstuk 1 wordt ook verklaard waarom het onderzoek in Indonesië 
werd uitgevoerd. De belangrijkste reden daarvoor was dat in de literatuur 
tegenstrijdige resultaten worden gerapporteerd met betrekking tot het verband 
tussen parodontitis en andere aandoeningen. Daarnaast zijn nog maar weinig studies 
verricht in Azië. Het gevolg daarvan is dat het onzeker is of de in de huidige 
internationale literatuur beschreven resultaten ook toepasbaar zijn voor Aziatische 
populaties zoals Indonesië. Tenslotte, kunnen ook de verschillende manieren van 
definiëren van parodontitis in de verschillende studies hebben bijgedragen aan het 
niet eensluidende of moeilijk te vergelijken resultaat van het onderzoek naar de 
relatie tussen parodontitis en andere aandoeningen. Daarom werd in dit proefschrift 
de associatie tussen parodontitis en systeemziektes zoals diabetes mellitus type 2 
(DM2) en reumatoïde artritis (RA) in Indonesië onderzocht. Bovendien werd in de 
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literatuur door middel van een systemic review onderzocht of atherosclerose 
patiënten baat zouden kunnen hebben bij behandeling van parodontitis. 
 
In hoofdstuk 2 wordt het vóórkomen van parodontitis in een groep 
Indonesische DM2 patiënten gerapporteerd. In dit onderzoek werd bovendien de 
relatie tussen parodontitis en DM2 aan de hand van een groot aantal in de literatuur 
beschreven methoden om parodontitis vast te stellen onderzocht. Bij. het vaststellen 
van het verband tussen parodontitis en vroeggeboorte is gebleken dat de wijze 
waarop parodontitis werd gedefinieerd van grote invloed is op de uitkomst van dit 
onderzoek. Hetzelfde zou kunnen gelden voor het verband tussen parodontitis en 
DM2. Bij 78 DM2 patiënten en 65 controle personen werd een volledig parodontaal 
onderzoek uitgevoerd inclusief bepaling van de pocketdiepte, gingivarecessie, plaque 
index en bloeding na sonderen. Op basis van deze gegevens werd de oppervlakte van 
het parodontaal ontstoken weefsel (PISA) berekend. De resultaten van het onderzoek 
in dit hoofdstuk beschreven onderzoek laten verschillen in vóórkomen en ernst van 
parodontitis zien tussen DM2 patiënten en gezonde individuen met Odds Ratio’s van 
respectievelijk 5.0 en 6.1. Met univariatie analyses kon worden aangetoond dat 
parodontitis significant vaker voorkomt en ernstiger is in DM2 patiënten. Met 
betrekking tot risicofactoren voor parodontitis bleken leeftijd en hoge bloeddruk als 
significante factoren aanwezig bij DM2 patiënten vergeleken met controle personen. 
In regressie analyses bleken DM2 en leeftijd een voorspellende waarde voor 
parodontitis te hebben. De conclusie was dat Indonesische DM2 patiënten vaker en 
ernstiger parodontitis hebben dan gezonde Indonesische individuen, onafhankelijk 
van andere verstorende variabelen (confounders) en de wijze van vaststellen van 
parodontitis. 
 
In hoofdstuk 3 wordt beschreven dat parodontitis kan bijdragen aan de 
infectie en ontstekingsdruk voor DM2 blijkens een verhoogd CRP. Hierdoor kan de 
regulatie van de bloedglucose, zoals dat zijn weerslag heeft in HbA1c waarden, 
verstoord raken. Volledig parodontaal onderzoek werd uitgevoerd bij 132 controle 
Indonesiërs en 101 Indonesiërs die behandeld werden voor DM2 en tevens werden 
HbA1c en CRP gemeten.  
Regressie analyses werden uitgevoerd om vast te stellen of de ernst van parodontitis 
en de CRP waardes het HbA1c kunnen voorspellen waarbij werd gecorrigeerd voor 
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confounders en effect modificatie. Uit de analyse bleek dat de ernst van parodontitis 
en de hoeveelheid CRP een voorspellende waarde hadden voor het HbA1c nivo in de 
groep van gezonde Indonesiërs die waren behandeld voor DM2. Een dergelijke 
relatie kon niet worden aangetoond in de DM2 patiënten. Verondersteld werd dat het 
potentiële effect van parodontitis op de bloed glucose instelling in DM2 patiënten 
werd gemaskeerd door de behandeling van DM2 en waarschijnlijk wel aanwezig zou 
zijn in onbehandelde en/of niet gediagnosticeerde DM2 patiënten.  
 
In hoofdstuk 4 wordt het onderzoek beschreven naar het vóórkomen en de 
ernst van parodontitis en de mogelijke samenhang met systemische ontsteking in een 
groep Indonesiërs met reumatoïde artritis (RA). In totaal werden 132 controle 
Indonesiërs en 78 Indonesiërs met RA onderzocht. Beide groepen werden volledig 
parodontaal onderzocht en  CRP, de BSE (bloedbezinking), reumafactor en 
anticyclische gecitrullineerde antistoffen (ACPA’s) werden gemeten. Er werden geen 
significante verschillen in vóórkomen en ernst van parodontitis geconstateerd tussen 
RA patiënten en de gezonde controle groep. Daarentegen kon wel worden 
aangetoond dat de ESR en CRP verhoogd waren in RA patiënten met parodontitis 
vergeleken met RA patiënten zonder parodontitis. Hieruit werd geconcludeerd dat 
hoewel het vóórkomen en de ernst van parodontitis niet hoger waren in Indonesische 
RA patiënten versus de gezonde controle groep, het kennelijk zo is dat parodontitis is 
geassocieerd met een verhoogde inflammatoire status in RA patiënten. 
 
In hoofdstuk 5 wordt een systematische review en meta-analyse beschreven 
betreffende de robuustheid van waarnemingen dat parodontale behandeling de 
biomakers voor atherosclerotische aandoeningen reduceert. De bestaande 
wetenschappelijke literatuur werd doorzocht op studies die het effect van 
parodontale behandeling vergeleken met geen behandeling. Parodontale behandeling 
was de voorspeller en ontstekings-, metabole- en of vasculaire markers de 
uitkomstfactoren. Meta-analyse van alle beschikbare studies liet zien dat parodontale 
behandeling een verlaging gaf van ontstekingsfactoen (CRP, Il-6) en metabole 
markers (totaal cholesterol en HbA1c). Dit effect was het sterkst in patiënten lijdend 
aan cardiovasculaire en of metabole aandoeningen zoals DM2. Deze reductie van 
biomakers onderschrijft het belang en de effectiviteit van parodontale behandeling 
aan bij deze patiënten om hun algehele gezondheid te verbeteren. 
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In hoofdstuk 6 worden de voornaamste onderzoeksbevindingen 
bediscussieerd en worden suggesties voor verder onderzoek gegeven. Uit de 
bevindingen komt naar voren dat ook in een Indonesische populatie parodontitis een 
aanzienlijke invloed kan hebben op de algehele gezondheid, met name bij DM2 en 
RA patiënten. De conclusie was dat CRPs een rol spelen in het systemisch effect van 
parodontitis en dat CRP serum spiegels kunnen dalen door parodontale behandeling. 
Daarnaast gaat een verbeterde parodontale conditie gepaard met een betere 
glycaemische instelling, reductie van RA activiteit en een verlaagd risico voor 
atherosclerotische aandoeningen. De diagnostiek en behandeling van parodontale 
aandoeningen zou daarom integraal onderdeel van de gezondheidszorg moeten zijn, 
niet alleen om de mondgezondheid te verbeteren maar ook de algehele gezondheid 



















Banyak penelitian menunjukkan bahwa periodontitis berhubungan dengan penyakit 
sistemik seperti, diabetes mellitus, rheumatoid arthritis, penyakit kardiovaskular, 
pneumonia bakterial,  kehamilan, osteoporosis dan penyakit serebrovaskular. 
Hubungan antara periodontitis dan penyakit sistemik kemungkinan merupakan 
hubungan dua arah. Penyakit sistemik tidak hanya memperparah periodontitis, tapi  
periodontitis juga dapat memperburuk penyakit sistemik. Dalam bab 1 dijelaskan 
latar belakang teoritis hubungan dua arah antara periodontitis dan penyakit 
sistemik. Penyakit sistemik dapat mempengaruhi periodontitis melalui respon 
inflamasi sistemik dengan melepaskan penanda inflamasi sistemik seperti C-reaktif 
protein (CRP). Pelepasan CRP sebagai penanda inflamasi sistemik dapat 
meningkatkan respon inflamasi lokal pada periodontitis. Di sisi lain, periodontitis 
dapat memperburuk penyakit sistemik dengan cara translokasi langsung bakteri atau 
produk bakteri serta melalui respon inflamasi sistemik berupa produksi CRP. 
Hubungan antara periodontitis dan penyakit sistemik  juga dapat ditunjukkan oleh 
bukti bahwa adanya perawatan periodontal dapat disertai dengan penurunan CRP 
serum, yang kemudian dapat menurunkan keparahan penyakit sistemik. Namun, 
dalam hubungan periodontitis dan penyakit sistemik, perlu mempertimbangkan 
faktor risiko dan/atau faktor yang memodifikasi hubungan tersebut seperti usia, 
jenis kelamin, dan merokok. Dalam bab 1 ini juga dijelaskan beberapa alasan 
penelitian dilakukan di Indonesia. Alasan utama adalah masih adanya pertentangan 
antara berbagai hasil penelitian mengenai hubungan antara periodontitis dan 
penyakit sistemik serta baru sedikit bukti yang menjelaskan adanya hubungan 
periodontitis dan penyakit sistemik di Asia demikian juga sampai saat ini baru 
sedikit penelitian telah dilakukan di Asia. sehingga, masih ada ketidakpastian apakah 
hasil penelitian di negara lain yang telah diterbitkan dalam literatur internasional 
sampai saat ini  dapat diekstrapolasi ke populasi Asia seperti Indonesia. Alasan 
terakhir adalah penerapan metode yang berbeda dalam mendefinisikan periodontitis  
mungkin telah berkontribusi terhadap perbedaan hasil dalam  penelitian-penelitian 
tentang hubungan periodontitis dan penyakit sistemik. Oleh karena itu, tujuan dari 
penelitian PhD dalam tesis ini adalah untuk mengetahui hubungan antara 
periodontitis dan penyakit sistemik seperti diabetes mellitus tipe 2 (DM2) dan 
rheumatoid arthritis (RA) di Indonesia. Selain itu, kajian secara sistematik tentang 
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manfaat perawatan periodontitis terhadap pasien atherosklerotik seperti penyakit 
kardiovaskular. 
Di dalam bab 2 dilaporkan prevalensi periodontitis pada pasien DM2 pada 
populasi orang Indonesia. Selain itu, penelitian ini juga mengkaji hubungan antara 
periodontitis dan DM2 menggunakan berbagai metode dalam mengoperasionalkan 
periodontitis. Penggunaan metode yang berbeda untuk mengoperasionalkan 
prevalensi dan keparahan periodontitis telah diketahui berpengaruh terhadap 
kekuatan hubungan tersebut, misalnya, dalam hubungan periodontitis dan kelahiran 
bayi prematur. Perbedaan metode dalam mengoperasionalkan periodontitis juga 
mungkin berpengaruh terhadap hubungan antara periodontitis dan DM2. 
Pemeriksaan periodontal secara menyeluruh terdiri atas kedalaman poket, resesi 
gingiva, indeks plak dan perdarahan saat probing dilakukan pada subyek penelitian 
yang terdiri atas 78 DM2 dan 76 orang sehat  . Berdasarkan data pemeriksaan 
periodontal tersebut dilakukan perhitungan luas permukaan periodontal yang 
terinflamasi (PISA). Hasil penelitian pada bab ini menunjukkan perbedaan 
prevalensi dan keparahan periodontitis antara DM2 dan orang sehat, dengan rasio 
kemungkinan masing-masing 5.0 dan 6.1. Analisis univariat menunjukkan 
prevalensi dan tingkat keparahan periodontitis lebih tinggi secara signifikan pada 
subyek DM2. Dalam analisis juga menunjukkan bahwa faktor risiko terhadap 
periodontitis yaitu umur dan hipertensi diketahui lebih tinggi secara signifikan pada 
DM2 dibandingkan dengan orang sehat yang dalam analisis regresi hanya DM2 dan 
usia yang terbukti menjadi prediktor untuk periodontitis. Dapat disimpulkan bahwa 
orang Indonesia yang menderita DM2 memiliki periodontitis lebih banyak dan lebih 
parah dibandingkan orang Indonesia sehat, terlepas dari faktor pengganggu atau 
metode yang digunakan dalam mengoperasionalkan periodontitis.  
Di dalam bab 3 dijelaskan hasil penelitian yang menunjukkan bahwa 
periodontitis dapat meningkatkan beban risiko inflamasi dan infeksi bagi DM2 yang 
dibuktikan dengan peningkatan CRP serum. Peningkatan inflamasi ini dapat 
mengganggu kontrol glukosa darah yang  diukur dengan adanya HbA1c dalam darah. 
Pemeriksaan periodontal secara menyeluruh, HbA1c dan CRP darah dilakukan pada 
132 orang Indonesia yang sehat dan 101 orang pasien DM2. Analisis regresi  
dilakukan untuk menilai apakah keparahan periodontitis dan CRP dapat sebagai 
prediktor untuk HbA1c setelah mengendalikan faktor yang dapat memodifikasi 
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hubungan tersebut dan faktor pengganggu. Hasil analisis ini menunjukkan bahwa 
keparahan periodontitis dan CRP merupakan prediktor untuk HbA1c pada kelompok 
orang Indonesia sehat. Hubungan seperti yang ditemukan pada orang Indonesia 
sehat tersebut tidak dapat ditunjukkan dalam kelompok pasien DM2. Sementara 
pada kelompok orang Indonesia sehat, PISA, CRP juga usia, jenis kelamin dan 
merokok menjadi prediktor untuk HbA1c. Namun tidak untuk pasien DM2. 
Diasumsikan bahwa efek periodontitis pada kontrol glukosa darah pada pasien DM2 
mungkin tertutupi oleh pengobatan pada pasien DM2, dan mungkin akan terlihat 
pada DM2 yang tidak terdiagnosis dan tidak terawat. 
Di dalam bab 4 dijelaskan penelitian yang bertujuanuntuk mengetahui 
prevalensi dan keparahan periodontitis dan hubungannya dengan inflamasi sistemik 
pada pasien RA. Pemeriksaan periodontal secara menyeluruh dilakukan pada 132 
orang Indonesia yang sehat dan 78 pasien RA. Pemeriksaan hsCRP, LED, faktor 
rheumatoid dan anti antibodi citrullinated siklik (ACPAs) serum juga dilakukan. 
Adapun hasil penelitian menunjukkan tidak ada perbedaan yang signifikan dalam 
prevalensi dan keparahan periodontitis yang ditemukan pada pasien RA dan orang 
sehat. Meskipun demikian, pada penelitian ini menunjukkan bahwa ESR dan hsCRP 
serum lebih tinggi pada pasien RA dengan periodontitis dibandingkan dengan pasien 
RA tanpa periodontitis. Dapat disimpulkan bahwa, meskipun prevalensi dan 
keparahan periodontitis tidak lebih tinggi pada pasien RA daripada kelompok 
kontrol sehat, periodontitis tampaknya berhubungan dengan peningkatan respon 
inflamasi pada pasien RA. 
Dalam bab 5 dijelaskan review sistemik dan meta-analisis yang melaporkan 
kekuatan hasil penelitian bahwa perawatan periodontal menurunkan penanda 
penyakit aterosklerotik. Sebuah pencarian literatur dilakukan berdasarkan penelitian 
yang asli tentang perawatan periodontal dibandingkan  tanpa perawatan 
periodontal. Perawatan periodontal adalah prediktor dan penanda inflamasi, 
metabolik dan / atau darah. Meta-analisis pada semua studi yang terseleksi, 
menunjukkan perbedaan yang signifikan pada CRP, IL-6, total kolesterol dan HbA1c 
pada perawatan periodontal terutama pada pasien yang menderita penyakit jantung 
dan / atau metabolik seperti DM2. Penurunan penanda-penanda tersebut 
menekankan efektivitas dan kebutuhan terapi periodontal pada individu-individu 
untuk meningkatkan kesehatan mereka.  
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Dalam bab 6 dibahas hasil penelitian utama dan perspektif penelitian yang 
akan datang. Secara umum, di Indonesia penyakit periodontal  mungkin memiliki 
dampak besar terhadap kesehatan umum, antara lain pada pasien DM2 dan RA juga 
dapat disimpulkan bahwa CRP mungkin memiliki peran kunci terhadap efek 
sistemik penyakit periodontal dan  CRP serum dapat menurun oleh perawatan 
periodontal. Selain itu, peningkatan kesehatan periodontal dapat berpengaruh pada 
kontrol glukosa darah pada pasien DM2 yang lebih baik, penurunan aktivitas 
penyakit RA dan mengurangi risiko penyakit kardiovaskular. Diagnosis dan 
perawatan penyakit periodontal harus dilakukan, dan menjadi bagian integral dari 
pelayanan kesehatan sehingga tidak hanya meningkatkan kesehatan mulut, tetapi 
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